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AND OUTLINE OF THE 
THESIS
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The enormous progress in treatment of Human Immunodeficiency Virus (HIV) has 
altered the diagnosis of an HIV infection from a death sentence to a chronic condition 
with a potential (near) normal life expectancy. Complacency should however be 
avoided as HIV treatment has its limitations and HIV cure remains elusive. Following a 
brief historical outline of the HIV epidemic, I will introduce two enduring challenges for 
people who are living with HIV (PLHIV) that are subject of this academic thesis.
HIV infects and kills vital cells of the human immune system that express a CD4 receptor, 
including T cells, monocytes/macrophages, and dendritic cells. HIV belongs to the 
lentiviruses, a group of retroviruses that causes a slowly progressive disease (lenti-, Latin 
for “slow”). Initial presentation of HIV infection can be asymptomatic or “flu-like” and 
is followed by a 2-15-year asymptomatic period of clinical latency. Without treatment, 
progressive depletion of CD4+ T cells occurs, leading to deterioration of the immune 
system, opportunistic infections and, eventually, acquired immunodeficiency syndrome 
(AIDS) and death. At present, the estimated worldwide HIV-infected population totals 
38 million people, including 1.8 million children.1 Of those, 25.4 million (67%) receive 
antiretroviral therapy (ART). 
The history of HIV/AIDS is short but turbulent and starts with reports of opportunistic 
infections and rare malignancies (e.g. Pneumocystis jirovecii pneumonia [PJP] and 
aggressive forms of Kaposi’s sarcoma) in previously healthy gay men in the United 
States in 1981.2,3 In 1982, the Centre for Disease Control and Prevention (CDC) defined 
this immunocompromised state of unknown cause as AIDS. One year later, HIV was 
identified as the causative agent.4 In the early years of the epidemic, treatment options 
were limited to PJP prevention by cotrimoxazole and palliative care. It would take until 
1987 before the United States Food and Drug Administration (FDA) approved the first 
antiretroviral drug (zidovudine). By that time, the HIV epidemic had already affected 5-10 
million people worldwide. In the mid-1990s, the introduction of the first protease inhibitor 
as part of combination antiretroviral therapy (cART) resulted in a dramatic decrease in 
AIDS-related morbidity and mortality. While cART can durably suppress HIV replication, 
it is not curative and must be taken for life. Hence, in the early nineties, initiation of cART 
was limited to PLHIV with clear signs of immune suppression, as indicated by CD4+ cell 
numbers below 250. Over time, highly toxic medication such as stavudine, zidovudine, 
and didanosine could be replaced by less toxic drugs. Furthermore, the advantage 
of early start of cART became more apparent, resulting in treatment for all PLHIV, 
instead of CD4+ guided cART initiation. Although the costs of cART remains significant 
in high-income countries, the costs of the average first-line cART have been reduced 
to less than $100 per year for many low-income countries. Moreover, standardization 
and simplification of cART have improved coverage in these countries.5 Although HIV 
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cure remains a distant prospect, professionals working with HIV are now cautiously 
optimistic. Comparing the landscape with 30 years ago, when individuals with HIV faced 
inevitable death, these individuals now have nearly normal life spans. 
Beneath this veneer of optimism lurk persistent challenges of chronic HIV, some of 
which are addressed in this thesis (graphically summarized in figure 1.1). First, adequate 
suppression of HIV-RNA requires optimal adherence to lifelong daily treatment with 
multiple drugs, with risks for side effects. Some of these side effects may manifest 
as central nervous system symptoms. Neuropsychiatric side effects are often poorly 
recognized, but may greatly impact quality of life. The first part of this thesis addresses 
these neuropsychiatric side effects of ARVs both during brain development (infancy 
and childhood) and in adulthood. Second, despite suppressive cART, the host immune 
system may not completely recover, predisposing individuals to the development of 
non-AIDS-related comorbidities such as cardiovascular disease and non-AIDS-related 
cancers. This incomplete normalization of the immune system is discussed in part 2 of 
this thesis. Better understanding and management of these challenges are essential for 







Immune cell architecture in chronic HIV (ch 6)






Figure 1.1 Outline of this thesis. Ch=chapter.
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PART 1 – NEUROTOXICITY OF ANTIRETROVIRAL 
THERAPY
Traditionally, HIV treatment regimens have been composed of three different drugs. Two 
nucleoside (or nucleotide)-reverse-transcriptase inhibitors (NRTIs) are usually combined 
with a third drug from a different class: non-nucleoside reverse transcriptase inhibitors 
(NNRTI), integrase inhibitors (INSTI), protease inhibitors (PI), CCR5 antagonists, or 
fusion inhibitors (FI). Together, these drugs are able to suppress the plasma HIV-RNA 
for a prolonged period of time. Treatment has to be continued indefinitely with optimal 
adherence in order to maintain viral suppression. 
Side effects, including neuropsychiatric symptoms, have been reported with all ARVs 
and are among the most common reasons for medication non-adherence and treatment 
switch. They often result from interactions with receptors other than the intended target 
(off-target toxicity), e.g. on the proximal tubules of the kidney for tenofovir disoproxil 
fumarate and in the bone marrow for zidovudine. 
ARVs are able to cross the blood-brain barrier, leading to detectable concentrations 
in the cerebrospinal fluid. Penetration of ARVs into the central nervous system (CNS) 
is essential for treating the brain HIV reservoir. However, ARVs also interact with CNS 
receptors, leading to neuropsychiatric toxicity. Neuropsychiatric side effects have been 
described for efavirenz, rilpivirine and INSTI. Most somatic side effects can easily be 
identified and monitored by physical examination or by routine laboratory screening. 
However, neuropsychiatric side effects have a great risk to be overlooked, especially 
because the HIV diagnosis itself may also cause psychological distress. Neuropsychiatric 
toxicity is a very broad concept, encompassing a wide range of symptoms, including 
disturbances in mood and cognition. Identification of these symptoms requires 
appropriate knowledge and skills, which are not always available in regular HIV clinics. 
Moreover, drug-related symptoms are difficult to distinguish from symptoms related to 
psychological, socioeconomic, lifestyle, or HIV-related factors. Therefore, detection and 
follow-up of neuropsychiatric side effects pose a serious challenge for HIV clinics, where 
health care workers are mostly trained in somatic care. 
In part 1 of this thesis, I focus on neuropsychiatric side effects related to two first-line 
HIV drugs: efavirenz and dolutegravir. The NNRTI efavirenz was introduced in 1998 as an 
equipotent, less toxic, alternative to PIs in initial cART regimens. Because of its excellent 
antiviral efficacy, availability in generic once-daily combination pills, and potential to be 
co-administered with tuberculosis drugs, it rapidly became the cornerstone of first-line 
cART. Efavirenz has always been known for its neuropsychiatric side effects, which are 
reported by one-third of adults and vary from sleep disturbances to depression and 
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psychosis.6 Initially, these symptoms were thought to develop and resolve within the first 
weeks of therapy.7 However, post-marketing studies in the late 2000s and early 2010s 
reported persistence of symptoms during long-term treatment.8-11 Reports on increased 
suicidality among individuals treated with efavirenz, and recreational use of efavirenz 
by HIV-negative individuals further fueled the debate on neuropsychiatric toxicity of 
efavirenz.12,13 
Surprisingly little is known about the central nervous system effects of efavirenz during 
periods of brain development. Based on reports of neural tube defects in early animal 
studies and retrospective case reports in humans,14,15 the use of efavirenz during early 
pregnancy had long been contraindicated.16 In 2012, the WHO changed this policy as 
risks for teratogenicity turned out to be negligible in a large meta-analysis.17 In addition, 
the FDA and the European Medicines Agency have now approved use of  efavirenz in 
children as young as three months old. Pediatric studies available at the start of this 
project lacked validated psychiatric assessment tools and there were no long-term 
developmental data of in utero efavirenz-exposed children.. Not only are children 
more vulnerable to neuropsychiatric side effects as their brains are still developing, 
they also have to take ART for decades longer than do adults. While most national 
and international guidelines,18-21  now substituted efavirenz for the newer, presumably 
more tolerable, ARV dolutegravir, the number of individuals receiving efavirenz-based 
cART in the near future will remain substantial. Given the paucity of data in children, 
this thesis specifically focused on the central nervous system effects of efavirenz during 
brain development.
Dolutegravir is a second-generation integrase inhibitor and received approval for use 
in 2013. Given its high genetic barrier to resistance and favorable efficacy and side 
effect profile, dolutegravir quickly gained in popularity among HIV treating physicians.22 
Moreover, generic versions became available for low-and middle income countries with 
a median price of $75 per year, making dolutegravir more affordable than efavirenz.23  By 
2025, an estimated 15 million people will be taking dolutegravir.24 Yet, also dolutegravir 
has been associated with neuropsychiatric side effects. A number of studies in Western 
Europe (including in The Netherlands) reported unexpectedly high discontinuation 
rates of dolutegravir, mostly because of intolerability.25,26 Findings in these studies 
were in sharp contrast with findings from previous randomized controlled trials, which 
presented excellent tolerability of dolutegravir.27-30 These real life studies, however, 
mostly relied on retrospective data retrieved from medical records. More detailed, 
prospective studies using validated psychiatric assessment tools are required to verify 
neurotoxicity of dolutegravir.
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Objectives and outline of part 1
Part one of this thesis addresses long-term central nervous system side effects of ARVs 
in different populations and models. 
This part specifically aims to improve our insight into:
     •   Efavirenz-related neuropsychiatric side effects in children living with HIV
     •   Long-term neurodevelopmental effects of in utero exposure to efavirenz
     •   Dolutegravir-related neuropsychiatric side effects in adults
Part 1 combines studies on central nervous system side effects of two first-line ARVs: 
efavirenz (chapter 2-4) and dolutegravir (chapter 5). 
For efavirenz, there is abundant evidence for its neuropsychiatric side effects in adults. 
Pregnant women and children are a vulnerable and exposed group but, compared to 
adults, poorly studied.  In chapter 2, we reviewed available evidence of efavirenz-related 
side effects in adults and children. We discussed different relevant pharmacokinetic and 
pharmacodynamic mechanisms of efavirenz and their relevance in children. Chapter 2 
also includes a correspondence in which we emphasized the importance of psychiatric 
testing in long-term safety evaluations of efavirenz in children. 
In chapter 3, we comprehensively assessed neuropsychiatric symptoms in Tanzanian 
school-aged children receiving long-term cART. In this cross-sectional study, we used 
validated psychiatric tools to compare competence (social involvement, activities, and 
school performance), psychopathology (internalizing end externalizing symptoms), 
cognitive performance and adherence in children on an efavirenz-based versus a non-
efavirenz-based regimen. 
We next focused on the effects of exposure to efavirenz during early brain development. 
Clinical studies on long-term developmental effects of perinatal efavirenz exposure were 
lagging behind and could be confounded by sociodemographic and HIV-related factors. In 
chapter 4, we used a rodent model to study the long-term neurodevelopmental effects of 
perinatal exposure to efavirenz. We examined behavior during early life, adolescence and 
adulthood, and performed immunohistochemistry analyses in the brain cortices of adult rats.
Recent studies suggesting a similar neuropsychiatric side effect profile in dolutegravir 
were hampered by lacking the use of validated psychiatric assessment tools.25,26 In 
chapter 5, we used validated psychiatric questionnaires on mood, impulsivity and 
substance use to assess these symptoms in ~200 long-term treated individuals, including 
82 on dolutegravir-based cART.
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PART 2 – IMMUNE DYSREGULATION DESPITE 
LONG-TERM SUCCESSFUL CART 
In part 2 of this thesis, I will focus on persistent immune system dysfunction and 
inflammation in chronic HIV infection. Despite prolonged suppressed HIV-RNA, 
individuals with HIV have shorter life expectancies than HIV-uninfected individuals, 
especially when cART initiation has been delayed. The present guidelines therefore 
recommend immediate start of cART. HIV infection predisposes individuals to non-
infectious comorbidities, such as cardiovascular disease and non-AIDS-related cancer 
as well as increased risks for pneumococcal infections.31 While parts of this increased 
risk may be explained by lifestyle factors (e.g. smoking, alcohol, and drug use), chronic 
immune dysfunction and inflammation are considered to be the root drivers.32,33 
cART attenuates these processes, but does not completely resolve them, even when 
administered early after infection. 
Human immune responses are classically divided into innate and adaptive immune 
responses. The innate immune response reacts rapidly and nonspecifically upon 
infection. Adaptive immune responses develop more slowly (1-2 weeks), are specific, 
and induce immunological memory. The different components of the immune system are 
in close contact and communicate either directly or indirectly through the elaboration 
of soluble mediators called cytokines and chemokines. The composition and function of 
the immune system are shaped by many factors, including heritability, age, sex, smoking 
and seasonality.34 It is widely known that HIV targets CD4+ T cells from the adaptive 
immune system.35  However, the detrimental effects of HIV on the immune system go far 
beyond CD4+ T cell depletion, dysfunction and senescence. Eventually, effects are seen 
for almost every cell population. 
The exact mechanisms underlying HIV-mediated immune system dysfunction and 
inflammation are incompletely understood. Persistent antigen exposure, either by 
ongoing HIV replication, co-infections (particularly with cytomegalovirus [CMV]), and/
or microbial translocation, all contribute to varying degrees.36-39 Therefore, numerous 
interventions have been studied to prevent chronic inflammation, including statins, 
valganciclovir (to treat asymptomatic CMV), and angiotensin-converting enzyme 
inhibitors.40 While some showed promising results, it is unlikely that these interventions 
will be potent or targeted enough to completely reverse persistent immune system 
dysfunction and inflammation. Development of a prolonged successful intervention 
requires an integrated view of the immunological changes in chronic HIV.
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The Human Functional Genomics Project (HFGP) was established to disentangle 
interindividual variation in human immune responses in healthy and patient populations 
(including individuals with HIV), by combining clinical, immunological and multi-omics 
data.41 In healthy individuals, the HFGP already provided an integrated understanding42 
of the effects of host and environmental factors,34 genetic factors,43 and the microbiome44 
on immune responses and cell  populations in the peripheral blood. 45 Because of these 
reasons we postulated that the HFGP would provide an excellent basis and study 
framework to explore the underlying mechanisms of the derailed inflammatory balance 
in chronic HIV.
Objectives and outline of part 2
Despite suppressive ART, immune dysfunction and inflammation persist to varying 
degrees, predisposing individuals to non-AIDS related comorbidities. Part 2 of this 
thesis comprehensively describes the immunological changes in long-term treated HIV, 
by embedding a cohort of long-term treated individuals with HIV in the HFGP. 
We specifically aimed to get a better understanding into the:
     •    Peripheral blood immune cell composition and its determinants in long-term 
treated stable HIV
     •    Functional capacity of innate and adaptive immune cells in long-term treated 
stable HIV
Chapter 6 presents an extensive overview of peripheral blood immune cells populations 
in virally suppressed PLHIV, including clinical (demographic factors and lifestyle, 
CMV, inflammation) and virological (markers of the HIV-1 reservoir) determinants and 
consequences for T-cell derived cytokine production capacity. 
In chapter 7, we used an integrative approach of functional and transcriptional analyses 
to assess the functional capacity of innate immune cells, followed by analysis of the 
contribution of microbial translocation, CMV seropositivity, and the HIV reservoir. 
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The non-nucleoside reverse transcriptase inhibitor efavirenz is part of the WHO 
guidelines for preferred first-line treatment of HIV-1-infected adults, pregnant and 
lactating women, and children. Efavirenz is well known to cause CNS toxicity. Although 
good data for CNS toxicity are available for adults, the opposite is true for children. 
Pediatric studies on this topic frequently suffer from small sample sizes or absence 
of thorough neuropsychiatric assessments. In this Personal View, we focus on two 
knowledge gaps of CNS toxicity of efavirenz in children. First, plasma concentrations of 
efavirenz are difficult to predict in children because of immaturity of and genetic variation 
in metabolic enzymes. Second, efavirenz exerts a lysergide (LSD)-like effect on brain 
serotonergic pathways and affects CNS metabolic pathways, including mitochondrial 
function. Whether these effects interfere with normal brain development is unknown. 
These uncertainties underline the imminent need for better monitoring of mental health 
and neurocognitive development in children given and exposed to efavirenz.
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INTRODUCTION
At the end of 2013, an estimated 3.2 million children were living with HIV, most of them 
in sub-Saharan Africa. Increased access to antiretroviral therapy (ART) over the past 
decade has substantially improved their life expectancy1. WHO guidelines recommend 
the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz as a preferred first-
line antiretroviral drug for the treatment of ART-naive, HIV-1-infected adults, pregnant 
and lactating women, and children2. Efavirenz owes this position to its excellent antiviral 
potency with proven long-term efficacy data, its once daily dosing, and its potential to be 
co-administered with anti-tuberculosis medication. A generic version of efavirenz also 
became available3. 
Although efavirenz is the standard of care, it is not well tolerated by all. Several side-
effects have been described, including skin rash, hepatotoxicity, and lipid disturbances4. 
Yet, the main adverse effects of efavirenz are caused by its CNS toxicity, resulting in 
neuropsychiatric symptoms in a substantial proportion of patients5. Although efavirenz 
could save the lives of millions of HIV-infected children, its neurotoxic effects could also 
have major negative effects on these children and their future. In this Personal View, 
we elaborate on the potential consequences of efavirenz for mental health and brain 
development in children, at a time when pediatric use of efavirenz is being expanded. 
We hereby focus on important pharmacokinetic and pharmacodynamic knowledge gaps 
and aim to increase awareness among clinicians and policy makers concerning potential 
CNS toxicity of efavirenz in children.
EFAVIRENZ-RELATED CNS SIDE-EFFECTS IN 
ADULTS AND CHILDREN
Neuropsychiatric symptoms occur in almost 30% of adult patients taking efavirenz, with 
symptoms ranging from impaired concentration and sleep disturbances to depression, 
anxiety, and hallucinations5. Intriguingly, reports have emerged concerning the 
recreational use of efavirenz for its psychoactive effects by both HIV-infected patients 
and non-infected peers6,7. Furthermore, a recent meta-analysis, combining data from 
four randomized controlled trials, showed a two-fold increase of suicidality among 
efavirenz-treated individuals8. These findings were, however, not replicated in a large 
observational cohort study9. Apart from neuropsychiatric symptoms, there is some 
evidence that efavirenz might worsen neurocognitive function. For example, efavirenz 
has been associated with less overall improvement of neurocognitive functioning in 
patients commencing ART, and with increased risks for neurocognitive impairment in 
patients on long-term treatment10-13. Patients usually habituate to the neuropsychiatric 
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side-effects after several weeks of treatment, partly due to auto-induction of efavirenz 
metabolism14. However, recent studies indicate that CNS side-effects can persist for 
years10,15,16, impairing quality of life and increasing the risk for non-adherence and treatment 
discontinuation. Indeed, both early and late treatment discontinuation are more likely 
for efavirenz than for several other ART regimens. The largest differences in treatment 
discontinuation have been observed when comparing efavirenz with dolutegravir 
(relative risk [RR] 4.3, 95% CI 2.2–8.3), maraviroc (3.3, 1.9–5.7), and raltegravir (2.7, 1.1–6.9)5. 
These findings are worrisome, taking into account the obvious consequences for drug 
resistance, disease progression, and HIV transmission. Because of concerns about the 
tolerability of efavirenz, the most recent version of the US adult and adolescent ART 
guidelines no longer advise efavirenz as part of the preferred first-line regimen17. 
It has been suggested that children tolerate efavirenz better than adults do, with 
rash, dizziness, and gastrointestinal symptoms as the most frequently reported side-
effects18,19. Important CNS symptoms were relatively uncommon in different studies in 
children19-22. It is possible that children do not experience the same CNS side-effects 
as adult patients, because there are many examples of differential predisposition to 
drug side-effects—e.g., hypersensitivity reactions. On the other hand, pediatric studies 
on this subject are hampered by small sample sizes, short follow-up periods, and 
absence of thorough neuropsychiatric assessments. Particularly in young children and in 
resource-poor settings, neuropsychiatric assessment can be very challenging. Moreover, 
neuropsychiatric symptoms can often be attributed to emotional and physical challenges 
related to living with HIV/AIDS. As a result, it can be expected that CNS side-effects 
of efavirenz in children are easily overlooked. Moreover, even minor CNS toxicity at 
an early age can be very problematic in the long term—e.g., in school-aged children, 
for whom mild neuropsychiatric symptoms, such as sleep problems and concentration 
disturbances, can have major consequences for school performance.
Although there is increasing awareness of the CNS side-effects of efavirenz in adults, the 
opposite seems true for children. For example, WHO recently increased the efavirenz 
doses for children, after concerns about subtherapeutic plasma concentrations and 
simplification of the dosing regimens by removal of 50 mg capsules2. As a consequence, 
more than a third of children will be exposed to potentially toxic concentrations of 
efavirenz (>4.0 mg/L)23. Efavirenz is now approved for use in children as young as 3 
months by the US Food and Drug Administration and the European Medicines Agency, 
as well as for pregnant women by WHO. Although the latter might be justified by a 
recent meta-analysis showing rather small risks of teratogenicity5, one could also argue 
that maternal CNS symptoms, such as anxiety and depression, which are common side-
effects of efavirenz, could already have negative consequences for the development 
of the fetus24,25. Additionally, efavirenz crosses the placenta and passes into breastmilk 
and is therefore present in the blood of fetuses and breast fed infants26,27. Although 
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fetal exposure to efavirenz has no apparent effects on gross brain anatomy, large-scale 
studies examining more subtle effects on brain function and neurodevelopment are 
lacking. Different pharmacokinetic and dynamic aspects of efavirenz in children need 
to be considered.
PHARMACOKINETIC ASPECTS OF EFAVIRENZ IN 
CHILDREN
The risk for CNS toxicity is closely related to plasma concentrations of efavirenz28. 
Efavirenz has a narrow therapeutic window with a large interindividual pharmacokinetic 
variability29. Target plasma concentrations of efavirenz in children are extrapolated from 
adults and range from 1.0 mg/L to 4.0 mg/L30. Earlier studies showed that only half (47–
66%) of efavirenz-treated children in sub-Saharan Africa achieved plasma concentrations 
within this therapeutic range (figure 1)23,31-33. It is likely that the proportion of children with 
subtherapeutic drug concentrations has declined after the increased dose regimens of 
efavirenz in the 2013 WHO guidelines, but inevitably, this has increased the number of 
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Figure 1. Subpopulations of AUC 0–24 efavirenz within the ARROW PK sub study
Figure adapted from Fillekes and colleagues23. The trimodal distribution of efavirenz AUC among 41 
HIV-infected Ugandan children shows the division between normal metabolizers (low), intermediate 
metabolizers (medium), and poor metabolizers (high).
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Several factors could contribute to variation in plasma concentrations of efavirenz 
in children. Besides adherence issues that come along with long-term pediatric HIV 
treatment, variations in drug formulations should be taken into acount33. Previous studies 
have shown that in infants and young children, the bioavailability of liquid formulations 
reaches only 46% of solid formulations, requiring liquid doses that are at least 150% of 
the tablet dose34,35. In the blood, efavirenz is highly bound to plasma proteins—mainly, 
albumin36. Malnutrition, which is still a common problem in sub-Saharan Africa, might 
reduce exposure to efavirenz, by decreasing albumin concentrations leading to higher 
free fraction drug concentrations available for clearance37. Next, differences in the 
metabolism of efavirenz could be relevant for the interindividual variation in plasma 
concentrations of efavirenz34,38. Cytochrome P450–2B6 (CYP2B6) and to a lesser 
extent cytochrome P450–3A4 (CYP3A4) metabolize efavirenz to its primary metabolite 
8-hydroxy-efavirenz36. These enzymes are mainly expressed in the liver and their activity 
varies greatly with age34,39,40. The expression of CYP2B6 is low in the neonate and 
increases to adult levels only after infancy, making plasma concentrations among young 
children difficult to predict39. The polymorphic nature of CYP2B6 further complicates 
dosing advices, whereby the CYP2B6 516 G→T, 785 A→G, and 983 T→C variants 
have been specifically associated with changes in plasma concentrations of efavirenz33. 
For example, adults and children with the CYP2B6 516 T/T genotype, so-called poor 
metabolizers, have higher plasma concentrations of efavirenz and report more CNS 
side-effects of efavirenz than do carriers of the G allele28,40. This 516G→T allelic variant 
is present in only 25.5% of the Caucasian population, but in up to 48.8% of people with 
African ancestry41. Current guidelines are only weight based and do not take enzyme 
maturation, nutritional status, and genetics into account. As a result, dosing might often 
be inappropriate, especially in infants and young children in sub-Saharan Africa, where 
the HIV epidemic has developed most substantially in recent decades.
PHARMACODYNAMIC ASPECTS OF EFAVIRENZ 
IN CHILDREN
The exact pharmacodynamic mechanisms that mediate the CNS toxicity of efavirenz 
remain to be elucidated. It is known that both efavirenz and its metabolite 8-hydroxy-
efavirenz easily penetrate the blood–brain barrier and enter the CNS42. At least two 
main hypotheses on the mechanisms of efavirenz and 8-hydroxy-efavirenz neuronal 
toxicity can be derived from the current literature (figure 2).
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Figure 2. Schematic representation of different potential pharmacodynamic 
mechanisms of efavirenz-induced neuroplastic changes 
(A) Efavirenz interferes with brain energy metabolism and leads to mitochondrial dysfunction in both 
neurons and glial cells43,44. (B) Efavirenz induces the production of the pro-inflammatory cytokines 
interleukin 1β and TNFα and reduces the production of the anti-inflammatory cytokine interleukin 10 in 
stimulated blood samples45 and could possibly result in CNS symptoms—possibly through interaction 
with glial cells, that serve both as source and target of cytokines in the CNS46. (C) Efavirenz exerts a 
weak lysergide (LSD)-like effect on the serotonin 5-HT 2A receptors47. TNFα = tumor necrosis factor α.
In-vitro and animal studies have shown that both components are able to interfere with 
neuronal bioenergetics, as manifested by neuronal mitochondriopathy, the reduction of 
brain creatine kinase, and the generation of amyloid β (a peptide known to be involved in 
the development of Alzheimer’s disease)44,48-50. Neuronal energy impairment and severe 
oxidative stress have been linked to neuronal degeneration and the development of 
HIV-associated dementia51,52. Impaired mitochondrial function in neurons also reduces 
neuronal differentiation and maturation, which are of crucial relevance for the developing 
brain in children53. 
Second, animal and human data support the hypothesis that efavirenz itself acts directly 
upon different neurotransmitter systems, through binding with catecholamine and 
indolamine transporters, and GABAA and serotonin (5-HT 2A) receptors47. Efavirenz 
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also potentially interacts with the cannabinoid system, as suggested by efavirenz-
induced selective cytotoxicity of tumor cells expressing the cannabinoid receptor 
type 1 (CB1)54. In-vivo experiments in rodents showed that efavirenz predominantly 
functions as an agonist of 5-HT 2A receptor, similar to lysergide (LSD) and other related 
hallucinogens47. Correspondingly, human data show that co-administration of the 5-HT 
receptor antagonist cyproheptadine prevents CNS side-effects of efavirenz55. 5-HT 
disturbances have been associated with mood and sleep disorders, which are among 
the most important CNS side-effects of efavirenz43,56. 
Importantly, 5-HT exerts neurotrophic actions during brain development57. For example, 
5-HT affects proliferation, differentiation, and migration of neurons, thereby regulating 
the formation of neural circuits throughout the developing brain58,59. Serotonergic drugs 
can therefore cause harmful effects in children and adolescents60, which is illustrated 
by an increased risk of suicide in adolescents given serotonergic anti-depressants 
(serotonin reuptake inhibitors [SSRIs])61,62. Additionally, antenatal exposure to SSRIs has 
been found to reduce social behavior, increase anxiety and the risk for autism, and 
delay psychomotor development in offspring, in both human and animal studies63-65. 
Exposure to efavirenz during pregnancy or childhood could thus have substantial 
consequences for neurodevelopment because of its 5-HT receptor binding properties. 
Besides the observed effects of efavirenz on mitochondrial function, neurotransmission, 
and our hypothesized neurodevelopmental effects, several other mechanisms have 
been suggested to play a part in efavirenz neurotoxicity. For example, disruption of 
neuronal calcium homoeostasis and induction of pro-inflammatory cytokines have been 
implicated in efavirenz-induced neuroplastic changes45,49,66. It is unknown to what extent 
these processes affect the developing brain.
CONCLUSIONS AND RECOMMENDATIONS
Since the introduction of ART, HIV has become a chronic disease and many children 
survive into adulthood. Treatment should therefore not only involve short-term 
morbidity and mortality, but also focus on quality of life. Mental health and psychosocial 
development are crucial issues in this respect. It is well known that neuropsychiatric 
symptoms are common in HIV-infected children and that, despite ART, the cognitive 
performance of HIV-infected children remains poor compared with healthy matched 
controls67,68. Several factors play a part, including neurotoxicity of HIV and chronic 
immune activation by HIV69,70. Further deterioration caused by potentially preventable 
side-effects of ART should be avoided.
In 2013, an estimated 740 000 children and 966 000 pregnant women living with HIV 
in low-income and middle-income countries received antiretroviral drugs71. Since the 
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WHO guidelines recommend efavirenz-based regimens as a first-line treatment, the 
total potential exposure of efavirenz in fetuses and children is substantial. This creates 
a difficult situation: saving as many lives as possible through the rapid roll out of an 
effective and uniform treatment versus the potential long-term neuropsychiatric and 
neurodevelopmental adverse effects of such an approach.
Several strategies have been proposed to counter the treatment challenges of efavirenz, 
including therapeutic drug monitoring and dose adjustments based on pretreatment 
CYP2B6 genotyping, the latter being particularly relevant for the youngest children72,73. 
Additionally, short-cycle therapy could serve as a safe alternative for HIV-1-infected 
adolescents, offering a drug-free weekend, less toxicity, and improved adherence74. 
Some experts suggest to completely abandon efavirenz as a first-line therapy, because 
six antiretroviral drug classes are currently available, including the more expensive 
integrase inhibitors, with potentially improved safety profiles75. On the other hand, data 
for long-term safety in children are only available for nevirapine and protease inhibitors, 
drugs that have their limitations as well. Therefore, we propose a different approach. 
First, to counter underdiagnosis of neuropsychiatric and neurodevelopmental side-
effects, screening in daily practice must be made a high priority for children given 
efavirenz and it must be closely linked to adequate care. Effective screening requires 
proper use, and if necessary, further development of validated and culturally adapted 
screening instruments that can be given in everyday care. The Strength and Difficulties 
Questionnaire is an example of such an instrument for the assessment of child behavior 
that has been translated into many languages, is easy to administer, and culturally 
neutral76. Second, increased insight in the neurodevelopmental and neuropsychiatric 
consequences of pediatric and in-utero efavirenz exposure is urgently needed. Third, 
long-term studies in children, comparing newer, promising treatment strategies (e.g., 
raltegravir and dolutegravir) on their safety are needed to develop evidence-based 
treatment guidelines. Until then, efavirenz should be monitored carefully in children and 
pregnant women.
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Recently, Murnane et al reported on the long-term safety and efficacy of switching from 
ritonavir-boosted lopinavir (LPV/r) to efavirenz (EFV) among virologically suppressed 
human immunodeficiency virus (HIV)–infected children in South Africa who were 
previously exposed to nevirapine1. Over 4 years of follow-up, they observed comparable 
virologic control (<1000 copies/mL), improved lipid profiles, slightly higher CD4 cell 
counts, and increased caretaker-reported adherence, in children randomized to 
EFV compared with those remaining on LPV/r. Given their findings and several other 
advantages of EFV (improved palatability, simplified co-treatment for tuberculosis, and 
preservation of second-line options), the authors support the current World Health 
Organization (WHO) recommendation of switching clinically stable children ≥3 years old 
to EFV.
Unfortunately, Murnane et al did not assess neuropsychiatric symptoms and 
neurocognitive function in their cohort. Central nervous system (CNS) symptoms are 
among EFV’s most notorious side effects in adults. Reported symptoms range from 
sleep disturbances to depression, anxiety, and cognitive problems, and may persist 
during long-term treatment2. In addition, in vitro and animal studies suggest that EFV 
impairs brain energy metabolism and exerts a weak lysergide-like effect on the serotonin 
2a (5HT2A) receptor2,3. In part due to the pervasive evidence of EFV-related CNS 
toxicity, the most recent adult European AIDS Clinical Society and US Department of 
Health and Human Services guidelines no longer recommend including EFV in first-line 
antiretroviral therapy regimens4,5.
In children, reliable data on CNS side effects remain scarce and inconclusive, and 
the impact of chronic EFV exposure on brain development remains unknown. As we 
recently demonstrated, currently available pediatric studies are hampered by small 
sample sizes, short follow-up periods, and a lack of validated neuropsychiatric tools6. 
While the exact rate of CNS toxicity in children remains to be determined, several 
reports have described severe side effects including psychosis, cerebellar ataxia, and 
seizures7-9. In most cases, these side effects were linked to polymorphisms in cytochrome 
P450 (CYP) 2B6, which cause impaired EFV clearance and toxic EFV plasma levels. 
Murnane et al did report that 2 children in the EFV group developed seizures and that 
these children had high EFV plasma levels and CYP2B6 polymorphisms. Their findings 
highlight the need for examination of other potential, subtler, CNS side effects and long-
term neurodevelopmental effects of EFV.
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In 2016, 2.1 million children were living with HIV worldwide10. Thanks to significant 
progress in pediatric HIV treatment, this generation has a good chance of reaching 
adulthood. It is therefore essential that researchers, policy makers, and healthcare 
workers focus beyond the goal of prolonging life. Murnane et al note that they intend 
to continue following their cohort to evaluate for longer-term outcomes. We believe 
that their study cohort, which combines a randomized design with a real-life clinical 
setting, offers an unique opportunity to examine the long-term CNS toxicity of EFV in 
the pediatric population. Until more data on CNS toxicity in children become available, 
safety conclusions about pediatric EFV treatment should be drawn with caution.
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Efavirenz is commonly prescribed for children with HIV infection, yet little is known 
about risks of neuropsychiatric side-effects. We aimed to compare competence (social 
involvement, activities, and school performance) and psychopathology (internalizing and 
externalizing problems), cognitive performance (intelligence and working memory), and 
adherence in Tanzanian children on an efavirenz-based versus a non-efavirenz-based 
regimen.
Methods 
In this multicenter, cross-sectional, observational study, we included consecutive 
children (aged 6–12 years) with HIV infection, on combination antiretroviral therapy 
(cART) for at least 6 months, and with viral loads of less than 1000 copies per mL from 
HIV care clinics of three primary health facilities and three referral hospitals in Moshi, 
Kilimanjaro, Tanzania. Children with acute illnesses, medication switch in the 6 months 
before the study visit, and any history of brain injury or developmental delay before 
cART initiation were excluded. All interviews and assessments were done by trained 
local research nurses under the supervision of a medical doctor. The primary outcomes, 
competence and psychopathology, were measured with the Child Behavior Checklist. 
We used ANCOVA to assess differences between groups. This study is registered with 
ClinicalTrials.gov, number NCT03227653.
Findings 
Between June 19, 2017, and Dec 14, 2017, 141 children were analyzed, of whom 72 (51%) 
used efavirenz-based cART and 69 (49%) used non-efavirenz-based cART. After 
controlling for age, sex, and clinical and demographic confounders, we observed lower 
competence (adjusted mean difference −2.43 [95% CI −4.19 to −0.67], p=0.0071), largely 
driven by lower school performance scores (adjusted mean difference −0.91 [–1.42 to 
−0.40], p=0.00055), in the efavirenz group than in the non-efavirenz group. More 
total (adjusted mean difference 5.96 [95% CI −1.12 to 13.04], p=0.098) and internalizing 
(adjusted mean difference 2.00 [–0.29 to 4.29], p=0.086) behavioral problems were seen 
in the efavirenz group than in the non-efavirenz group, although these findings were 
non-significant. No differences were found in externalizing problems (adjusted mean 
difference 0.78 [95% CI −1.55 to 3.11], p=0.51).
Interpretation 
Our results suggest that treatment with efavirenz in children is associated with a mild 
increase in neuropsychiatric symptoms, especially in children who receive doses higher 
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than or equal to the WHO recommended doses for efavirenz. Clinical awareness 
and adequate follow-up of neuropsychiatric symptoms in efavirenz in children remain 
warranted.
Keywords 
efavirenz, ART therapy, child, adverse effects, Africa South of the Sahara, central nervous 




In 2017, an estimated 1.8 million children worldwide were living with HIV, of whom 
52% received combination antiretroviral therapy (cART)1. The Tanzanian national HIV 
guidelines recommend including efavirenz in first-line cART for children aged 3 years 
or older2,3. In children, efavirenz has several advantages compared with its alternatives 
nevirapine and ritonavir-boosted lopinavir, including superior antiviral efficacy, 
simplified co-treatment for tuberculosis, and lower risks for long-term metabolic and 
bone complications4. Among adults on efavirenz, a third reports neuropsychiatric side-
effects such as nightmares, depression, and hallucinations5. Although most of these 
symptoms decrease after weeks to months, some can persist for years, with negative 
consequences for quality of life, adherence, and treatment discontinuation6,7. Apart 
from neuropsychiatric symptoms, efavirenz has been linked to impaired neurocognitive 
performance8. In part because of these tolerability concerns, the latest WHO guidelines9 
no longer recommend efavirenz as the general drug of choice for people with HIV 
infection.
Although children generally seem to tolerate efavirenz well, data about neuropsychiatric 
side-effects remain inconclusive10,11. Until now, only one clinical trial had published 
psychiatric data about children on efavirenz. By use of a brief behavioral screener, the 
Strengths and Difficulties Questionnaire (SDQ), the authors observed no differences 
in psychopathology between efavirenz and ritonavir-boosted lopinavir12,13. By contrast, 
other studies14,15 reported high frequencies (36–39%) of neuropsychiatric symptoms. 
Several case reports14,16,17 also described the occurrence of severe symptoms, including 
psychosis, ataxia, and seizures. These discrepancies between studies might be partly 
explained by the large heterogeneity between cohorts, small sample sizes, or lack of 
validated tools for comprehensive pediatric psychiatric assessments11. Potential long-
term neuropsychiatric side-effects need to be identified because these symptoms 
might interfere with neurodevelopment and psychosocial maturation. In our study, we 
aimed to comprehensively assess behavior and cognition in children with HIV infection 
in Tanzania by use of validated psychiatric tools. Our primary goal was to compare 
competence and psychopathology between children treated with efavirenz-based 
cART and children treated with alternative, non-efavirenz-based cART (nevirapine or 
ritonavir-boosted lopinavir). Second, we aimed to compare cognitive performance and 
adherence between treatment groups. We hypothesized that treatment with efavirenz 
would be associated with lower competence, more psychopathology, reduced cognitive 
performance, and lower adherence compared with alternative cART.
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METHODS
Study design and participants
In this multicenter, cross-sectional, observational study, we enrolled consecutive HIV-1-
positive children who were registered at the HIV clinics at Kilimanjaro Christian Medical 
Centre (a tertiary referral hospital), Mawenzi Regional Hospital (a referral hospital), 
Kibosho Hospital, Majengo Health Centre, Pasua Health Centre, and Kiboriloni 
Dispensary in Moshi District, Kilimanjaro Region, Tanzania. Inclusion criteria were age 
6–12 years, presence of a caretaker (parent or guardian who was part of the upbringing 
of the child), treatment with cART for at least 6 months, and an HIV-1 RNA count of less 
than 1000 copies per mL within 12 months of the study visit. Exclusion criteria were 
acute illnesses, medication switch in the 6 months before the study visit, and any history 
of brain injury or developmental delay before cART initiation.
The institutional review boards of the Kilimanjaro Christian Medical University College 
(Moshi, Kilimanjaro, Tanzania; number 2028) and the National Institute for Medical 
Research (Dar es Salaam, Tanzania; number 2447) approved the study protocol. Written 
informed consent in Kiswahili from parents or guardians of all participants was obtained 
before enrolment. Children aged 12 years provided oral assent.
Procedures
An overview of the study methods and procedures is provided in the appendix 
(p 87). Caretakers completed an extensive questionnaire on the demographic and 
socioeconomic status of the household, HIV disclosure, and the health status of the 
child. Clinical data, including HIV-1 RNA results, were obtained retrospectively from the 
child’s clinical file. We assessed nutrition using height and body-mass index for age-
adjusted Z scores (2007 WHO growth reference data for children and adolescents 
aged 5–19 years).
For behavioral assessments, we used the Child Behavior Checklist for ages 6–18 years 
(CBCL/6–18). The CBCL is a standardized 120-item questionnaire that provides a 
comprehensive caretaker report of a child’s competence, and behavioral and emotional 
problems18. The competence section of the CBCL includes questions on the child’s 
activities (sports, hobbies, and jobs), social involvement (organizations and friends), 
and school performance (grades and special classes). The problem section consists of 
syndrome scores that together yield an internalizing (anxiety or depression, withdrawn 
behavior, or somatic complaints) and externalizing (rule-breaking or aggressive behavior) 
problem score. The total problem score is the sum of all problem items. Four main 
scores can be calculated: total competence, total problems, internalizing problems, and 
externalizing problems. Raw scores were converted into age-specific, sex-specific, and 
(Kenyan) population-specific T scores to calculate the number of children within the 
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borderline clinical range18. The CBCL is available in Kiswahili and has been previously 
applied in HIV-positive children in sub-Saharan Africa19. 
We applied Raven’s Colored Progressive Matrices (RCPM) and the digit span test to 
assess cognitive performance. RCPM was used to measure general non-verbal cognitive 
ability. RCPM consists of 36 multiple-choice colored matrices in which items are 
ordered by increasing difficulty. RCPM is non-verbal, easy, and rapid to administer and 
score, and has been validated for use in children living in Kenya20. The digit span test 
(from the Wechsler Intelligence Scale for Children-III) was used to measure short-term 
and working memory21. A string of numbers was read out to the child, who was asked 
to repeat them in the same order (digit forwards) or reversed order (digit backwards). 
The test was discontinued if the child failed on two consecutive trials. The total score 
corresponds to the maximum number of digits the child repeated correctly. The digit 
span test has been used in HIV-positive children in sub-Saharan Africa22. 
For adherence, we used a questionnaire designed by the Pediatric European Network 
for Treatment of AIDS23. To determine non-adherence, caretakers were asked how 
many times the child had missed his or her medication in the previous 3 days. Next, 
caretakers marked adherence since the last clinical visit on a visual analogue scale. In 
addition, structured questions were asked about other aspects of cART adherence. 
Non-adherence was defined as one or more missed doses over the previous 3 days 
or marking less than 100% adherence since the last clinical visit on the visual analogue 
scale. 
Finally, we applied a CNS symptom checklist with symptoms that have been linked to 
efavirenz in the scientific literature7,11. Caretakers and children were asked whether the 
child had experienced any of these symptoms in the week before the study visit. 
Interviews and cognitive assessments were done by six local research nurses, who were 
experienced in pediatric HIV treatment and counselling. During a 1-week programme, 
a Dutch medical doctor (LVdW) and a Tanzanian paediatrician (DNM) trained the 
research nurses in conducting the interview and cognitive assessments. The research 
nurses were supervised by LVdW or DNM throughout the study period.
Before enrolment, children were screened by their own physician or the study doctor 
for acute illnesses and signs of gross developmental delay. The study visit consisted 
of two parts. To minimise information bias, caretakers were informed about the study 
background (CNS side-effects of HIV drugs) and procedures, without disclosing our 
hypothesis. After informed consent, a research nurse interviewed the caretaker and 
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child on adherence and general wellbeing. Next, a second research nurse interviewed 
the caretaker about demographic and clinical parameters, and read out the items of 
the CBCL, while the initial nurse continued with cognitive assessment of the child. To 
optimise cognitive test performance, all visits took place in quiet, private rooms and 
were completed before 1300 h. Data were stored securely and anonymously in the 
Castor Electronic Data Capture programme (Amsterdam, Netherlands).
Outcomes
Primary outcome measures were competence and psychopathology (internalizing and 
externalising symptoms), as defined by the CBCL. Secondary outcome measures were 
non-verbal cognitive ability, short-term and working memory, and non-adherence. Finally, 
we added CNS symptoms linked to efavirenz in the scientific literature as exploratory 
outcomes. The characteristics of the outcome variables of this study are presented in 
the appendix (p 76).
Data analysis
The study required 128 participants (64 participants per group) to detect a medium 
effect difference in CBCL total problem scores (Cohen’s f=0.25, equal to a difference of 
3.9 in CBCL total problem T scores), with 80% power and α set at 0.05. We compared 
general characteristics between the efavirenz group and non-efavirenz group using 
Student’s t test (or Mann-Whitney U test) for continuous variables and Pearson’s χ2 test 
(or Fisher’s exact test) for categorical variables. We used ANCOVA to assess between-
group differences in the raw main scores (total competence, total problems, internalizing 
problems, and externalising problems). Significant differences were assessed by post-
hoc ANCOVA for the individual competence or syndrome scores (e.g., anxiety or 
depression for internalizing problems). We assessed between-group differences in 
cognitive performance scores with ANCOVA and in non-adherence with Pearson’s χ2 
test. We analyzed the presence of CNS symptoms using logistic regression models. 
The following covariates were included because of group differences or their clinical 
relevance in disease severity and mental health: age, sex, parental loss, HIV disclosure, 
previous hospital admission, history of tuberculosis treatment, previous treatment 
failure, and cART duration. During data collection, we discovered that 28 (39%) of 71 
children received lower efavirenz doses than recommended by WHO3. Thereafter, 
we decided to add a subgroup analysis in which children who were prescribed lower 
efavirenz doses than recommended by WHO were excluded. We analyzed data using 
SPSS Statistics, version 25.
This study is registered with ClinicalTrials.gov, number NCT03227653.
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Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full access 
to all the data in the study and had final responsibility for the decision to submit for 
publication.
RESULTS
Between June 19, 2017, and Dec 14, 2017, 144 children were enrolled at the six study sites. 
Three children were excluded from analysis because of age less than 6 years, unreported 
severe developmental delay, and cART switch the week before the study visit (figure). 
141 children were analyzed, of whom 72 (51%) used efavirenz-based cART and 69 (49%) 
used non-efavirenz-based cART. Groups were balanced for age, sex, and nutritional 
status parameters (table 1). Socioeconomic characteristics did not differ between 
groups (appendix p 68). Children in the non-efavirenz group used cART for a longer 
time (p<0.0001), had a more advanced WHO clinical stage at start of cART (p=0.011), 
had more often experienced previous treatment failure (p<0.0001), and had more often 
been admitted to the hospital (p=0.0016) than children in the efavirenz group. Children 
in the efavirenz group more often had received tuberculosis treatment (p=0.022) and 
had more often had their own HIV status disclosed (p=0.016) than children in the non-
efavirenz group. In addition, we observed a non-significant higher prevalence of parental 
loss in the efavirenz group than in the non-efavirenz group (p=0.078). With the exception 
of co-trimoxazole (table 1), no relevant co-medication was used. At the time of analysis, 
none of the children was undergoing tuberculosis treatment. Ten (14%) of 69 children 
in the non-efavirenz group had previously discontinued efavirenz. Efavirenz had been 
switched to nevirapine in three (30%) of ten children or to ritonavir-boosted lopinavir in 
seven (70%) of ten children after a median of 407 days (IQR 179–975) for the following 
reasons: treatment failure (seven [70%] of ten children), neuropsychiatric side-effects 
(one [10%] of ten children), end of tuberculosis treatment (one [10%] of ten children), 
and unspecified (one [10%] of ten children)
53
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Figure 1 Study Flowchart
cART=combination antiretroviral therapy. *The efavirenz dose (mg/kg) could not be determined for 
one of the participants because of missing bodyweight data
Overall, 15 (22%) of 69 children in the non-efavirenz group and 21 (30%) of 71 children 
in the efavirenz group scored below the normal range for total competence (defined 
as scores below the 16th age-specific, sex-specific, and Kenyan population-specific 
percentile; appendix p 70). Table 2 shows the mean (SD) raw scores on the CBCL 
per treatment group, as well as the unadjusted and the confounder-adjusted models. 
In general, the covariates age and duration of cART had the largest effect on the 
confounder-adjusted models (appendix p 83). Children in the efavirenz group scored 
lower than children in the non-efavirenz group on the competence scale (adjusted mean 
difference -2.43 [95% CI -4.19 to -0.67], p=0.0071). Post-hoc analyses showed that these 
lower competence scores were primarily driven by lower school performance scores 
(adjusted mean difference -0.91[95% CI -1.42 to -0.40], p=0.00055).
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Age, years 9.4 (1.8) 9.9 (1.9) 0.094
Sex 0.61
Male 33 (48%) 31 (43%) ..
Female 36 (52%) 41 (57%) ..
WHO BMI z-score* -0.80 (1.09) -0.84 (1.03) 0.81
WHO height z-score* -1.00 (0.80) -1.16 (1.04) 0.33
HIV-RNA <40 copies per mL 54 (78%) 54 (75%) 0.69
Time since last HIV-RNA measurement, median (IQR) days 100 (56-168) 133 (57-198) 0.074
Vertical transmission 69 (100%) 72 (100%) ..
WHO clinical stage at start cART
Stage 1 10/68 (15%) 9/70 (13%) 0.011
Stage 2 16/68 (24%) 29/70 (41%)
Stage 3 21/68 (31%) 25/70 (36%)
Stage 4 21/68 (31%) 7/70 (10%)
Prior treatment failure† 23 (33%) 1 (1%) <0.0001
Time on cART, median (IQR) years 7.6 (5.4-8.7) 3.5 (2.1-5.6) <0.0001
Time on efavirenz, median (IQR) years .. 3.1 (2.0-5.1) ..
Prior efavirenz discontinuation 10 (14%) .. ..
cART backbone
abacavir + lamivudine 23 (33%) 17 (24%) 0.11
zidovudine + lamivudine 45 (65%) 52 (72%)
tenofovir disproxil fumarate + lamivudine 0 (0) 3 (4%)
zidovudine + abacavir + lamivudine 1 (1%) 0 (0)
cART 3rd drug
nevirapine 43 (62%) .. ..
lopinavir-ritonavir 26 (37%) ..
History of tuberculosis treatment 12 (17%) 25 (35%) 0.022
Co-trimoxazol treatment 33 (48%) 36 (50%) 0.95
Previous hospital admission‡ 53 (77%) 36 (50%) 0.0016
Caretaker’s relationship
Parent 49 (71%) 41 (57%) 0.36
Relative 16 (23%) 25 (35%)
Orphanage caretaker 2 (3%) 2 (3%)
Other 2 (3%) 4 (6%)
Parental loss
None (both alive) 44 (64%) 33 (46%) 0.078
Single 19 (28%) 26 (36%)
Double 6 (9%) 13 (18%)
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School attendance
Nursery school 8 (12%) 10 (14%) 0.50
Primary school 61 (88%) 60 (83%)
No school 0 (0) 2 (3%)
HIV-status disclosed 13 (19%) 27 (38%) 0.016
Data are mean (SD), n (%), median (IQR), or n/N (%). Data were analyzed with Student’s t test (or 
Mann-Whitney U test) for continuous variables and Pearson’s χ2 test (or Fisher’s exact) for categorical 
variables. cART=combination antiretroviral therapy.
* Z scores calculated using WHO 2007 growth reference data for children and adolescents aged 5–19 
years.
† Defined as any immunological, virological, or clinical failure documented in the medical file.
‡ Defined as any previous hospital admission reported by the caretaker or documented in the medical file.
Except for internalizing problems, psychopathology was relatively uncommon in our 
study population. Scores above the normal range (defined as scores above the 84th 
age-specific, sex-specific, and Kenyan population-specific percentile; appendix p 70) 
were seen in eight (12%) of 69 children in the non-efavirenz group versus nine (13%) of 
72 children in the efavirenz group for total problems, in 17 (25%) of 69 children versus 
22 (31%) of 72 children for internalizing problems, and in six (9%) of 69 children versus 
seven (10%) of 72 children for externalising problems. We observed non-significantly 
higher total problem scores (adjusted mean difference 5.96 [95% CI -1.12 to 13.04], 
p=0.098) and higher internalizing problem scores (adjusted mean difference 2.00 [–0.29 
to 4.29], p=0.086) in the efavirenz group than in the non-efavirenz group, but we found 
no differences in externalising problems (adjusted mean difference 0.78 [–1.55 to 3.11], 
p=0.51).
Using South African RCPM norm scores for children, which measure general non-verbal 
cognitive ability, four (6%) of 69 children in the non-efavirenz group and two (3%) of 
72 children in the efavirenz group scored below the 10th percentile (appendix p 71), 
indicating that non-verbal cognitive ability was largely unaffected in both groups. We 
found no group differences in general non-verbal cognitive ability, and we did not 
observe an effect of efavirenz on short-term memory or working memory (table 2). 
Non-adherence was reported by 24 (35%) of 69 children in the non-efavirenz group 
and 20 (28%) of 72 children in the efavirenz group (p=0.47; appendix p 72). Additional 
information on adherence is summarised in the appendix (p 72).
Finally, we explored the presence of CNS symptoms that have been linked to efavirenz 
in the scientific literature (table 3; appendix p 85). In accordance with the results from 
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the CBCL, children in the efavirenz group more frequently reported problems paying 
attention at school (19 [26%] of 72 children vs eight [12%] of 69 children), depressed 
or anxious feelings (17 [24%] of 72 children vs six [9%] of 69 children), and feelings of 
uneasiness (20 [28%] of 72 children vs 12 [17%] of 69 children) than did children in the 
non-efavirenz group (table 3). Abnormal dreaming was less frequently reported among 
children in the efavirenz group than among children in the non-efavirenz group (table 3).
When comparing the prescribed efavirenz dose with the dose recommended in the 
WHO 2016 guidelines,3 we observed that 40 (56%) of 71 children in the efavirenz group 
had been prescribed the recommended dose, with 28 (39%) of 71 children receiving 
lower doses and three (4%) of 71 children receiving higher doses than recommended 
(figure). Children in the low-dose efavirenz group did not differ from children in the 
recommended and high-dose efavirenz group in age (p=0.69), sex (p=0.22), or number of 
children with less than 40 copies of HIV RNA per mL (p=1.00; appendix p 73). To assess 
whether under-dosing of efavirenz had affected our results, we repeated our analyses 
after excluding children who were prescribed lower doses than recommended by WHO 
(appendix p 74). In line with our initial analyses, we observed lower competence scores 
in children in the efavirenz group (n=43) than in those in the non-efavirenz group (n=69; 
adjusted mean difference -2.55 [95% CI -4.56 to -0.55)], p=0.013) as well as lower school 
performance scores (adjusted mean difference -1.06[95% CI -1.61 to -0.50], p=0.00027; 
appendix p 74). In addition, children in the efavirenz group had higher total problem 
scores (adjusted mean difference 8.92 [95% CI 1.24–16.60], p=0.023) and internalizing 
problem scores (adjusted mean difference 3.11 [95% CI 0.60 to 5.63], p=0.016), but no 
difference in externalising problem scores (adjusted mean difference 0.82 [95% CI -1.70 
to 3.34], p=0.52) compared with children in the non-efavirenz group (appendix p 74). 
Post-hoc analyses of the individual internalizing syndromes showed that children in the 
efavirenz group had higher scores on anxious and depressed behaviors (adjusted mean 
difference 0.84 [95% CI -0.12 to 1.80], p=0.087), withdrawn behavior (adjusted mean 
difference 1.17 [–0.11 to 2.44], p=0.073), and somatic complaints (adjusted mean difference 
1.11 [–0.03 to 2.25], p=0.057) than children in the non-efavirenz group (appendix p 74), 
but these results were not significant. Finally, children in the efavirenz group scored 
higher for thought problems (adjusted mean difference 1.25 [95% CI 0.16–2.34], p=0.025) 
and attention problems (adjusted mean difference 1.60 [0.030 to 3.17], p=0.046) than 
did children in the non-efavirenz group (appendix p 74). Results for non-adherence 
(appendix p 72) and cognitive test performance (appendix p 74) did not change. Further 
exclusion of three children who were prescribed higher doses than recommended did 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this cross-sectional, observational study, we found that efavirenz-based cART was 
associated with lower total competence and school performance scores among long-
term treated Tanzanian children with HIV infection than was non-efavirenz-based cART. 
Higher total problem and internalizing problem scores were also observed in children 
in the efavirenz group than in those in the non-efavirenz group, although these results 
were not significant. We found no difference in cognitive performance and adherence 
between children on efavirenz and children on alternative cART. Except for externalising 
problems, the effects on problem scores became more pronounced after exclusion of 
children who received low efavirenz doses.
The most striking findings in our study were the lower competence and school 
performance scores in children on efavirenz than in children on alternative cART. 
Since groups were equally intelligent (RCPM), and short-term and working memory 
seemed unaffected (digit span), these factors cannot explain the differences in school 
performance. Hence, other factors, such as other neurocognitive problems or mood 
problems, might have played a part. For example, 19 (26%) of 72 children on efavirenz 
reported problems paying attention at school compared with eight (12%) of 69 children 
in the non-efavirenz group (table 3). Follow-up research into these attentional control 
networks (inhibiting irrelevant distractions, sustaining attention, dividing attention, and 
shifting attention) might be fruitful.
Second, our results suggest that children on efavirenz have increased psychopathology. 
We observed higher total and internalizing problems in children on efavirenz than in 
children on alternative cART, with internalizing problems being characterised by anxious 
and affective symptoms. The effects were more pronounced in an added subgroup 
analysis among children who were prescribed doses higher than or equal to WHO 
recommended doses. In addition, children on efavirenz more frequently reported 
symptoms of depression or anxiety and feelings of uneasiness (table 3). Our results 
differ from findings by Coovadia and colleagues,12,13 who reported no difference in 
psychopathology, defined by the SDQ, between South African children on efavirenz 
and children on ritonavir-boosted lopinavir. These differences could be partly explained 
by differences in age (with mean age 4.3 years in their population vs 9.6 years in our 
population), culture, and ethnicity. In addition, different psychiatric tools were used to 
define psychopathology. Both the SDQ and the CBCL are considered to be effective 
screeners for identification of child psychopathology24. The SDQ is shorter, does not 
have a section on school performance, and has slightly lower sensitivity compared 
with the CBCL24. Subtle, internalizing symptoms might have been overlooked with 
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the SDQ13. In adults on long-term efavirenz, internalizing problems, such as symptoms 
of depression, anxiety, and stress, also dominate the neuropsychiatric side-effect 
profile6,25. Overall, these symptoms seem to be more pronounced in adults than in 
children, with greater consequences for quality of life and treatment discontinuation11. 
It is possible that children, because of differential predisposition to drug side-effects, 
simply suffer less from CNS side-effects of efavirenz than do adults. However, 
caretakers generally consider internalizing problems less problematic because these 
problems are characterised by internal distress, rather than overtly socially negative 
or disruptive behavior. These features make internalizing problems difficult to detect, 
especially when relying on parent-based or caretaker-based reports, as is the case 
with our study. Finally, children on efavirenz less frequently reported signs of abnormal 
dreaming than did children on alternative cART (table 3), probably because all children 
from our study received efavirenz for 6 months or more, and this and similar problems 
are thought to resolve after the first weeks of treatment13. Importantly, the course of 
psychiatric symptoms in children is hard to predict, especially during crucial periods 
such as transition to adolescence and adulthood. For example, our group25 recently 
showed that depression scores were reduced in adolescents, but increased in adults, on 
efavirenz in Tanzania. The increasing evidence for higher risks of suicidality among adults 
on efavirenz than among adults on non-efavirenz-based cART emphasizes the need for 
clinical follow-up of neuropsychiatric symptoms in children on efavirenz26. Finally, in-vitro 
and animal studies have shown that efavirenz can interfere with cell energy homoeostasis 
and interact with the brain serotonin system27. Serotonin fulfils an important role for 
brain development, and exposure to serotonergic drugs (e.g., antidepressants of the 
class serotonin reuptake inhibitors) during childhood or pregnancy has been linked to 
behavioral and developmental problems28. Future studies are needed to assess long-
term developmental consequences of pediatric efavirenz.
Exclusion of children on suboptimal efavirenz doses increased group differences in 
behavioral and emotional problems. No specific indications for efavirenz dose reduction 
were recorded in the clinical files of these children. Moreover, we did not observe 
differences in general characteristics or viral suppression between children in the low-
dose efavirenz group and the recommended and high-dose efavirenz group. Efavirenz 
has a narrow therapeutic window, and a plasma concentration of less than 1000 ng/
mL has been consistently linked to virological failure and a plasma concentration of 
more than 4000 ng/mL has been linked to CNS toxicity29. In addition to drug dose, 
efavirenz exposure is determined by adherence, absorption, and metabolism7. Efavirenz 
is metabolized in the liver by cytochrome P450-2B6 (CYP2B6), and certain genetic 
variants of this enzyme have been strongly associated with higher plasma concentrations. 
These genetic variants are more common in sub-Saharan Africa (e.g., the 516G→T 
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substitution is prevalent in 48.8% of African ancestry)30. We did not measure plasma 
concentrations of efavirenz in our study, and the results from our subgroup analysis have 
to be interpreted with caution. Nevertheless, they might also support dose dependency 
of efavirenz-related neuropsychiatric symptoms.
The major strength of our study is that, by applying standardized validated pediatric 
psychiatric tools, we were able to comprehensively assess emotions, behaviors, and 
cognition in a substantially large, representative sample of school-aged children with 
HIV infection in sub-Saharan Africa. Different limitations should also be acknowledged. 
First, we did not measure efavirenz plasma concentrations or CD4 cell counts. Second, 
we cannot completely rule out effects of HIV on the brain in view of the finding that 
33 (23%) of 141 children had HIV RNA counts of 40–1000 copies per mL (table 1) and 
data about cumulative exposure and HIV RNA counts in the cerebrospinal fluid were 
unavailable. Third, no blinding was applied. Nevertheless, we consider it unlikely that 
the lack of blinding had an important confounding effect because assessments were 
highly standardized and followed the protocol strictly, and study nurses recorded 
scores without interpreting behavior. Finally, the cross-sectional observational design 
of our study comes with limitations, and no causal relationships can be identified. 
Groups differed for several clinical parameters, parental loss, and disclosure of HIV. 
Overall, the non-efavirenz group had a more severe clinical course, probably leading to 
underestimation of the effects of efavirenz in the crude models. Although we tried to 
correct for these clinical factors by adding them to our statistical models, we cannot rule 
out underestimation of the severity of the side-effect profile of efavirenz.
In conclusion, use of efavirenz in our pediatric cohort was associated with a mild increase 
in neuropsychiatric symptoms, especially in children who received doses higher than or 
equal to the WHO recommended doses for efavirenz. These findings, together with 
the pervasive evidence of efavirenz-related side-effects in adults and serotonergic 
properties of efavirenz, highlight the need for roll-out of pediatric formulations of 
alternative antiretroviral drugs. Until then, clinical awareness of neuropsychological 
symptoms remains warranted for children on efavirenz. This clinical awareness requires 
development of culturally adapted instruments and training of more mental health 
workers, especially in low-income settings, such as Tanzania. If symptoms are present 
in efavirenz-treated children, close follow-up is indicated. Referral for psychosocial 
support or switching to alternative cART should be considered if symptoms persist. 
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RESEARCH IN CONTEXT PANEL
Evidence before this study
Neuropsychiatric side-effects of efavirenz in adults with HIV infection are increasingly 
being acknowledged. Whether neuropsychiatric side-effects of efavirenz are also 
common in children remains unclear. To identify pediatric studies on neuropsychiatric 
side-effects of efavirenz, we searched PubMed on June 6, 2018, using the search terms 
“efavirenz” AND “children”, including relevant synonyms (see appendix p 67 for the 
extensive search strategy). The search was unrestricted by language or publication date 
and yielded 987 search results. After manual title and abstract screening, we selected 
158 pediatric studies evaluating clinical outcomes of efavirenz. Full-text screening 
of these papers and relevant references resulted in 39 relevant papers. Two studies 
used pediatric psychiatric assessment tools. One trial compared psychopathology 
between children receiving ritonavir-boosted lopinavir versus efavirenz and found no 
differences in emotional problem scores between groups using the 25-item Strengths 
and Difficulties Questionnaire (SDQ). Another observational study reported better 
SDQ scores in adolescents on efavirenz than in those on non-efavirenz-containing 
regimens. By contrast, five case reports described severe neuropsychiatric symptoms, 
including ataxia, psychotic symptoms, and seizures, during the course of efavirenz 
treatment, which were linked to high efavirenz plasma concentrations in three papers. 
The remaining 32 papers reported clinical observations of neuropsychiatric symptoms 
in trials and observational studies, without using psychiatric tools. These studies were 
largely inconclusive, with some showing prevalence of up to 39%.
Added value of this study
Using validated psychiatric tools, we present the first comprehensive psychiatric 
evaluation of children with HIV infection in sub-Saharan Africa on efavirenz. Our findings 
show an association between pediatric efavirenz and a mild increase in neuropsychiatric 
symptoms, especially in children on adequate or above recommended doses by WHO.
Implications of all the available evidence
WHO recommends efavirenz as a key component of pediatric HIV treatment. Our 
findings emphasize the need for further pediatric behavioral studies comparing efavirenz 
with alternative, newer drugs. Meanwhile, early detection and adequate follow-up of 
neuropsychological symptoms in efavirenz-treated children should be made a priority.
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SUPPLEMENTARY METHODS 
Research into context panel – Search strategy and list of included 
papers
Step 1   Database search
Database PubMed
Date  6-6-2018
Search terms  ((Efavirenz[TW] OR “efavirenz”[Supplementary Concept] OR “HIV-1 
reverse transcriptase inhibitor”[TW] OR “NNRTI”[TW] OR sustiva[TW] 
OR stocrin[TW] OR EFV[TW] OR EFZ[TW]) AND (children[TW] 
OR “adolescent”[TW] OR teenager[TW] OR teenagers[TW] OR 
baby[TW] OR babies[TW] OR adolescent[TW] OR adolescents[TW] 
OR adolescence[TW] OR toddler[TW] OR toddlers[TW] OR 
youngster[TW] OR youngsters[TW] OR “young people”[TW] OR 
youth[TW] OR youths[TW] OR juvenile[TW] OR juveniles[TW] OR 
newborn[TW] OR newborns[TW] OR “infant, newborn”[MeSH] OR 
“infant”[MeSH Terms] OR infant[TW] OR infants[TW] OR infantile[TW] 
OR “child”[TW] OR child[TW] OR neonate[TW] OR neonates[TW] 
OR pediatrics[TW] OR pediatric[TW] OR kid[TW] OR kids[TW] OR 
“pediatrics”[TW] OR pediatrics[TW]))
Yield  987 papers
Step 2   Title/abstract screening
Excluded No EFV (or no unspecified ART)
  No pediatric study
  No primary data or case report No clinical outcomes
Yield  158 papers
Step 3  Full text screening
Excluded No full text available
   No EFV treatment (or outcomes not specified for EFV) No data on 
CNS toxicity or adherence
Yield  39 papers + 5 relevant reviews/letters
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Caretaker’s age, mean (SD) years 44 (12) 44 (13) 0·98
Number of siblings, median (IQR) 2 (2) 2 (2) 0·90
Ethnicity
Chagga 39/69 (56·5) 34/71 (47·9) 0·53
Pare 4/69 (5·8) 10/71 (14·1)
Masai 1/69 (1·4) 2/71 (2·8)
Meru 2/69 (2·9) 2/71 (2·8)
Other 23/69 (33·3) 23/71 (32·4)
Religion
Christianity 56/69 (81·2) 59/72 (81·9) 1·00
Islam 13/69 (18·8) 13/72 (18·1)
Caretaker’s education
No education 2/69 (2·9) 3/72 (4·2) 0·35
Primary education 53/69 (76·8) 48/72 (66·7)
Secondary education 8/69 (11·6) 16/72 (22·2)
Tertiary education 6/69 (8·7) 5/72 (6·9)
Highest qualified profession caretaker
Agriculture 22/69 (31·9) 19/72 (26·4) 0·26
Laborer 21/69 (30·4) 23/72 (31·9)
House/home maker 0/69 (0·0) 4/72 (5·6)
Self-employed 22/69 (31·9) 22/72 (30·6)
Unemployed 4/69 (5·8) 2/72 (2·8)
Student 0/69 (0·0) 2/72 (2·8)
Highest food source
Purchase 50/67 (74·6) 50/70 (71·4) 0·88
Own source 15/67 (22·4) 18/70 (25·7)
Support relatives 2/67 (3·0) 2/70 (2·9)
Monthly income caretaker (Tshs)*
<100,000 34/67 (50·7) 35/69 (50·7) 0·85
100,000-500,000 22/67 (32·8) 20/69 (29·0)
>500,000 2/67 (3·0) 2/69 (2·9)
Refuses to answer or unknown 9/67 (13·4) 12/69 (17·4)
Place of residence
Town 23/69 (33·3) 32/72 (44·4) 0·23
Water availability
Infrequent 3/67 (4·5) 3/71 (4·2) 0·38
Weekly 0/67 (0·0) 1/71 (1·4)
69
Daily 1/67 (1·5) 5/71 (6·9)
Always 63/67 (94·0) 63/71 (87·5)
House type
Stone house 59/67 (88·1) 62/72 (86·1) 0·23
Mud house 6/67 (9·0) 10/72 (13·9)
Wooden house 2/67 (3·0) 0/72 (0·0)
House status
Dilapidated 1/67 (1·5) 3/72 (4·2) 0·53
Major repairs needed 19/67 (28·4) 15/72 (20·8)
Incompletely built 16/67 (23·9) 22/72 (30·6)
Minor or no repairs needed 31/67 (46·3) 32/72 (44·4)
Toilet type
Bush or none 0/67 (0·0) 1/72 (1·4) 0·58
Traditional pit 24/67 (35·8) 21/72 (29·6)
Modern pit 16/67 (23·9) 15/72 (20·8)
Flush 27/67 (40·3) 35/72 (48·6)
Livestock owned
None 27/67 (40·3) 28/72 (38·9) 0·47
<5 18/67 (26·9) 14/72 (19·7)
≥5 22/67 (32·8) 30/72 (42·3)
Data are depicted as n/N (%) unless stated otherwise. Data analyzed using student’s T-test (or Mann 
Whitney-U) for continuous variables and Pearson’s chi-square (or Fisher’s exact) for categorical var-











































































































































































































































































































































































































































































































































































































































































































































































































































































































Children below the normal South African cut-off 
scores
4/69 (5·8) 2/72 (2·8)
Children below the normal Kenyan cut-off scores 0/43 (0·0) 0/34 (0·0)
Children scoring below the 10th percentile of the age adjusted South African1 and Kenyan2 normative 
scores. Kenyan normative scores were only available until the age of 10 years and 3 months.
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Supplementary table 4. Adherence





Non-adherence* 24/69 (34·8) 20/72 (27·8) 0·47
Non-adherence excl. low-dose efavirenz† 24/69 (34·8) 10/43 (23·3) 0·21
Medication reminder 39/69 (56·5) 39/72 (54·2) 0·87
Person reminding
Parent 28/39 (71·8) 18/39 (46·2) 0·013
Relative 6/39 (15·4) 16/39 (41·0)
Orphanage caretaker 0/39 (0·0) 1/39 (2·6)
Other 3/39 (7·7) 1/39 (2·6)
Not specified 2/39 (5·1) 3/39 (7·7)
Interference medication with daily life
A lot 0/69 (0·0) 1/72 (1·4) 0·39
Quite a lot 6/69 (8·7) 3/72 (4·2)
Not much 12/69 (17·4) 9/72 (12·5)
Not at all 51/69 (73·9) 59/72 (81·9)
Way of interference with daily life‡
Time restrictions 0/18 (0·0) 1/13 (7·7) 0·46
Fatigue 4/18 (22·2) 6/13 (46·2)
Other physical complaints 4/18 (22·2) 2/13 (15·4)
Other 1/18 (5·6) 0/13 (0·0)
Not reported 9/18 (50·0) 4/13 (30·8)
Reason missed doses past 2 weeks
Run out of medication 3/69 (4·3) 1/72 (1·4) 0·63
Forgotten 4/69 (5·8) 6/72 (8·3)
Medication expired 0/69 (0·0) 1/72 (1·4)
Interference school hours, meals, sleep 1/69 (1·4) 0/72 (0·0)
Different routine from normal 0/69 (0·0) 1/72 (1·4)
Other 0/69 (0·0) 1/72 (1·4)
No missed doses past 2 weeks 61/69 (88·4) 62/72 (86·1)
Data depicted as n/N (%). Data analyzed using Pearson’s chi-square (or Fisher’s exact).
* Defined as ≥1 missed doses over the previous three days or marking <100% adherence since the last 
clinical visit on a visual analogue scale (VAS).1
†Non-adherence after exclusion children who received low doses of efavirenz
‡Percentage of children and caretakers who reported interference of medication with daily life.
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Age, years 10·1 (1·7) 9·9 (2·1) 0·69
Sex, male 15/28 (53·6) 16/43 (37·2) 0·22
HIV-RNA <40 copies per mL 21/28 (75·0) 32/43 (74·4) 1·00
Data are depicted as n/N (%) or mean (SD). Data analyses using Student’s t test for continuous varia-





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 9. Crude and adjusted models of the Child Behavior Checklist 
items and the neurocognitive scores
Item Model Variable B (95% CI) P-value
Total Competence Crude model Study group -0·12 (-1·49 to 1·25) 0·86
Adjusted model Study group -2·43 (-4·19 to -0·67) 0·0071
Age 0·54 (0·15 to 0·93) 0·0071
Sex -0·91 (-2·22 to 0·41) 0·17
HIV disclosure 1·36 (-0·19 to 2·91) 0·084
Lost one parent 0·92 (-0·53 to 2·38) 0·21
Lost both parents -1·77 (-3·74 to 0·19) 0·076
Prior treatment failure -1·78 (-3·80 to 0·24) 0·084
Prior hospital admission 0·24 (-1·21 to 1·69) 0·74
History of TB -0·91 (-2·46 to 0·63) 0·24
Time (years) on cART -0·52 (-0·83 to -0·2) 0·0015
Activities Crude model Study group 0·08 (-0·74 to 0·91) 0·84
Adjusted model Study group -0·90 (-2·01 to 0·21) 0·11
Age 0·29 (0·04 to 0·54) 0·021
Sex -0·33 (-1·16 to 0·50) 0·43
HIV disclosure 0·83 (-0·15 to 1·81) 0·096
Lost one parent 0·34 (-0·58 to 1·26) 0·47
Lost both parents -0·75 (-2·00 to 0·49) 0·23
Prior treatment failure -0·81 (-2·09 to 0·48) 0·22
Prior hospital admission 0·14 (-0·78 to 1·05) 0·77
History of TB -0·56 (-1·54 to 0·42) 0·26
Time (years) on cART -0·2 (-0·40 to 0·00) 0·048
Social Crude model Study group 0·38 (-0·26 to 1·02) 0·24
Adjusted model Study group -0·61 (-1·46 to 0·23) 0·15
Age 0·17 (-0·02 to 0·36) 0·074
Sex -0·64 (-1·27 to -0·01) 0·048
HIV disclosure 0·33 (-0·41 to 1·07) 0·38
Lost one parent 0·56 (-0·14 to 1·27) 0·11
Lost both parents -0·19 (-1·14 to 0·75) 0·69
Prior treatment failure -0·95 (-1·92 to 0·02) 0·056
Prior hospital admission 0·42 (-0·28 to 1·12) 0·24
History of TB -0·43 (-1·17 to 0·32) 0·26
Time (years) on cART -0·24 (-0·39 to -0·09) 0·0020
School Crude model Study group -0·59 (-0·97 to -0·22) 0·0022
Adjusted model Study group -0·91 (-1·42 to -0·40) 0·00055
Age 0·07 (-0·04 to 0·18) 0·24
Sex 0·05 (-0·33 to 0·43) 0·78
HIV disclosure 0·25 (-0·20 to 0·70) 0·27
Lost one parent 0·04 (-0·38 to 0·47) 0·84
79
Lost both parents -0·84 (-1·41 to -0·27) 0·0043
Prior treatment failure -0·01 (-0·59 to 0·58) 0·98
Prior hospital admission -0·31 (-0·73 to 0·11) 0·15
History of TB 0·05 (-0·40 to 0·50) 0·83
Time (years) on cART -0·07 (-0·16 to 0·02) 0·12
Total problems Crude model Study group 2·07 (-3·11 to 7·25) 0·43
Adjusted model Study group 5·96 (-1·12 to 13·04) 0·098
Age -2·01 (-3·58 to -0·44) 0·013
Sex 0·87 (-4·40 to 6·13) 0·74
HIV disclosure -1·66 (-7·89 to 4·57) 0·60
Lost one parent -0·33 (-6·19 to 5·52) 0·91
Lost both parents 10·89 (2·99 to 18·80) 0·0073
Prior treatment failure 4·22 (-3·93 to 12·37) 0·31
Prior hospital admission 2·83 (-2·99 to 8·64) 0·34
History of TB -0·39 (-6·62 to 5·85) 0·90
Time (years) on cART 0·45 (-0·81 to 1·72) 0·48
cART=combination antiretroviral therapy. TB=tuberculosis.
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Item Model Variable B (95% CI) P-value
Internalizing problems Crude model Study group 1·60 (-0·06 to 3·25) 0·058
Adjusted model Study group 2·00 (-0·29 to 4·29) 0·086
Age 0·04 (-0·46 to 0·55) 0·86
Sex 0·06 (-1·64 to 1·76) 0·95
HIV disclosure -1·52 (-3·54 to 0·49) 0·14
Lost one parent 0·24 (-1·66 to 2·13) 0·80
Lost both parents 2·66 (0·11 to 5·22) 0·041
Prior treatment failure 2·09 (-0·55 to 4·72) 0·12
Prior hospital admission 1·7 (-0·18 to 3·58) 0·075
History of TB 0·21 (-1·8 to 2·23) 0·83
Time (years) on cART -0·22 (-0·63 to 0·19) 0·28
Externalizing problems Crude model Study group -0·15 (-1·85 to 1·56) 0·87
Adjusted model Study group 0·78 (-1·55 to 3·11) 0·51
Age -0·79 (-1·31 to -0·28) 0·0029
Sex -0·22 (-1·95 to 1·51) 0·80
HIV disclosure 0·37 (-1·68 to 2·42) 0·72
Lost one parent -0·74 (-2·67 to 1·18) 0·45
Lost both parents 2·37 (-0·23 to 4·97) 0·074
Prior treatment failure 1·03 (-1·66 to 3·71) 0·45
Prior hospital admission -0·7 (-2·61 to 1·22) 0·47
History of TB 1·05 (-1·00 to 3·10) 0·31
Time (years) on cART 0·25 (-0·16 to 0·67) 0·23
Social problems Crude model Study group 0·08 (-0·79 to 0·96) 0·85
Adjusted model Study group 0·61 (-0·61 to 1·83) 0·32
Age -0·27 (-0·54 to 0·00) 0·053
Sex 0·20 (-0·71 to 1·11) 0·66
HIV disclosure 0·15 (-0·93 to 1·22) 0·79
Lost one parent -0·50 (-1·51 to 0·51) 0·33
Lost both parents 0·70 (-0·66 to 2·06) 0·31
Prior treatment failure -0·66 (-2·07 to 0·74) 0·35
Prior hospital admission 0·25 (-0·76 to 1·25) 0·63
History of TB -0·62 (-1·70 to 0·45) 0·25
Time (years) on cART 0·16 (-0·06 to 0·38) 0·15
Thought problems Crude model Study group 0·19 (-0·51 to 0·88) 0·60
Adjusted model Study group 0·81 (-0·16 to 1·78) 0·10
Age -0·16 (-0·37 to 0·06) 0·16
Sex 0·31 (-0·42 to 1·03) 0·40
HIV disclosure -0·25 (-1·11 to 0·60) 0·56
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Lost one parent 0·34 (-0·46 to 1·14) 0·40
Lost both parents 1·35 (0·27 to 2·44) 0·015
Prior treatment failure 0·51 (-0·60 to 1·63) 0·36
Prior hospital admission 0·17 (-0·62 to 0·97) 0·67
History of TB -0·54 (-1·39 to 0·32) 0·22
Time (years) on cART 0·12 (-0·05 to 0·29) 0·17
Attention problems Crude model Study group 0·11 (-0·93 to 1·14) 0·84
Adjusted model Study group 1·19 (-0·21 to 2·59) 0·096
Age -0·31 (-0·63 to 0·00) 0·048
Sex 0·16 (-0·89 to 1·20) 0·77
HIV disclosure -0·26 (-1·49 to 0·98) 0·68
Lost one parent -0·07 (-1·23 to 1·09) 0·91
Lost both parents 2·52 (0·96 to 4·09) 0·0018
Prior treatment failure 0·79 (-0·82 to 2·41) 0·33
Prior hospital admission 0·78 (-0·37 to 1·93) 0·18
History of TB -0·69 (-1·92 to 0·55) 0·27
Time (years) on cART 0·17 (-0·08 to 0·42) 0·17
cART=combination antiretroviral therapy. TB=tuberculosis.
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Item Model Variable B (95% CI) P-value
Raven’s Colored 
Progressive Matrices
Crude model Study group 2·33 (0·28 to 4·38) 0·026
Adjusted model Study group 1·29 (-1·36 to 3·93) 0·34
Age 1·33 (0·74 to 1·92) <0·0001
Sex -1·83 (-3·79 to 0·14) 0·068
HIV disclosure -0·57 (-2·9 to 1·75) 0·63
Lost one parent 0·47 (-1·71 to 2·66) 0·67
Lost both parents -0·45 (-3·40 to 2·50) 0·76
Prior treatment failure 0·09 (-2·95 to 3·13) 0·95
Prior hospital admission -0·51 (-2·68 to 1·66) 0·64
History of TB 2·10 (-0·23 to 4·42) 0·077
Time (years) on cART -0·02 (-0·49 to 0·45) 0·93
Digit Forwards Crude model Study group 0·51 (-0·26 to 1·27) 0·19
Adjusted model Study group 0·57 (-0·43 to 1·56) 0·26
Age 0·42 (0·20 to 0·64) 0·00023
Sex 0·51 (-0·23 to 1·25) 0·18
HIV disclosure 0·55 (-0·32 to 1·43) 0·21
Lost one parent -0·21 (-1·04 to 0·61) 0·61
Lost both parents -0·62 (-1·73 to 0·49) 0·27
Prior treatment failure -0·15 (-1·3 to 0·99) 0·80
Prior hospital admission 0·1 (-0·72 to 0·91) 0·82
History of TB 0·26 (-0·61 to 1·14) 0·55
Time (years) on cART 0·13 (-0·04 to 0·31) 0·14
Digit Backwards Crude model Study group 0·47 (-0·16 to 1·10) 0·15
Adjusted model Study group 0·46 (-0·34 to 1·26) 0·25
Age 0·43 (0·25 to 0·61) <0·0001
Sex 0·50 (-0·09 to 1·09) 0·098
HIV disclosure -0·08 (-0·79 to 0·62) 0·82
Lost one parent -0·16 (-0·82 to 0·5) 0·63
Lost both parents -0·86 (-1·75 to 0·03) 0·059
Prior treatment failure 0·25 (-0·67 to 1·17) 0·59
Prior hospital admission -0·27 (-0·93 to 0·38) 0·41
History of TB 0·43 (-0·27 to 1·13) 0·23
Time (years) on cART 0·07 (-0·07 to 0·21) 0·35
Depicted are crude models (incl. study group) and the final models (incl. study group and all covariates: 
age, sex, cART duration, prior treatment failure, prior admission, history of tuberculosis treatment, pa-
rental loss and HIV disclosure). P-values represent the p-values for the study group or the respective 
covariate. cART=combination antiretroviral therapy. TB=tuberculosis.
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Supplementary table 10. Crude, final and intermediate models for large mean 
differences
Dependent variable Model B (95% CI) P-value
Total competence Crude model -0·12 (-1·49 to 1·25) 0·86
Final model -2·43 (-4·19 to -0·67) 0·0071
excl. cART duration -1·01 (-2·60 to 0·57) 0·21
excl. age -1·67 (-3·39 to 0·04) 0·055
excl. prior treatment failure -1·95 (-3·63 to -0·27) 0·023
excl. lost one parent -2·24 (-3·98 to -0·51) 0·012
excl. sex -2·40 (-4·16 to -0·64) 0·0080
excl. prior admission -2·45 (-4·20 to -0·71) 0·0062
excl. HIV disclosure -2·47 (-4·24 to -0·70) 0·0067
excl. lost both parents -2·64 (-4·40 to -0·89) 0·0034
excl. history of tuberculosis -2·70 (-4·40 to -1.00) 0·0021
School performance Crude model -0·59 (-0·97 to -0·22) 0·0022
Final model -0·91 (-1·42 to -0·40) 0·00055
excl. cART duration -0·71 (-1·16 to -0·26) 0·0020
excl. age -0·82 (-1·30 to -0·33) 0·0011
excl. prior admission -0·88 (-1·39 to -0·37) 0·00082
excl. history of tuberculosis -0·90 (-1·39 to -0·41) 0·00041
excl. lost one parent -0·90 (-1·40 to -0·40) 0·00050
excl. prior treatment failure -0·91 (-1·39 to -0·43) 0·00028
excl. sex -0·91 (-1·42 to -0·41) 0·00051
excl. HIV disclosure -0·92 (-1·43 to -0·41) 0·00051
excl. lost both parents -1·01 (-1·53 to -0·49) 0·00018
Total problems Crude model 2·07 (-3·11 to 7·25) 0·43
Final model 5·96 (-1·12 to 13·04) 0·098
excl. age 3·15 (-3·72 to 10·02) 0·37
excl. cART duration 4·70 (-1·43 to 10·82) 0·13
excl. prior treatment failure 4·83 (-1·91 to 11·56) 0·16
excl. prior admission 5·67 (-1·38 to 12·72) 0·11
excl. history of tuberculosis 5·84 (-0·97 to 12·66) 0·092
excl. lost one parent 5·89 (-1·07 to 12·85) 0·096
excl. sex 5·92 (-1·13 to 12·97) 0·099
excl. HIV disclosure 6·01 (-1·05 to 13·06) 0·095
excl. lost both parents 7·25 (0·06 to 14·43) 0·048
Attention problems Crude model 0·11 (-0·93 to 1·14) 0·84
Final model 1·19 (-0·21 to 2·59) 0·096
excl. cART duration 0·71 (-0·51 to 1·93) 0·25
excl. age 0·75 (-0·60 to 2·10) 0·27
84
excl. prior treatment failure 0·98 (-0·36 to 2·31) 0·15
excl. history of tuberculosis 0·99 (-0·37 to 2·34) 0·15
excl. prior admission 1·11 (-0·29 to 2·51) 0·12
excl. lost one parent 1·18 (-0·20 to 2·55) 0·093
excl. sex 1·18 (-0·21 to 2·58) 0·096
excl. HIV disclosure 1·20 (-0·20 to 2·59) 0·092
excl. lost both parents 1·49 (0·05 to 2·92) 0·043
Depicted are crude models (incl. study group), the final models (incl. study group and all covariates: 
age, sex, cART duration, prior treatment failure, prior admission, history of tuberculosis treatment, 
parental loss and HIV disclosure), and intermediate models (incl. study group and all covariates minus 
the covariate of interest). P-values represent the p-values for study group in the different models.
85
Supplementary table 11. Crude, final and intermediate OR models for large ORs
Dependent variable Model OR (95% CI) P-value
Abnormal dreaming Crude model 0·54 (0·27 to 1·05) 0·071
Final model 0·32 (0·11 to 0·90) 0·031
excl. age 0·55 (0·22 to 1·38) 0·20
excl. cART duration 0·39 (0·16 to 0·94) 0·036
excl. history of tuberculosis 0·38 (0·14 to 1·04) 0·059
excl. sex 0·34 (0·12 to 0·95) 0·040
excl. prior admission 0·33 (0·12 to 0·93) 0·036
excl. HIV disclosure 0·32 (0·11 to 0·91) 0·032
excl. prior treatment failure 0·31 (0·11 to 0·86) 0·024
excl. lost one parent 0·31 (0·11 to 0·89) 0·029
excl. lost both parents 0·29 (0·10 to 0·84) 0·022
Feelings of uneasiness Crude model 1·83 (0·81 to 4·10) 0·14
Final model 3·45 (1·02 to 11·63) 0·046
excl. cART duration 2·38 (0·84 to 6·76) 0·10
excl. lost both parents 2·94 (0·92 to 9·47) 0·070
excl. lost one parent 3·04 (0·93 to 9·93) 0·065
excl. history of tuberculosis 3·23 (0·99 to 10·52) 0·051
excl. prior admission 3·26 (0·98 to 10·84) 0·054
excl. HIV disclosure 3·30 (1·00 to 10·90) 0·050
excl. prior treatment failure 3·34 (1·06 to 10·52) 0·039
excl. age 3·40 (1·07 to 10·84) 0·039
excl. sex 3·48 (1·04 to 11·68) 0·043
Depressed or anxious Crude model 3·25 (1·20 to 8·81) 0·021
Final model 6·98 (1·43 to 34·03) 0·016
excl. prior treatment failure 4·39 (1·15 to 16·70) 0·030
excl. prior admission 5·51 (1·16 to 26·29) 0·032
excl. lost one parent 5·70 (1·24 to 26·31) 0·026
excl. HIV disclosure 6·51 (1·36 to 31·10) 0·019
excl. sex 6·92 (1·44 to 33·25) 0·016
excl. age 7·00 (1·49 to 32·85) 0·014
excl. history of tuberculosis 7·27 (1·55 to 34·04) 0·012
excl. lost both parents 7·31 (1·52 to 35·17) 0·013
excl. cART duration 7·82 (1·79 to 34·10) 0·0062
Attention problems at school Crude model 2·73 (1·11 to 6·75) 0·029
Final model 6·92 (1·81 to 26·48) 0·0047
excl. cART duration 4·31 (1·31 to 14·24) 0·017
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excl. prior admission 6·14 (1·66 to 22·73) 0·0066
excl. history of tuberculosis 6·31 (1·74 to 22·93) 0·0051
excl. age 6·34 (1·72 to 23·28) 0·0054
excl. prior treatment failure 6·79 (1·92 to 24·03) 0·0030
excl. sex 6·92 (1·81 to 26·45) 0·0047
excl. lost one parent 7·12 (1·89 to 26·77) 0·0037
excl. HIV disclosure 7·21 (1·90 to 27·40) 0·0037
excl. lost both parents 8·27 (2·19 to 31·24) 0·0018
Depicted are crude models (incl. study group), the final models (incl. study group and all covariates: 
age, sex, cART duration, prior treatment failure, prior admission, history of tuberculosis treatment, 
parental loss and HIV disclosure), and intermediate models (incl. study group and all covariates minus 
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Supplementary figure 1. Study overview 
*Due to missing of body weight, the efavirenz dose (mg/kg) could not be determined for one of the 
participants. cART=combination antiretroviral therapy. EFV =efavirenz. WHO=World Health Organi-
zation. NVP=nevirapine. LPV/r=ritonavir-boosted lopinavir. RCPM=Raven’s Coloured Progressive Ma-
trices. PENTA=Pediatric European Network for the Treatment of AIDS. CNS=central nervous system. 
Adapted versions of the following icons were used in this figure: “Dizzy” by Gan Khoon Lay, “Check-
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Efavirenz is recommended as a preferred first-line drug for women of childbearing 
potential living with human immunodeficiency virus. Efavirenz is known for its central 
nervous system side effects, which are partly mediated by serotonergic actions. The 
neurotransmitter serotonin exerts neurotrophic effects during neurodevelopment and 
antenatal exposure to serotonergic agents has been linked to developmental delay. 
Although the teratogenic risks of efavirenz appear to be minimal, data on long-term 
developmental effects remain scarce. Here, we aimed to investigate the short- and long-
term behavioral and neurodevelopmental effects of perinatal efavirenz exposure. We 
treated pregnant rats from gestation day 1 until postnatal day 7 with efavirenz (100 mg/kg) 
or vehicle. We measured behavioral outcomes in male offspring during the first 3 postnatal 
weeks, adolescence and adulthood, and conducted brain immunohistochemistry 
analyses after sacrifice. Perinatal efavirenz exposure resulted in reduced body weight 
and delayed reflex and motor development. During adulthood, we observed a decrease 
in the total number of cells and mature neurons in the motor cortex, as well as an 
increase in the number of Caspase-3-positive cells and serotonergic fibers. Together, our 
data show a developmental delay and persistent changes in the brain motor cortex of 
rats exposed to efavirenz perinatally. Because over 1 million children born annually are 
exposed to antiretroviral therapy, our findings underline the need for clinical studies on 
long-term neurodevelopmental outcomes of perinatal exposure to efavirenz.
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INTRODUCTION
Every year, an estimated 1.4 million women living with human immunodeficiency virus 
(HIV) become pregnant. The use of antiretroviral therapy (ART) during pregnancy, 
delivery, and breastfeeding successfully reduces the risk of mother-to-child transmission 
of HIV to <5%1. The latest interim guidelines of the World Health Organization (WHO) 
recommend dolutegravir as the general drug of choice for people living with HIV2. 
However, due to concerns about neural tube defects among first-trimester dolutegravir 
exposures, efavirenz (EFV) remains the preferred option in women of childbearing 
potential during the periconception period3. Research on the safety of EFV during 
pregnancy has focused largely on infant health shortly after birth4. Although risks for 
gross teratogenicity seem to be minimal, research on long-term neurodevelopmental 
effects of perinatal exposure to EFV remains scarce5,6.
EFV passes through the placenta and is present in breast milk, resulting in detectable 
concentrations in the blood of fetuses and breast-fed infants7,8. After entry into the blood 
stream, both EFV and its primary metabolite 8-hydroxy-efavirenz (8-OH-EFV) readily 
penetrate the cerebrospinal fluid and target various cellular pathways within the central 
nervous system (CNS), predominantly the serotonergic system9-12. For example, EFV acts 
as a serotonin(5-HT)6 receptor inverse agonist, 5-HT2A, 5-HT2C, and 5-HT3A receptor 
antagonist, and a blocker of the 5-HT transporter (5-HTT)13. In rats, EFV preferentially 
binds to the 5-HT2A receptor14.
Importantly, 5-HT exerts neurotrophic functions during early development15,16. Increases 
in brain 5-HT levels, induced by genetic 5-HTT inactivation, have been shown to alter 
the serotonergic innervation of the prefrontal cortex17, migration of inhibitory neurons 
to the neocortex18, and maturation of the sensory cortex19. The latter has also been 
observed after pharmacological 5-HTT inhibition by prenatal selective serotonin 
reuptake inhibitor (SSRI) exposure18,20. Both genetic and pharmacological 5-HTT 
modulation during early development have been associated with a delay in reflex and 
motor development, disturbed sensorimotor gating, decreased social behavior, and 
anxiety and depression-like phenotypes21-25. Moreover, children perinatally exposed to 
SSRIs show reduced language and motor development, and a twofold increased risk of 
autism spectrum phenotypes26-28. Given that EFV particularly targets the serotonergic 
system, we hypothesized that perinatal EFV exposure might also lead to long-lasting 
neurodevelopmental consequences.
Here, we aimed to investigate the short- and long-term behavioral and neurodevelopmental 
effects of perinatal EFV exposure in a rodent model. We conducted a behavioral test 
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battery including tests for reflex development, motor performance, sensorimotor gating 
and anxiety- and depressive-like behavior, during early life, adolescence, and adulthood. 
Throughout the treatment period, we monitored maternal care. Because we observed 
changes in motor behavior, we investigated the cytoarchitecture of the motor cortex 
to study the underlying cellular mechanisms. Our results indicate that perinatal EFV 
exposure is associated with neurodevelopmental delay, accompanied by long-lasting 
changes in motor cortex morphology.
MATERIALS AND METHODS
Animals
Rats used in this experiment were bred in-house from Wistar male breeders and 
nulliparous Wistar females weighing 185–215 g, purchased from Charles River, Cologne, 
Germany. After a 2-week acclimatization period, female rats were subjected to a timed 
mating procedure (using Impedance Checker MK-10B, Muromachi Kikai, Tokyo, Japan) 
as described previously25. Pregnancy was determined by observation of a vaginal plug 
the day after breeding gestational day (GD) 1. Pregnant rats were alternately assigned 
to daily treatment with EFV or vehicle from GD1 to postnatal day (PND) 7 by order 
of birth. PND7 resembles the human functional brain maturity around birth29. Litters 
were culled to 10 pups and pups were weaned on PND21. One EFV-exposed pup died 
at PND17 (cause unknown) and was excluded from analysis. Male offspring from four 
EFV-exposed (n = 24) and four vehicle-exposed nests (n = 20) were used for experiments. 
Developmental milestones and behavior were assessed during the first 3 weeks of life 
(PND2–21), adolescence (PND34–35), and adulthood (PND69–70). After completion of 
the last experiments, rats (PND73–75) were sacrificed. Animal numbers used for each test 
are reported in the respective figure panels, where appropriate, and in Supplementary 
Table 1.
Sample sizes were based on power calculations from previous studies using comparable 
animal models and similar behavioral or molecular analyses23-25,30. Animals were tested 
randomly and both investigators and caregivers were blinded to the groups during 
experiments and outcome assessment. Blinding was ensured using coded treatment 
containers of identical appearance. Videos of the reflex and motor performance tests 
were re-analyzed by a second blinded researcher resulting in similar results. Animals were 
housed in pairs in standard Macrolon® type 3 cages in temperature-controlled rooms 
(21 °C ± 1 °C) under a standard 12-h light/dark cycle (lights on at 07:00 hours) with food and 
water available ad libitum (Sniff, long cut pellet, Bio Services, Uden, The Netherlands). 
Experiments were carried out in accordance with the European Communities Council 
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Figure 1. shows a schematic representation of the experimental timeline
Pregnant dams were treated with efavirenz (EFV) (n = 4) or vehicle (n = 4) from GD1 until PND7. At GD4, 
plasma levels of EFV were determined 1.5 h post administration. Developmental milestones and be-
havior were assessed during the first 3 weeks of life (PND2–21), adolescence (PND34–35), and adult-
hood (PND69–70). Maternal care was monitored from PND2 until PND9. After completion of the last 
experiments, rats (PND73–75) were sacrificed and their brains were removed for immunohistochemis-
try analyses. GD gestational day, PND postnatal day
Directive (2010/63/EU) and approved by the Committee for Animal Experiments of the 
Radboud university medical center Nijmegen, The Netherlands (ref no. 2012-236).
Drug treatment
EFV or vehicle was administered blindly by oral gavage in a volume of 5 mL/kg. We 
used a dose of 100 mg/kg, based on previous work demonstrating plasma levels within 
the human therapeutic range (1.0–4.0 mg/L31) and unpublished pilot work. Drug solution 
was prepared by diluting EFV oral suspension (Stocrin suspension 30 mg/mL, Merck 
Sharp & Dohme, Haarlem, The Netherlands) with distilled water. As vehicle, we used 
a 1% cellulose suspension (Genfarma B.V., Maarssen, The Netherlands), enriched with 
the EFV solution additives, consisting of medium chain triglyceride oil (Newpharma, 
Liège, Belgium) and strawberry and peppermint essence (Lecocq N.V./S.A., Zonhoven, 
Belgium).
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Measurement of EFV in blood plasma
Ninety minutes after drug administration at GD4, we collected blood, obtained by 
tail cut, of all pregnant rats (n = 8). Blood was collected in Microvette CB 300 tubes 
(containing EDTA; Sarstedt, Germany) and centrifuged for 15 min at 4 °C with a speed of 
4000 rpm. The supernatant (plasma) was stored at -20 °C until analysis. Supernatants 
from the experimental group were used for determination of plasma peak EFV levels 
using a validated reversed phase ultra-performance liquid chromatography with 
ultraviolet detection bioanalytical assay, validated for human plasma. For the current 
analysis, quality control samples prepared with blank rat plasma were included to assure 
validity of the assay. During the bioanalysis, the quality control samples in rat plasma did 
not deviate more than 15% from the theoretical value.
Maternal care
Maternal care was scored from PND2 to PND9 using a procedure adapted from Ivy et 
al.32. Litters were observed during three sessions per day of 75 min each: at 7:30 a.m., 
1:30 p.m. (light phase), and 7:30 p.m. (dark phase). Throughout each session, behavior was 
scored every third minute (25 observations per session). The behaviors scored include: 
(1) nursing more than half of the nest, (2) licking or grooming any pup, (3) spending time 
out of the nest, (4) self-licking or grooming, and (5) eating or drinking.
General development
Body weight was measured daily during early life (PND2–21), adolescence (PND34), and 
adulthood (PND70). In addition, we recorded eye opening every morning from PND13 
until both eyes were open. Scores were defined as: (0) both eyes closed, (1) one eye 
open, (2) both eyes open. An eye was considered “open” if the palpebral fissure was ≥2 
mm33.
Behavioral development
The experimental test battery was adapted from Kroeze et al. and included the 
following functional domains25: reflex development (righting reflex, negative geotaxis, 
and acoustic startle reflex), motor development (swimming performance and bar 
holding), sensorimotor gating (prepulse inhibition [PPI]), and anxiety- and depressive-
like behavior (elevated plus maze and forced swim test).
Reflex development—righting reflex, negative geotaxis, acoustic startle reflex
During the righting reflex test, rats (PND2–10) were placed on their back, while recording 
the time until they returned to prostate position, with a maximum of 60 s34. Negative 
geotaxis was examined using a 40° inclined wooden plank with a wire mesh. Rats 
(PND4–14) were placed facing down the slope and allowed to turn 180° within 90 s21. All 
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test sessions were recorded for later rescoring by a second researcher. See below for 
methods of the acoustic startle reflex.
Motor development—swimming performance, bar holding
During the swimming performance test, rats (PND8, 10, 12, 14, 22) were dropped 
from ± 20 cm into a basin filled with 27 °C water and observed for 5–10 s. Scoring was 
based on the position of the nose in the water: (1) entire head underwater, (2) nose 
underwater, ears partially underwater with the back of head above water level, (3) nose 
above water level but ears partially underwater, (4) entire head above water level35. Bar 
holding was tested by positioning rats (PND10–21) with their forepaws on a wooden bar 
(3 mm × 40 cm), suspended 45 cm above the bench surface. The latency to fall from the 
bar was recorded, with a maximum of 50 s. If the rat fell immediately, the procedure was 
repeated up to three times25,36.
Acoustic startle reflex and sensorimotor gating—PPI
At PND21, 35, and 70, acoustic startle and PPI experiments were performed in four 
acoustic startle chambers (San Diego Instruments, San Diego, USA), according to the 
methods of Sontag et al.37. Acoustic startle response was defined as the mean startle 
amplitude from the 10 test blocks of the startle trials. The percentage of prepulse 
inhibition was calculated using the formula: 100 – (average of startle amplitude on 
prepulse trial/average of startle amplitude on startle trial) × 100%37.
Anxiety-like behavior—elevated plus maze
The elevated plus maze is a polyvinylchloride apparatus with two open (50 × 10 cm, light 
intensity 12.1 lux) and two enclosed (50 × 10 × 40 cm, light intensity 4.5 lux) arms, elevated at 
a height of 50 cm38. Rats (PND69) were placed in the center of the elevated plus maze 
facing one of the open arms and allowed to freely explore the maze for 5 min. Movements 
were measured using the EthoVision XT9 Tracking System, Noldus, Wageningen, The 
Netherlands.
Depressive-like behavior—forced swim test
During the induction phase, rats (PND69) were placed in cylindrical glass tanks (24 cm 
diameter × 65 cm height filled to 35 cm with 22 °C water) for 15 min. After 24 h, rats 
(PND70) were placed in the same tank for 5 min (test phase). Immobility was defined 
as no movements or minimal movements necessary to keep the nose above water 
level for ≥2 s. While slight movements of forepaws or paw placement on cylinder walls 
were still considered immobility, active climbing, diving, and swimming were scored as 
mobility24. The duration of immobility (s) was recorded with Observer XT 12.5 (Noldus 
Information Technology, Wageningen, The Netherlands). Both phases of the forced swim 
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test (induction and test phase) were performed at the end of the testing days (after 
completion of the other behavioral tests).
Immunohistochemistry
After a minimum of 2 days after completion of the last behavior experiments, rats 
(PND73–75) were deeply anesthetized by an intraperitoneal injection of sodium 
pentobarbital (200 mg/kg) and perfused transcardially with cold phosphate-buffered 
saline (PBS), followed by 4% paraformaldehyde (PFA). Brains were quickly removed 
and immersed in 4% PFA for 48 h. Next, brains were washed in PBS, placed in a 30% 
sucrose solution, frozen on dry-ice, and stored at -80 C. In all, 16 μm sections were cut 
on a Microm Cryostat, mounted on Superfrost® Plus slides (Thermo Fisher Scientific, 
Waltham, MA, USA), air-dried and stored desiccated at -20 °C. Cryosections were 
obtained and stained immunohistochemically as previously described17, using the 
following antibodies: mouse anti-NeuN (1:500, Merck Millipore, Bedford, MA, USA; 
MAB377), rabbit anti-Cleaved Caspase-3 (Casp3, 1:500, Cell Signaling Technologies, 
Danvers, MA, USA; ASP175), rabbit anti-5-HT (1:500, Sigma-Aldrich Chemie, Zwijndrecht, 
The Netherlands; S5545), and rabbit anti-TH (1:500, Merck Millipore, Bedford, MA, USA; 
AB152), species-specific Alexa-conjugated secondary antibody (1:500, Thermo Fisher 
Scientific; A32732). After washing in PBS, sections were counterstained with fluorescent 
2-(4-Amidinofenyl)-1H-indole-6-carboxamidine (DAPI,1:1000, Thermo Fisher Scientific; 
62248) diluted in PBS for 15 min, washed extensively in PBS and embedded in 90% 
glycerol in PBS. For visualization, a Leica DMRA fluorescence microscope equipped 
with a DFC340FX camera and LASAF software was used.
Quantification
For quantification of cells and fibers in coronal sections, pictures of at least five brains 
per group were acquired similar to Witteveen et al.39. Stained cells were counted in 
radial units of 0.1-mm wide in the presumptive primary motor cortex (M1) of anatomically 
matched brain sections using Photoshop CS6 (Adobe). The overall cortical length, above 
white matter, of M1 was divided into 10 equal bins (bin1 within the deep cortical layers 
and bin10 within the presumptive layer 1) within this rectangle, ImageJ, including the 
NeuronJ plugin, was used for counts and measurements (National Institutes of Health, 
Bethesda, USA).
Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM) unless indicated 
otherwise. Continuous behavioral data were analyzed using repeated-measures analysis 
of variance (ANOVA). In case of significant violations of sphericity or error variances, the 
Greenhouse–Geisser adjustment was applied and df were adjusted. Significant ANOVA 
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results were followed by post-hoc independent T-tests, in order to identify the specific 
time points with the largest effect of EFV. Differences in non-continuous data were 
analyzed by Pearson’s chi-square (or Fisher’s exact). Immunohostochemical data were 
analyzed using one-way ANOVA. We observed extreme outliers in the acoustic startle/
PPI test and removed these according to Tukey’s principles. Cumulative behavioral 
development was defined using area-under-the-curves (AUC) for continuous data 
(righting reflex, negative geotaxis, bar holding) and sum scores for non-continuous data 
(swimming performance). Spearman’s correlations were used to correlate behavioral 
development with immunohistochemistry results. Statistical analyses were performed 
using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism3 software 
(California Corporation). All tests were performed using a two-tailed hypothesis, with 
significance set at 0.05. The Benjamini–Hochberg procedure was used for multiple 
comparisons behavioral post-hoc analyses with a false discovery rate (FDR) of 0.1.
RESULTS
Pregnancy outcomes and maternal care
On GD4, 1.5 h following the administration of EFV, mean ( ± SEM) EFV plasma levels in 
EFV-treated dams (n = 4) were 0.28 ± 0.13 mg/l. Gestational length did not differ between 
EFV (22.0 ± 0.0 days) and controls (22.3 ± 0.2 days, p = 0.69). No apparent anatomical 
abnormalities were seen in the EFV-exposed offspring. Furthermore, there were 
no significant differences in the number of pups per litter (EFV 10.8 ± 0.7 vs. controls 
8.8 ± 1.3, p = 0.34), nor differences in the survival rates for pups at weaning. Finally, the 
mean ( ± SEM) percentage of female pups per litter did not differ between groups (EFV 
42 ± 3% vs. controls 41 ± 6%, p = 0.89; Supplemental Table S2). To examine effects of EFV 
on dam–pup interactions, maternal behavior was scored from PND2 until PND9 and did 
not differ between groups (p > 0.10 for main effects of EFV and interaction between time 
and EFV; Fig. 2a).
General development
Figure 2b shows the body weights of EFV- and vehicle-exposed rats during early life 
(PND2–PND21), adolescence (PND34), and adulthood (PND70). Body weight increased 
with age (F(1.2, 49.3) = 6209.51, p < 0.0001). Perinatal EFV exposure was associated with 
reduced weight gain (main effect EFV: F(1, 41) = 29.09, p < 0.0001; time × EFV interaction 
effect: F(1.2 ,49.3) = 7.99, p = 0.0045). Body weight was significantly reduced in EFV-
exposed rats for all testing days (post-hoc FDR-adjusted p-values ≤ 0.0052). Eye opening 
was scored daily from PND13–PND18. On PND17, EFV-exposed rats showed a delay in 










































































































Figure 2. Perinatal exposure to EFV significantly affects body weight, eye opening, 
reflex and motor development, without effects on maternal care
a No effect of EFV on maternal behaviors. (n = 4 litters per group, PND2–9). b, c Effects of perinatal 
EFV on general development. b Main effect of EFV on body weight, with EFV-exposed rats showing 
reduced body weight. c EFV affects eye opening (PND17) scored as (0) both eyes closed; (1) one eye 
open; (2) two eyes open (d, e). Effect of perinatal EFV on reflex development. d No effect of EFV on 
righting time (s) in the righting reflex test. e Main effect of EFV on negative geotaxis test, with EFV-ex-
posed rats exhibiting longer latencies (s) until turning 180°. f, g Effects of perinatal EFV on motor 
development. f No main effect of EFV on the latency (s) to fall off the bar in the bar holding test, with 
a trend in EFV × time interaction. g EFV affects swimming performance (PND14), scored as (1) entire 
head underwater, (2) nose underwater, ears partially underwater with the back of head above water 
level, (3) nose above water, ears partially underwater, (4) entire head above water (PND8, 10, 12, 14, 22). 
EFV n = 24, Ctrl n = 19. Data represent mean ( ± SEM), #p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001, analyzed 
using repeated-measures ANOVA (a, b, d, e, f) or Fisher’s exact (c, g). Ctrl vehicle, EFV efavirenz, PND 
postnatal day, N nursing, LG licking/grooming, C contact, X out of nest, SG self-grooming, ED eating/
drinking, ANOVA analysis of variance
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Reflex and motor development
The time until the rats were able to roll from back to the front (righting reflex) reduced with 
age (F(3.8, 158.4) = 20.09, p < 0.0001; Fig. 2d). There were no main or interaction effects of 
EFV on righting time. In the negative geotaxis test, the time until turning decreased with 
age (F(5.0, 207.6) = 127.04, p < 0.0001; Fig. 2e). Rats perinatally exposed to EFV showed a 
developmental delay for negative geotaxis (main effect F(1, 41) = 13.59, p = 0.00066; time 
× EFV interaction F(5.1, 207.6) = 0.1.17, p = 0.32). Post-hoc analyses showed longer turning 
times in EFV-exposed animals on PND11 and PND12 (post-hoc FDR-adjusted p-values for 
both days p = 0.075). We observed an improvement of performance in the bar holding test 
over time (F(7.5, 306.6) = 35.02, p < 0.0001; Fig. 2f). We did not see any main effect of EFV 
on bar holding (F(1, 41) = 1.17, p = 0.29), but we observed a trend in time × EFV interaction 
(F(7.5, 306.6) = 1.81, p = 0.079), with significant differences between groups on PND20 
(post-hoc FDR-adjusted p = 0.0048). In the swimming test, EFV-exposed rats scored 
significantly lower than their controls on PND14 (FDR-adjusted p = 0.00046, Fisher’s 
exact; Fig. 2g). Finally, startle reflexes were assessed. The amplitudes of the startle 
response increased over time (F(1.5, 57.1) = 33.32, p < 0.0001; Fig. 3a), with a main effect 
of EFV (F(1, 37) = 5.65, p = 0.023), and a trend for time × EFV interaction (F(1.5, 57.1) = 2.72, 
p = 0.087). Post-hoc analyses showed significantly lower startle responses in the EFV 
group in early life (PND21, post-hoc FDR-adjusted p = 0.049) and adolescence (PND35, 
post-hoc FDR-adjusted p = 0.049), but not in adulthood (PND70, post-hoc FDR-adjusted 
p = 0.95). Taken together, these data demonstrate that EFV exposure affected early reflex 
and motor development, which normalized in later life.
Development of sensorimotor gating and anxiety- and depressive-like behavior
For all prepulses, the effects of PPI increased over time (F(1.7, 56.3) = 36.76, p < 0.0001 for 
3 dB, F(2, 70) = 33.21, p < 0.0001 for 5 dB, and F(1.18, 42.4) = 8.57, p = 0.0037 for 10 dB). We did 
not observe any main or interaction effects of EFV on PPI, regardless of the prepulse 
strength (Fig. 3b–d). We found no group differences in elevated plus maze open arm time 
(F(1, 41) = 0.01, p = 0.92; Fig. 3e). The number of open arm entries (F(1, 41) = 0.11, p = 0.74) and 
closed arm entries (F(1, 41) = 0.01, p = 0.92) also did not differ between control- and EFV-
exposed rats (Fig. 3f, g), suggesting that EFV did not affect anxiety. Finally, no differences 
were found in the total distance moved (F(1, 41) = 0.86, p = 0.361; Fig. 3h), indicating that 
EFV had also no effect on exploratory locomotion. Due to video recording errors, 
swimming scores could not be determined for two EFV-exposed rats. While there were 
no differences between the groups in the total duration of immobility (F(1, 39) = 0.64, 
p = 0.48), or the total number of immobility counts (F(1, 39) = 0.598, p = 0.44), there was a 
significant difference in latency to the first episode of immobility (F(1, 39) = 9.88, p = 0.003), 

































































































































































































































Figure 3. Perinatal EFV exposure affects the startle reflex and latency to immobility 
in the forced swim test, but has no effects on prepulse inhibition, or anxiety- and 
depressive-like behavior
a–d Effect of perinatal EFV on acoustic startle reflexes and prepulse inhibition (PPI). a Main effect 
of EFV on average startle amplitude development, with EFV-exposed rats exhibiting shorter startle 
amplitudes. No effect of EFV on PPI on b PND21, c PND35, and d PND70. PPI was calculated as: 
100–(average of all startle amplitudes on prepulse trial/startle amplitude on startle trial) × 100%. Three 
different prepulses were tested: 3 dB (PP3), 5 dB (PP5) or 10 dB (PP10) above background noise. e–h 
No effect of perinatal EFV on anxiety-like behavior in the elevated plus maze. e Number of open arm 
entries, f number of closed arm entries, g time (s) spent in open arms, and h total distance (cm) moved. 
i–k Effects of perinatal EFV on depressive-like behavior in the forced swim test. i No effect of EFV on 
the time (s) spent immobile, or j the number of immobility times. k Main effect of EFV on the latency 
(s) to immobility, with EFV-exposed rats exhibiting shorter latencies. EFV n = 24 (n = 22 for the forced 
swim test) and Ctrl n = 19. Data represent mean ( ± SEM), *p < 0.05, **p < 0.01, analyzed using repeat-
ed-measures ANOVA (a–d) or one-way ANOVA (e–k). Ctrl vehicle, EFV efavirenz, PND postnatal day, 
PP prepulse, ANOVA analysis of variance
101
Motor cortex cytoarchitecture
To investigate whether perinatal EFV exposure affected the architecture of the primary 
motor cortex (M1), we assessed the M1 cell composition in randomly selected brains from 
adult animals (PND73–75; Fig. 4a). We observed a reduction in the total number of DAPI+ 
cells in the M1 of the EFV-exposed compared with the control group (p = 0.045; Fig. 
4a–c and Supplemental Figure S1b). This decrease was present in the superficial layers 
(bin8, p = 0.014; bin9, p = 0.00030) and to a lesser extent in deep layers (bin6, p = 0.0096). 
Groups did not differ, however, in M1 cortical thickness (p = 0.37; Supplemental Figure 
S1g). To assess whether the observed reduction in cells was neuron specific, we 
immunostained the M1 for the neuronal nuclei marker NeuN (Fig. 4a, d, e). We found a 
significant reduction of NeuN+ neurons in the M1 of the EFV-exposed group (p < 0.0001; 
Fig. 4d and Supplemental Figure S1c), which was present in all layers (bin1–bin9, p < 0.05; 
Fig. 4e). Next, we focused on cell apoptotic features of perinatal EFV exposure in the 
M1 (Fig. 4a, f, g). We observed a significant increase of Casp3+ cells in the M1 of EFV-
exposed animals (p = 0.023; Fig. 4f and Supplemental Figure S1d), which was apparent in 
deep (bin1, p = 0.0087; bin3, p = 0.0059; bin5, p = 0.049 and bin6, p = 0.0071) and superficial 
layers of the M1 (bin7, p = 0.023 and bin9, p = 0.041; Fig. 4g) of the M1. The number of 
NeuN+ neurons positive for Casp3 was higher in the EFV-exposed group compared 
with the control group (p = 0.037; Fig. 4h, i and Supplemental Figure S1e,f). In addition, 
we noticed a small population of Casp3+ cells that were astrocytes (positive for GFAP) 
(Supplemental Figure S1a). When comparing nuclear size (using NeuN), we observed 
significantly reduced nuclear sizes in superficial layers of the EFV-exposed group (bin8, 
p = 0.0054; bin9, p = 0.0080; Fig. 4j, k), suggesting a possible difference in apoptotic state. 
Together, these data suggest (neuronal) cell loss in M1 cortical areas, which persists into 























































































































































































































































































































Figure 4. Perinatal exposure of EFV increases apoptosis in neurons of the motor 
cortex (M1)
(a) Immunostaining for DAPI, mature neurons (NeuN) and apoptosis (Caspase-3; Casp3) in the primary 
motor cortex (M1) of EFV-exposed (n = 8) and Ctrl-exposed (n = 8) animals. The boxed areas are enlarged 
in (j). b, c Significant decrease of the total number of DAPI+ cells in the superficial cortical layer of the 
EFV-exposed group. d, e Quantification of mature neurons (Neun+) showing a significant decrease in 
Neun+ cells in deep and superficial layers in the EFV-exposed group. f, g Quantitative results showing 
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a significant increase in Casp3+ cells in deep and superficial layers of the M1 of EFV-exposed animals. 
h, i A significant increase in Casp3+/Neun+ cells in the EFV group compared with controls. k Significant 
differences in the area occupied by Neun+ nuclei in two bins of superficial layers between EFV-treated 
and control animals. Data show mean ( ± SEM) number of cells, *p < 0.05, **p < 0.01, ***p < 0.001, analyz-
ed using one-way ANOVA. Ctrl vehicle, EFV efavirenz, ANOVA analysis of variance
Given the serotonergic pharmacological profile of EFV, we hypothesized that early 
EFV exposure could have long-term effects on the serotonergic system and potentially 
indirectly on other neurotransmitter systems such as the catecholaminergic system30. 
To test this hypothesis, we immunostained M1 cortical slices for 5-HT and TH (Fig. 5a, 
b) and found that perinatal EFV exposure was associated with increased 5-HT+ fiber 
length (p = 0.028; Fig. 5c, e) in deep and superficial layers of the M1 (bin2, p = 0.034; 
bin6, p = 0.040; Fig. 5c). We found no differences in TH+ fiber length (p = 0.19; Fig. 5d, e), 
suggesting that perinatal exposure to EFV influences the development and maintenance 
of the serotonergic, but not the catecholaminergic, system
Correlations between reflex and motor development and M1 cytoarchitecture
Swimming performance correlated positively with the number of cells (DAPI+; rs = 0.631, 
p = 0.009, Supplemental Figure S2) and post-mitotic neurons (NeuN+; rs = 0.642, p = 0.007) 
in the M1. In addition, we found a significant positive correlation between negative 
geotaxis and 5-HT+ fiber length (rs = 0.700, p = 0.036) and a trend between negative 
geotaxis and the number of DAPI+ cells in M1 (rs = −0.492, p = 0.053). These results suggest 
that the M1 of animals that performed better on the motor-related tests contained more 





























































































Control EFV Control EFV
Figure 5. Perinatal exposure to EFV affects serotonergic (but not catecholaminergic) 
innervation of the M1
a, b Camera lucida drawings of immunostaining for a 5-HT+ and b TH+ fibers in deep and superficial 
layers of the M1 in EFV-exposed and Ctrl-exposed brains (n = 7 per group for TH+ and n = 5 per group 
for 5-HT+). c Significant increase in 5-HT+ fiber length in bin2 and 6 in the EFV group. d, e Significant 
increase in 5-HT+ fiber length, but no difference in TH+ fiber length in the total M1 area of the EFV-ex-
posed group. Data show mean ( ± SEM) number of fibers, *p < 0.05 analyzed using one-way ANOVA. 
5-HT serotonin, Ctrl vehicle, EFV efavirenz, TH tyrosine hydroxylase, ANOVA analysis of variance
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DISCUSSION
In this study, we demonstrate that perinatal exposure to EFV in rats results in a transient 
delay in reflex and motor development and in persistent changes in M1 cytoarchitecture. 
Since maternal care was not affected by EFV treatment, the behavioral changes most 
likely arise from direct EFV brain toxicity. Correspondingly, EFV exposure caused 
persistent structural changes in motor cortical layers, reflected by a reduction in the 
number of mature neurons. The increased number of Casp3+ neurons points to neuronal 
cell death as the underlying cause. Finally, we found increased serotonergic, but not 
catecholaminergic, innervation of the M1 in EFV-exposed rats compared with controls, 
indicating that EFV, either directly or indirectly, affects the serotonergic system.
At the outset of our study, no studies had been published on long-term 
neurodevelopmental effects of EFV. Given EFV’ ability to interfere with the brain 
serotonergic system12-14 , we focused on behavioral domains known to be affected by 
genetic or pharmacological inactivation of the 5-HTT: reflex development22,40 , motor 
performance21,25, and emotion24,41. We found that perinatal EFV exposure resulted in 
delayed reflex development, reflected by increased latencies in the negative geotaxis 
test, and reduced startle responses. The reduced startle responses may indicate 
decreased capability of these rats to react to new auditory stimuli, but also point to 
a reduced ability to initiate motor responses. Correspondingly, EFV-exposed rats 
performed poorer in the swimming and bar holding tests. Adequate swimming requires 
the smooth integrative organization of multiple reflexes, including vestibular reflexes 
and extensor-flexor reflexes, which progressively develop during the postnatal phase 
of CNS maturation35. The delayed development of swimming ability in EFV-exposed 
rats suggests that early EFV exposure might modify these integrated neuromuscular 
mechanisms. The fact that bar holding performance was reduced, as well indicates that 
muscle strength may have contributed to reduced swimming performance. We observed 
no group differences in PPI, the elevated plus maze test, or behavioral despair in the 
forced swim test. We did, however, observe shorter latencies to immobility in the forced 
swim test, possibly reflecting motor-related problems. Taken together, these results 
suggest that perinatal exposure to EFV affects reflex and motor development, but not 
emotional behavior. The results are in line with recent findings showing that, compared 
to HIV-unexposed infants, HIV-uninfected infants perinatally exposed to EFV (aged 12–14 
months) are at an increased risk for motor delay (particularly those born prematurely)6.
Alterations in care provided by the mother can potentially mediate effects of EFV on 
motor development. As one-third of EFV-treated adults report CNS symptoms10,42 , and 
EFV-treated adult rats show anxiety and depressive-like behavior14,43 , dams treated with 
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EFV may have provided lower-quality care of pups than mothers treated with vehicle. For 
this reason, we measured maternal care and did not find significant differences between 
EFV- and vehicle-treated dams. Hence, the observed behavioral and morphological 
neurodevelopmental changes in EFV-exposed rats likely reflect (in)direct drug toxicity, 
rather than indirect effects mediated by altered maternal care.
To elucidate to what extent perinatal drug toxicity effects could explain the observed 
delay in reflex- and motor development, we investigated the cytoarchitecture of the 
motor cortex (region M1) in adult rats. In the M1 of perinatally EFV-exposed rats, we 
observed a marked decrease in total cell numbers, including mature neurons, and an 
increase in the number of neurons that expressed the apoptotic marker Casp3. These 
findings indicate that perinatal EFV causes cell death later in life, leading to a partial loss 
of neurons. The positive correlation between motor development and number of cells 
suggests that the delayed motor function is related to reduced cell number in the M1. 
The EFV-induced loss of cells may be attributed to EFV’ (in)direct ability to interfere 
with cellular metabolism. For example, EFV has been shown to decrease neuronal ATP 
storage, leading to increased levels of reactive oxygen species and cell death44,45.
Alternatively, perinatal EFV exposure could indirectly lead to neurodevelopmental 
changes and cell death, by targeting the serotonergic system. We therefore determined 
whether the observed neuronal loss and cell death were related to changes in the 
serotonergic system. We measured the length of 5-HT+ and TH+ fibers in the M1 and 
observed an increased length of 5-HT+, but not TH+, fibers, which correlated with 
reduced performance in the negative geotaxis test. This result resembles the case of 
perinatal SSRI exposure, which also results in increased cortical serotonergic innervation 
in later life19,46. 5-HT is one of the earliest neurotransmitter in the brain and performs 
neurotrophic functions during early development47. Hence, any interference with the 
serotonergic system by perinatal drug exposure can have profound long-lasting indirect 
effects on neurodevelopmental events. The 5-HT2, 5-HT3, and 5-HT6 receptors are 
involved in cell division48, differentiation49, survival50, and neuronal migration pathways47. 
EFV, as a 5-HT receptor (ant)agonist13, could directly interfere with these processes, 
consequently leading to neuronal cell death45. Elucidation of the exact molecular 
and cellular consequences at various developmental time points after perinatal EFV 
exposure in cortical and other brain areas requires further research.
We observed no signs of EFV-related pregnancy complications or teratogenicity, 
which is in line with findings in a recent meta-analyses including 2026 first-trimester 
EFV exposures5. Still, EFV-exposed rats showed delayed maturation (delayed eyelid 
opening) and reduced body weights throughout life. Reduced birth weights have been 
reported in EFV-exposed infants, although most studies in humans report comparable 
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birth weights with infants exposed to other ART4,51,52. Interpretation of these data is 
difficult as drug-related effects cannot easily be isolated from other HIV-related factors. 
Interestingly, the reduced body weight finding is in line with animal and human data 
derived from other early-life 5-HT stimulation models24,25,53. There are several ways 
in which EFV exposure might reduce body weight: by 5-HT-dependent mechanisms, 
through interference with hypothalamic 5-HT receptors and central regulation of eating 
behavior54, or by 5-HT-independent mechanisms such as increased metabolism and 
altered adipocyte differentiation55.
In contrast to other behavioral EFV studies14,43 , we measured plasma levels of EFV. 
Using a 100 mg/kg daily dose, we produced EFV plasma levels that were detectable, 
yet below the therapeutic range in humans (1.0–4.0 mg/L)56. One could argue that our 
experiment was not representative for the human situation. However, it is known that the 
main neurotoxic metabolite of EFV approximates human exposure, despite apparently 
relatively low EFV plasma levels55, In addition, even at relatively low concentrations, EFV 
has been shown to extensively accumulate in brain tissue in rats57. Finally, at similar doses 
in rats, EFV has been shown to induce neurotoxic changes12. We, therefore, postulate 
that our experimental set-up was sufficiently valid to induce the desired effects.
The major strength of using a rat model is that potential HIV-related and socioeconomic 
confounders of adverse neurodevelopmental effects of EFV in humans (e.g., parental loss; 
co-medication) can be eliminated. As EFV did not affect maternal care, developmental 
effects through care provided by the mother can be excluded. Our study also has 
limitations. We performed multiple behavioral tests with the same animals, which could 
have influenced test outcomes. We expect this carry-over effect to be limited, as tests 
were generally not stressful. Furthermore, behavioral and molecular experiments were 
performed with the same animals. Motor behavior was measured mostly during early 
life, while we only have molecular data from adult rats. This makes it difficult to draw 
detailed mechanistic conclusions The significant correlations between adult M1 cortical 
architecture and early motor performance, however, suggest that the M1 molecular 
changes arise early during development and persist throughout adulthood. Future 
studies using multiple time points and, if possible, interventions, are needed to study 
underlying mechanisms into more detail.
There is a clear indication of HIV treatment during pregnancy as it not only protects 
the (unborn) child, but also benefits the mother’s health. The vast majority of children 
exposed to EFV during pregnancy will be HIV uninfected with normal life expectancies. 
However, this outcome may come at a cost. As we demonstrate, perinatal exposure 
to EFV in rats leads to a transient delay in reflex and motor development, and a long-
lasting loss of neurons in the motor cortex. Thus, EFV could affect the development of 
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children who may already be experiencing multiple adverse conditions (such as having 
a mother living with HIV). Our findings underline the need for long-term clinical studies 
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SUPPLEMENTAL MATERIAL







Body weight 24 19
Eye opening 24 19
Righting reflex 24 19
Negative geotaxis 24 19
Startle reflex* 23 16
PPI* 20 16-17
EPM 24 19
Forced swim test† 22 19
Immunohistochemistry‡
DAPI+, NeuN, Casp3 8 8
TH 7 7
5-HT 5 5
5-HT serotonin; Casp3 caspase 3; EPM elevated plus maze; NeuN neuronal nuclei marker; PPI prepulse 
inhibition; TH tyrosine hydroxylase.
*Extreme outliers excluded from analyses according to Tukey’s principles. †Due to video-recording 
error swimming scores could not be determined for two efavirenz-exposed rats.






Gestational length, days 22 (0.2) 22 (0.0) 0.69
No. of pups per litter 10.8 (0.7) 8.8 (1.3) 0.34
No. of still births 0 (0.0) 0 (0.0) -
No. of neonatal deaths 0.5 (0.3) 0.0 (0.0) 0.34
Gender pups, % female 42 (7) 41 (12) 0.89
Efavirenz plasma level (mg/L) 0.28 (0.13) - -



















































































































































































































Supplemental Figure S1. Perinatal exposure of EFV increases apoptosis in several 
types of motor cortex cells including astrocytes (a-f), but has no effect on motor 
cortical thickness 
Ctrl vehicle ; EFV efavirenz (a) Swatch of immunostaining showing colocalization with Caspase3 
(Casp3) and GFAP, an astrocyte marker, in the motor cortex of EFV- (n=8) and Ctrl-exposed (n=8) 
animals. (b,c,d) Significant decrease in the total number of cells (b), total number of mature neurons 
(c) and total number of cells that are Casp3+ (d) in the EFV-exposed group compared with the Ctrl-ex-
posed group. (e) Significant increase in the total number of Casp3+ neurons. (f) Increased percentage 
of neurons that are Casp3+ in the EFV-exposure group. (g) No differences in the total length of a 
cortical  swatch (h,i) No differences in the percentage of area occupied by NeuN+ cells and average 
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Spearman correlations
P-values
Supplemental Figure S2. Spearman correlations between behavioral development 
and immunohistochemistry data of control (n=8) and efavirenz-exposed (n=8) animals 
Cumulative behavioral development was defined using area-under-the-curve for righting reflex 
(PND2-10), negative geotaxis (PND4-14) and bar holding (PND10-21) and total sum score for swimming 
performance (PND 8,10,12,14,22). Immunohistochemistry data reflect the total number of DAPI+ cells, 
mature neurons (NeuN+), apoptotic cells (caspase3 (Casp3)), total serotonin (5-HT+) fiber length, and 
total TH+ fiber length in the primary motor cortex (M1). 
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Contradictory data have been reported concerning neuropsychiatric side effects of 
the first-line antiretroviral drug dolutegravir, which may be partly due to lack of control 
groups or psychiatric assessment tools. Using validated self-report questionnaires, we 
compared mood and anxiety (DASS-42), impulsivity (BIS-11), and substance use (MATE-Q) 
between dolutegravir-treated and dolutegravir-naive people living with HIV (PLHIV). We 
analyzed 194, mostly male, PLHIV on long-term treatment of whom 82/194 (42.3%) used 
dolutegravir for a median (IQR) of 280 (258) days. Overall, 51/194 (26.3%) participants 
reported DASS-42 scores above the normal cut-off, 27/194 (13.5%) were classified as 
highly impulsive, and 58/194 (29.9%) regularly used recreational drugs. Regular substance 
use was positively associated with depression (p = 0.012) and stress scores (p = 0.045). 
We observed no differences between dolutegravir-treated and dolutegravir-naive 
PLHIV. Our data show that depressed and anxious moods and impulsivity are common 
in PLHIV and associate with substance use and not with dolutegravir use.
Keywords: dolutegravir, side effects, central nervous system, depression, impulsive 
behavior, anti-retroviral agents 
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INTRODUCTION
All recent national and international guidelines include the integrase inhibitor (INSTI) 
dolutegravir (DTG) in the list of first-line antiretroviral drugs (ARVs) for people living 
with HIV (PLHIV)1. DTG has an excellent efficacy, limited drug-drug interactions, a high 
genetic barrier to resistance and is generally well tolerated2. Moreover, generic versions 
became available for low-and middle income countries with a median price of as low as 
$75 per year3. Contradictory findings have been reported concerning neuropsychiatric 
side effects of DTG. While early randomized trials reported low discontinuation rates 
due to side effects among DTG-treated individuals (2–4%)4-8, several recent observational 
studies showed rates up to 15%9-13. The majority of these side effects involved 
neuropsychiatric symptoms, including insomnia and depressive symptoms. Data on the 
prevalence and nature of the neuropsychiatric side effects, as well as associated risk 
factors (e.g. female sex, older age or concomitant use of the ARV drug abacavir [ABC]10) 
are limited. In addition, it remains unclear whether these neuropsychiatric symptoms are 
specific for DTG or represent an INSTI class effect14. Most currently available studies 
lacked psychiatric assessment tools or proper control groups and often relied on 
spontaneous recording of side effects in medical records. In addition, many did not take 
possible confounders, such as recreational drug use, into account. As mental health and 
adherence are critical for successful cART, more data on the tolerability of DTG and 
other INSTI are needed. Using validated psychiatric assessment tools, we compared 
mood, impulsivity, and recreational substance use between DTG-treated and DTG-naïve 
individuals, as well as between INSTI-treated and non-INSTI treated individuals.
METHODS
This cross-sectional observational study is part of the 200HIV Human Functional 
Genomics Project (HFGP), which focuses on interactions between genetic variations, 
microbial communities and phenotypic variation, including mental health (www.
humanfunctionalgenomics.org)15. The Medical Ethical Review Committee Arnhem-
Nijmegen (Ref. 2012–550) approved the study protocol and all participants provided 
written informed consent. Between December 2015 and February 2017, a consecutive 
series of PLHIV from the HIV-clinic of Radboud university medical center, Nijmegen, The 
Netherlands were asked to participate in our study. Caucasian individuals aged ≥ 18 years, 
on cART ≥ 6 months with HIV-RNA load ≤ 200 copies/mL and without active hepatitis B/C 
or signs of acute infections, were considered eligible. Here, we analyzed all DTG-treated 
individuals and DTG-naive individuals from the HFGP. Eight participants were excluded 
because of prior discontinuation of DTG. These individuals did not differ from the DTG-
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treated individuals in age, sex, CD4 nadir, or scores on the self-report questionnaires. 
DTG had been discontinued after a median (IQR) of 111(350) days. In 7/8 (87.5%) patients, 
possible side effects leading to discontinuation were recorded (multiple reasons could be 
recorded per patient): sleep disturbances (n = 2), psychiatric symptoms (n = 2), headache 
(n = 3), fatigue (n = 2), dizziness (n = 1), gastro-intestinal complaints (n = 1), and itch (n = 
1). Socio-demographic information and information on health status were collected using 
an extensive questionnaire, including questions on recently experienced concentration 
disturbances and headache complaints. Clinical data were extracted from clinical files. 
Mood disorders, anxiety, and substance use are among the most commonly reported 
psychiatric diagnoses in PLHIV16. In addition, we and others observed high levels of 
impulsivity, translating into risk behavior PLHIV17-19. We selected golden standard 
questionnaires focused on mood and anxiety, impulsivity, and substance use meeting 
the following conditions: 1. self-reporting 2. available in Dutch 3. maximum length of 
ten minutes 4. validated in healthy and patient populations. The 42-item version of the 
Depression Anxiety Stress Scale-42 (DASS-42) measures levels of depression, anxiety 
and stress, with higher scores indicating higher symptom levels. The DASS-42 has a high 
internal consistency and reliability, and has been validated in Dutch populations20,21. The 
Barratt Impulsiveness Scale-11 (BIS-11) assesses overall impulsivity and three subscales 
– attention, motor and non-planning. Higher scores indicate greater impulsivity22. The 
Dutch version of the BIS-11 has been validated in normal and clinical samples23. We used 
the substance use module of the Dutch version of the Measurements in the Addictions 
for Triage and Evaluation Questionnaire (MATE-Q), which assesses psychoactive 
substance use, both in the recent past (≤ 30 days prior study visit) and in lifetime24. 
The MATE-Q is based on the WHO’s Composed International Diagnostic Interview 
(CIDI, version 2.1) and has been validated in Dutch populations25. We conducted a 
post-hoc power analysis25 for multivariate analysis of variance (MANOVA) with three 
dependent variables (DASS-42 or BIS-11 subscales) and two groups (DTG vs. DTG-naive) 
in G*POWER26. The available total sample size of 194 allowed detection of a DTG-effect 
of f2 = 0.06 (considered small-medium)27, with 80% power and α = 0.05. Comparisons 
of general characteristics between DTG and DTG-naive individuals were made using 
Student’s T-test (or Mann–Whitney U) for continuous variables and χ2 (or Fisher’s 
exact) for categorical variables. Differences in DASS-42 and BIS-11 scores between 
DTG and DTG-naive were analyzed using MANCOVA. In case of missing values of < 
15%, values were imputed by pooling the scores of the affected subscale(s). Logistic 
regression analyses were performed for dichotomous data (regular substance use 
and DASS-42 or BIS-11 scores above the normal cut-off). Spearman’s correlations were 
applied to explore associations between substance use, and DASS-42 and BIS-11 scores. 
Additional MANCOVAs were performed to compare DTG with other INSTI (elvitegravir 
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and raltegravir), INSTI with non-INSTI, and DTG-ABC with DTG-non- ABC. Subgroup 
analyses were performed for older individuals (age ≥ 55 years), females, and those on 
non-efavirenz cART (given efavirenz’ association with neuropsychiatric symptoms)28. Age, 
nadir CD4+ cell count, and duration of HIV infection were included as covariates in the 
adjusted models. To avoid inflating the risk of Type 1 errors, only adjusted MANCOVAs 
with p < 0.05 were followed by univariate analyses (with Bonferroni correction). A two-
tailed p of < 0.05 was considered statistically significant. Data were analyzed using SPSS 
(SPSS 24, Inc. Chicago, Illinois, USA).
RESULTS
After exclusion of eight individuals with missing values of ≥ 15% in the DASS-42 or BIS-11, we 
analyzed 194 individuals of whom 82/194 (42.3%) used DTG-containing cART (Fig. S1 Study 
Flowchart, electronic supplementary material). Study participants had a median (IQR) age 
of 52.5 (13.3) years and the majority (176/194 [90.7%]) were male. DTG-treated individuals 
were slightly younger compared to DTG-naïve individuals (p = 0.013) and had a shorter 
duration of HIV infection (p = 0.0024) and cART (p = 0.0015; Table 1). The median (IQR) 
duration of DTG treatment was 280 (258) days. DTG was combined with ABC in 59/82 
(72.0%) individuals, with emtricitabine-tenofovir in 13/82 (15.9%), with boosted atazanavir or 
darunavir in 8/82 (9.8%), and as dual therapy with lamivudine in 2/82 (2.4%). 
Psychiatric symptoms were common in our population. Overall, 51/194 (26.3%) individuals 
scored above the normal cut-off for depression, anxiety or stress (DASS-42), and 27/194 
(13.9%) individuals were classified as highly impulsive (BIS-11 total score ≥ 72)23. Scores 
did not significantly differ between DTG-treated and DTG-naive individuals, after 
adjustment for age, nadir CD4+ cell count, and duration of HIV infection. Similarly, we 
observed no differences when comparing DTG (n = 82) with other INSTIs (raltegravir and 
elvitegravir, n = 49), or INSTIs (n = 132) with non-INSTIs (n = 62) (see Table 2 and Tables S1-
S3, electronic supplementary material, for [M]ANCOVAs and neuropsychiatric scores 
for the different ARV classes). Limiting our analysis to females (n = 5 for DTG and n = 11 
for DTG-naive) did not change these results. In individuals aged ≥ 55 years, BIS-11 scores 
differed significantly between individuals on DTG (n = 27) and non-DTG regimens (n = 53, 
F(3,73) = 2.8, p = 0.047, ηp2 = 0.10), with lower non-planning impulsivity scores in those on 
DTG (adjusted mean difference [95%CI] = -3.15 (-5.51 to -0.8), p = 0.0093). After exclusion 
of individuals on efavirenz (n = 1 for DTG and n = 16 for DTG-naive), we observed a 
marginal group difference in BIS-11 scores (F(3,170) = 2.7, p = 0.045, ηp2 = 0.05), driven by 
higher motor impulsivity scores in the DTG group (adjusted mean difference [95%CI] = 
1.17 [0.13 to 2.22], p = 0.027). Within the DTG group, individuals on ABC (n = 59) 
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Age, years 50.5 (17.4) 54.4 (13.7) 0.013
Age ≥55 years, n/N (%) 27/81 (32.9) 53/112 (47.3) 0.055
Sex, male, n/N (%) 77/82 (93.9) 99/112 (88.4) 0.22
BMI, kg/m2 24.0 (3.6) 24.3 (4.1) 0.87
Time since HIV diagnosis, years 7.1 (6.7) 9.3 (10.4) 0.0024
Nadir CD4+ count, cells/μl 270 (230) 225 (240) 0.31
CD4+ count, cells/μl 640 (280) 680 (345) 0.18
cART-naive, n/N (%) 11/82 (13.4) 19/112 (17.0) 0.55
Time on cART, years 5.6 (6.4) 7.6 (10.8) 0.0013
Time on DTG, days 280 (258) - -
cART backbone, n/N (%)
Tenofovir-emtricitabine 13/82 (15.9) 72/112 (64.3) <0.0001
Abacavir-lamivudine 59/82 (72.0) 25/112 (22.3) <0.0001
cART regimen, n/N (%)
NNRTI 1/82 (1.2) 56/112 (50.0) <0.0001
Efavirenz 1/82 (1.2) 16/112 (14.3) 0.0013
PI 8/82 (9.8) 21/112 (18.8) 0.10
INSTI 82/82 (100.0) 50/112 (44.6) <0.0001
Raltegravir - 35/112 (31.3) -
Elvitegravir - 14/112 (12.5) -
Psychofarmaca, n/N (%) 12/82 (14.6) 14/112 (12.5) 0.68
Benzodiazepines 7/82 (8.5) 6/112 (5.4) 0.40
Tricyclic antidepressants 1/82 (1.2) 3/112 (2.7) 0.64
Selective serotonin reuptake inhibitors 5/82 (6.1) 3/112 (2.7) 0.29
Methylphenidate 1/82 (1.2) 1/112 (0.9) 1.00
Other 5/82 (6.1) 7/112 (6.3) 1.00
Reported frequent headache, n/N (%) 11/80 (13.8) 16/109 (14.7) 1.00
Reported concentration problems, n/N (%) 19/80 (23.8) 26/109 (23.9) 1.00
Data depicted as median (IQR) unless stated otherwise. Data analyzed using Mann-Whitney U or χ2 
(or Fisher’s exact) where applicable. 
cART, combination antiretroviral therapy; DTG, dolutegravir; NNRTI, non-nucleoside reverse tran-





















































































































































































































































































































































































































































































































































































































































































































































































































































































































Mean (SD) DASS-42 and BIS-11 scores, prevalence of scores above the normal cut-off, and prevalence 
of substance use for DTG-treated and DTG-naive individuals. Data analyzed using univariate analyses 
of covariance (DASS-42 and BIS-11 scores) or logistic regression models (scores > cut-off and substance 
use). Age, nadir CD4+ cell count and duration of HIV infection were included as covariates in the ad-
justed models.
*Cut-off scores for the DASS-42 are: depression scores >9, anxiety scores >7, and stress scores >14.
† BIS-11 total scores of ≥72 indicate high impulsivity.18
‡Classified according to the CDC definition: for men, ≥15 drinks per week and for women, ≥8 drinks/
week. http://www.cdc.gov/alcohol/faqs.htm#heavyDrinking (page accessed July 1, 2018, Page last re-
viewed: March 29, 2018, Content source: Division of Population Health, National Center for Chronic 
Disease Prevention and Health Promotion, Centers for Disease Control and Prevention)
§Defined as use of any psychoactive substance (with the exception of alcohol and tobacco) during 
periods ≥ 1 time per week including ≥ 1 time during the 30 days prior to the study visit.
║Not statistically analyzed given the low number of events.
¶Recreational drug class belonging to alkyl nitrites (inhalants).
BIS-11, Barratt Impulsiveness Scale-1; DASS-42, Depression Anxiety Stress Scale-42; DTG, dolutegravir; 
GHB, γ-Hydroxybutyric acid; MATE-Q, Measurements in the Addictions for Triage and Evaluation 
Questionnaire. 
had lower DASS-42 scores compared to those on alternative backbones (n = 23, F(3,75) 
= 4.6, p = 0.0052, ηp2 = 0.16). Post-hoc analyses showed significantly lower scores for 
anxiety (adjusted mean difference [95%CI] = -3.96 [-6.16 to -1.76], p = 0.00060), and a 
trend for lower stress scores (adjusted mean difference [95%CI] = -0.81 [-6.15 to 0.52], 
p = 0.097) in individuals on DTG-ABC combinations.  
In addition to symptoms of mood and impulsivity, we evaluated the frequency of 
substance use in our study sample. Regular substance use was defined as use of any 
psychoactive substance (with the exception of alcohol and tobacco) during periods ≥ 
1 time per week including ≥ 1 time during the 30 days prior to the study visit. A high 
proportion of the participants regularly used recreational drugs (58/194 [29.9%]), with 
cannabis, γ-Hydroxybutyric acid (GHB), and alkyl nitrites (“poppers”) as the most 
commonly used agents. We observed significant positive associations between regular 
substance use and depression (p = 0.012) and stress scores (p = 0.045), and a trend 
with attentional impulsivity scores (p = 0.092) (Table 3). Substance use did not differ 
between treatment groups (Table 2), nor did it confound our primary analyses (Table 
S4, Electronic supplementary material for adjusted MANCOVAs with and without 
substance use). Finally, we found no differences in self-reported headache complaints 
and concentration disturbances (Table 1).
125
Table 3. Spearman’s correlations between substance use and DASS-42 and BIS-11 
scores
 Item
Regular substance use Heavy alcohol drinking Active smoking
ρ P-value ρ P-value ρ P-value
DASS-42 total 0.17 0.022 0.030 0.68 0.054 0.45
Depression 0.18 0.012 -0.0049 0.95 0.093 0.20
Anxiety 0.096 0.18 0.060 0.41 0.099 0.17
Stress 0.14 0.045 0.060 0.41 0.0068 0.93
BIS-11 total 0.099 0.17 -0.011 0.88 0.18 0.014
Attentional 0.12 0.092 -0.021 0.77 0.13 0.071
Motor 0.093 0.20 -0.041 0.57 0.086 0.23
Non-planning 0.056 0.44 0.020 0.79 0.19 0.0073
BIS-11, Barratt Impulsiveness Scale-1; DASS-42, Depression Anxiety Stress Scale-42
DISCUSSION
In the present study, we found a high frequency of depressed and anxious moods and 
impulsivity in long-term treated PLHIV, which was associated with regular substance 
use and not with DTG use. Similarly, we observed no differences when comparing DTG 
with other INSTIs, and INSTIs with non-INSTIs. Our findings are in line with data from 
clinical trials, which reported relatively few DTG-related neuropsychiatric side effects. 
Moreover, studies show improvement of neuropsychiatric symptoms after substituting 
efavirenz for DTG29-31 and a recent meta-analysis showed no increased risk for 
suicidality among DTG-treated individuals32. However, our findings are in contrast with 
observational studies, which predominantly focused on individuals who discontinued 
DTG or other INSTIs. These individuals commonly reported neuropsychiatric symptoms 
at time of switch10,33-35. In our cohort, a minority of individuals (9% of ever DTG users) had 
discontinued DTG before, with a very small portion (3% of ever DTG users) potentially 
related to neuropsychiatric side effects. Our data support that DTG is well tolerated by 
most individuals. The occurrence of neuropsychiatric side effects in a small subset of 
DTGtreated individuals, however, cannot be ruled out. Mechanistically, DTG penetrates 
the blood brain barrier and may inhibit organic cation transporter 2 (OCT2), which 
is involved in the transport of serotonin and dopamine36,37. While one study indeed 
showed that DTG-treated individuals with a genetic variant of the gene encoding for the 
OCT2 (SLC22A2 C > A) were at higher risk of having abnormal scores of the Symptom 
Checklist (SCL)-90-R37, the lack of a control group of DTG-naive PLHIV limits causal 
inference. Several risk factors have been proposed for DTG-related neuropsychiatric 
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side effects, including older age11,12,34,38-40, female sex9,39,40, and a backbone containing 
ABC9,33,35,40. In our study, separate analyses in older individuals and females showed 
similar results, though the latter should be interpreted with caution given the small 
sample of females. Interestingly, we observed lower rather than higher levels of mood 
symptoms in individuals on DTG-ABC combinations. This may be caused by channeling 
due to certain patient characteristics, e.g. by prescribing TDF-containing backbones 
to PLHIV with cardiovascular disease or hepatitis B, conditions that have also been 
associated with an increased prevalence of neuropsychiatric symptoms41,42. Still, our 
observations are in line with several other studies reporting no associations between 
DTG-ABC use and neuropsychiatric symptoms11,39. In addition, no differences in DTG 
plasma trough concentrations were found between patients on ABC, rilpivirine, or 
darunavir43,44. Together, these findings argue against a previously suggested DTG-ABC 
pharmacokinetic amplification of side effects. Finally, efavirenz co-treatment, which was 
most prevalent in the DTG-naive group, did not seem to obscure group differences in 
mood symptoms. 
The currently available real life studies on DTG-related neuropsychiatric side effects 
often relied on spontaneous recordings of psychiatric symptoms in patient files in 
retrospective designs. The application of standardized validated psychiatric assessment 
tools is a major strength of the current study, increasing reliability and validity. Using 
comparable questionnaires, we and others previously observed unexpectedly high levels 
of neuropsychiatric symptoms among individuals on long-term efavirenz45-47. Absence of 
high symptom levels in individuals on DTG-containing regimens, when applying similar 
methodology in a sample that was sufficiently powered for detection of small-medium 
effects, strongly argues against such a phenomenon in DTG. Another strength of our 
study is that, by selecting individuals on long-term cART with suppressed viral loads 
and no acute infections, we reduced the chance of potential HIV-related confounders. 
Our study has several limitations. First, our study was not primarily designed to assess 
adverse effects of DTG and we did not examine participants before and after initiation 
of DTG. Second, we cannot rule out that our study population may have consisted of 
a selection of people more tolerant to DTG as we excluded individuals who previously 
discontinued DTG from our analyses. Third, while we used validated questionnaires to 
assess mood and impulsivity, we did not employ a gold-standard instrument for examining 
drug-induced neuropsychiatric symptoms in general (including sleep disturbances), like 
the Scandinavian Society of Psychopharmacology UKU Rating Scale48. Fourth, we have 
limited data on females and non-Caucasian individuals and future research should 
confirm the tolerability of DTG and generalizability of our findings to these populations. 
Despite these drawbacks, we believe that our data, obtained from a sufficiently large 
patient sample using validated psychiatric tools, supports the safety of dolutegravir in 
the majority of PLHIV. Still, psychiatric symptoms were common in our population, with 
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scores above the normal cut-off in 26.3% and 13.9% on the DASS-42 and BIS-11 respectively. 
While these cannot be accounted for by DTG, other factors are likely to contribute. 
For example, traumatic experiences, stigma, and substance use disorders have been 
shown to contribute to high levels of mental health problems in PLHIV49,50. Indeed, 
we found significant associations between regular substance use and depression and 
stress scores. By working synergistically in promoting behaviors that impede treatment 
adherence, substance use and depression may also lead to cART discontinuation51-53.
Our study highlights the need for proactive screening of mental health problems 
and substance use in PLHIV, and subsequent referral for adequate psychiatric care if 
needed. Finally, future studies on neuropsychiatric side effects of ARVs should not only 
use validated instruments, but also integrate host and lifestyle factors such as substance 
use.
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ABSTRACT
Long-term changes in the immune system of successfully treated people living with HIV 
(PLHIV) remain incompletely understood. In this study, we assessed 108 white blood cell 
(WBC) populations in a cohort of 211 PLHIV on stable antiretroviral therapy and in 56 
HIV-uninfected controls using flow cytometry. We show that marked differences exist in T 
cell maturation and differentiation between PLHIV and HIV-uninfected controls: PLHIV 
had reduced percentages of CD4+ T cells and naïve T cells and increased percentages 
of CD8+ T cells, effector T cells, and T helper 17 (Th17) cells, together with increased Th17/
regulatory T cell (Treg) ratios. PLHIV also exhibited altered B cell maturation with reduced 
percentages of memory B cells and increased numbers of plasmablasts. Determinants 
of the T and B cell composition in PLHIV included host factors (age, sex, and smoking), 
markers of the HIV reservoir, and CMV serostatus. Moreover, higher circulating Th17 
percentages were associated with higher plasma concentrations of interleukin (IL) 6, 
soluble CD14, the gut homing chemokine CCL20, and intestinal fatty acid binding protein 
(IFABP). The changes in circulating lymphocytes translated into functional changes 
with reduced interferon (IFN)-γ responses of peripheral blood mononuclear cells to 
stimulation with Candida albicans and Mycobacterium tuberculosis. In conclusion, this 
comprehensive analysis confirms the importance of persistent abnormalities in the 
number and function of circulating immune cells in PLHIV on stable treatment.
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INTRODUCTION
Combination antiretroviral therapy (cART) has drastically curtailed morbidity and 
mortality in people living with HIV (PLHIV)1. Still, PLHIV remain at an increased risk for 
pneumococcal infections, Mycobacterium tuberculosis (M. tuberculosis) reactivation and 
impaired vaccine responses2-6. Moreover, HIV infection predisposes to non-infectious 
comorbidities, such as cardiovascular disease and non-AIDS-related cancer, which share 
an underlying pathophysiological pathway characterized by a persisting and inappropriate 
activation of innate and adaptive immune cells7,8. Together, these observations point 
towards a disbalance in the homeostasis of the immune system, characterized by 
immunodeficiency on the one hand, and chronic inflammation on the other hand.
HIV-1 preferentially infects and kills activated CD4+ T cells, leading to rapid and 
severe CD4+ T cell depletion in the gut and increased microbial translocation9-12. A 
small proportion of these cells remains latently infected with replication competent 
virus and defective proviruses, called the HIV-1 reservoir13. The HIV-1 reservoir and 
increased microbial translocation, together with lifestyle factors and co-infections 
such as cytomegalovirus (CMV) may all contribute to the disrupted immune function 
in PLHIV10,13-17. However, published data have shown inconsistent or even contradictory 
findings. Heterogeneity in study populations, limited sample sizes of study populations 
and differences in lifestyle factors, including use of tobacco and recreational drugs, may 
underlie these inconsistencies and emphasize the need for an integrative approach in 
evaluating the immune system in PLHIV on stable cART.
The Human Functional Genomics Project (HFGP) aims to disentangle variation in the 
immune system in different cohorts of healthy individuals and individuals with underlying 
conditions. It combines multiple levels of analyses and data integration, including 
demographic and lifestyle data, data from ‘omics technologies’, and functional immune 
data18. As part of this project, we previously identified relevant environmental and 
host factors for circulating white blood cell (WBC) populations in healthy individuals19. 
Embedded within the HFGP, we established a cohort of 211 virally suppressed PLHIV 
(200HIV) and showed that these individuals exhibited a sustained pro-inflammatory 
immune phenotype with priming of the interleukin (IL)-1β pathway20. In the present study, 
we used the same cohort to comprehensively assess the peripheral WBC composition 
during treated HIV infection with a special focus on the adaptive immune system. 
We compared their WBC populations with those of healthy individuals and assessed 
associations with demographic and lifestyle factors, different HIV-specific factors, and ex 
vivo cytokine responses of peripheral blood mononuclear cells (PBMCs) to stimulation 




This study is part of the HFGP (www.humanfunctionalgenomics.org)18. Between 14 
December 2015 and 6 February 2017, individuals living with HIV were recruited from 
the HIV clinic of Radboud university medical center. Inclusion criteria were Caucasian 
ethnicity, age ≥ 18 years, receiving cART > 6 months, and latest HIV-RNA levels ≤200 
copies/ml. Exclusion criteria were: signs of acute or opportunistic infections, antibiotic 
use <1 month prior to study visit, and active hepatitis B/C. The control population 
consisted of 56 healthy adult individuals (56P cohort), who did not suffer from any acute 
or chronic conditions and who were longitudinally sampled four times in three-month 
intervals. Inclusion, sampling and sample processing of both cohorts were conducted 
simultaneously and by the same personnel. The 56P participants were selected as a 
subset of a larger cohort of 534 healthy individuals (500FG) which was phenotypically 
assessed two years earlier according to the same methods19,21. Differences in cell-cell 
associations were compared between 200 HIV and 500FG cohort. The reason is that 
the larger sample size of this control cohort (n=534 vs n=56) improved statistical power, 
whilst batch effects between PLHIV and 500FG were deemed of less significance when 
comparing within-group correlations  between cohorts. General information from all 
participants was recorded in the Castor Electronic Data Capture program (Castor EDC, 
CIWIT B.V., Amsterdam, The Netherlands), using questionnaires on socio-demographic 
information, lifestyle and life-events. Clinical data were extracted from medical files and 
the ‘Stichting HIV Monitoring’ registry (Amsterdam, The Netherlands).
Ethics
The study protocols were approved by the Medical Ethical Review Committee region 
Arnhem-Nijmegen (ref. 42561.091.122) and conducted in accordance with the principles 
of the Declaration of Helsinki. All study participants provided written informed consent.
Cell processing
Venous blood was collected in sterile 10 ml EDTA BD Vacutainer® tubes between 8 and 
11 am and processed within 1-4 hours. Cell counts were determined using a Sysmex XN-
450 automated hematology analyzer (Sysmex Corporation, Kobe, Japan). Erythrocyte-
lysed whole blood samples were obtained after 10 minutes incubation of 1.5 ml EDTA-
anticoagulated blood with lysis buffer containing 3.0 M NH4Cl, 0.2 M KHCO3 and 2 mM 
Na4EDTA. The remaining WBC were washed twice, by adding 25 ml phosphate-buffered 
saline 1x (PBS, Braun, Melsungen, Germany) and centrifuging at 452 x g for 5 min at room 
temperature. Before staining, cells were resuspended in 300 μl of PBS enriched with 
0.2% bovine serum albumin (BSA, Sigma-Aldrich, Zwijndrecht, Netherlands). Isolation 
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of PBMCs was performed by density centrifugation of EDTA-anticoagulated blood 
diluted 1:1 in pyrogen-free PBS over Ficoll-Paque (VWR, Amsterdam, The Netherlands) 
as described previously22. Cells were adjusted to 5.0 x 106 cells/ml.
Flow cytometry 
Supplementary Table 1 summarizes the antibody clones and the fluorochrome conjugates 
used for the different panel fluorescent staining mixes. Staining was performed on 
100 μl/well erythrocyte-lysed blood (panel 1-3,5) or 0.5 x 106 cells/well freshly isolated 
PBMCs (panel 4). Cells were stained according to previously described procedures 
(see also Supplementary Methods)19.
Samples were measured on a 10-color Navios flow cytometer (Beckman Coulter, 
Fullerton, CA, USA), equipped with three solid-state lasers (488 nm, 638 nm, and 405 
nm)19. Gating was conducted manually and verified by two independent specialists to 
prevent gating errors. Samples were analyzed within 4-5 hr after blood collection, using 
five distinct and complementary 10-color antibody panels: 1. general; 2. T cell; 3. B cell; 4. 
intracellular T cell/Treg; 5. chemokine receptors (CCR). Staining and gating strategies can 
be found in Supplementary Figure 1. Flow cytometry data were analyzed using Kaluza 
software version 1.3. In our analyses, we focused on a set of 108 manually annotated 
WBC subsets based on the original 500FG study (panel 1-4)19, with the addition of a fifth 
panel in which we classified monocytes, CD4+ memory and regulatory T cells, and CD8+ 
cells according to their expression of the CXCR3, CCR4, and CCR6 (panel 5).
PBMC stimulation experiments
Freshly isolated PBMCs were incubated with different stimuli (Supplementary Table 2) 
including bacterial (Staphylococcus aureus, M. tuberculosis, Streptococcus pneumoniae 
[S. pneumoniae]), fungal (Cryptococcus gattii, Candida albicans [C. albicans] hyphae 
and yeast) and other relevant antigens (Imiquimod, TLR7 ligand), in round-bottom 96-
well plates (Greiner Bio-One, Frickenhausen, Germany) with 0.5 x 106 cells/well at 37°C 
and 5% CO2 in the presence of 10% human pooled serum for seven days. Supernatants 
were stored at -20°C. Levels of the lymphocyte-derived cytokines IL-17, IL-22, and 
interferon (IFN)-γ were measured in the supernatants (PeliKine Compact or Duoset 
ELISA, R&D Systems).
Plasma markers
Serum levels of immunoglobulin (Ig)M and IgG were measured by immunonephelometry 
using a Beckman Coulter Imager and Beckman Coulter reagents. Measurements were 
standardized using certified European reference material 470 (ERM®-DA470). CMV IgG 
antibodies were measured in serum using ELISA (Genway Biotech Inc., San Diego, CA, 
USA) according to the manufacturer’s instructions. Markers of systemic inflammation, 
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high-sensitive C-reactive protein (hsCRP) and soluble CD14 (sCD14), and microbial 
translocation, intestinal fatty acid binding protein (IFABP), were measured by ELISA 
(Quantikine, R&D Systems) according to the manufacturer’s instructions. IL-6 was 
measured using a SimplePlex Cartridge (Protein Simple, San Jose, CA, USA). Circulating 
plasma CCL20, IL-17A, and IFN-γ were measured using the commercially available Olink 
Proteomics AB Inflammation Panel as described previously23,24.
Cell-associated HIV-1 DNA and cell-associated HIV-1 RNA 
quantification in CD4+ T cells 
The HIV reservoir was assessed by analyzing CD4+ cell-associated HIV-1 DNA (CA-
DNA) and CA-RNA. In virally suppressed patients, the CA-DNA roughly equals the 
integrated HIV-1 DNA, being replication competent or not25, while CA-RNA is associated 
with recent HIV-1 transcriptional activity and serves as a proxy for the active proviral 
reservoir26. CA-DNA and CA-RNA were measured in triplicate by droplet digital PCR 
(ddPCR – Bio-Rad) in CD4+ T cells isolated using EasySep Human CD4+ T Cell Isolation 
Kit (Stemcell technologies, Vancouver, Canada) as described previously27. CA-DNA was 
extracted by the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol with the addition of 75µl elution buffer on the column heated 
at 56°C for 10 minutes. CA-RNA was extracted using the Innuprep RNA kit (Westburg, 
Leusden, The Netherlands) with 30µl elution buffer. Total RNA was reversely transcribed 
to cDNA by qScript cDNA SuperMix according to manufacturer’s protocol (Quantabio, 
Beverly, MA, USA). CA-DNA was normalized by measuring the reference gene RPP30 
(Supplementary Table 3 and Supplementary Methods) in duplicate by ddPCR and 
expressed per million CD4+ T cells. CA-RNA was normalized using three reference 
genes per patient, (B2M, ACTB and GADPH), which were measured with LightCycler 
480 SYBR Green I Master mix. HIV-1 RNA copies were divided by the geometric mean 
of the reference genes and expressed per million PBMCs. ddPCR data analysis was 
performed using the ddpcRquant tool with standard settings for thresholding and 
absolute quantification28.
Statistical analyses
A detailed description of the statistical methods can be found in the Supplementary 
Methods. Given the impact of cohort differences in the absolute cell numbers of main 
WBC types (e.g. CD4+) on the numbers of their subsets (e.g. CD4+ regulatory T cells 
[Tregs]), results were primarily reported as WBC percentages, unless stated otherwise. 
WBC percentages were calculated by dividing the cell count of each subpopulation 
by its respective parent (one level up) or, where relevant, grandparent (two levels up; 
Supplementary Table 4). Data curation of cytokine, soluble marker, and immunoglobulin 
data was done according to previous methods21. For comparisons between cohorts, we 
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used all four longitudinally collected data points from the 56P cohort as independent 
measurements. Because of the known seasonality effects on WBC, this approach was 
considered preferable over selecting one of the data collection points or summarizing 
the data points. Data were normalized using an inverse rank transformation algorithm.
Comparisons in baseline characteristics between groups were made using Student’s 
t-test (or Mann-Whitney U test) for continuous variables, and Pearson’s Chi-square test 
(or Fisher’s exact) for categorical variables. Linear regression was used to compare 
WBC between cohorts, and to calculate associations between WBC and clinical and 
virological factors. All analyses were corrected for age, sex, time since January 2015 and 
seasonal effects. Cytokine analyses between cohorts were also corrected for CD4+ and 
CD8+ T cell percentages. Spearman correlations were used as the distance metric for 
unsupervised hierarchical WBC count clustering. Two-sided FDR-corrected p-values < 
0.05 were considered statistically significant29. Effect sizes are reported as Spearman’s 
Rho or standardized beta coefficients (β). Data were analyzed using the statistical 
programming language R (version 3.4.3, R Core Team, 2012).
RESULTS
General and HIV-specific characteristics 
Data from 211 PLHIV and 56 controls were analyzed in this study (Table 1). PLHIV were 
older (median [IQR] 52.5 [46.2 – 59.4] vs 30.0 [25.1 – 52.2] years, p<0.0001) and more 
often male (193/211 [91.5%] vs 34/56 [60.7%], p<0.0001) than controls. PLHIV had received 
cART for a median of 6.6 (4.2–11.9) years and 205/210 (98%) had plasma HIV-1 RNA <50 
copies/mL at time of study visit. Analyzing the HIV reservoir, we found detectable levels 
of total CA-DNA in 207/208 (99.5%) and CA-RNA in 210/210 (100%); CA-DNA and CA-
RNA levels were highly correlated (Supplementary Figure 2A; R=0.68, p<2.2·10-16). In 
general, PLHIV with higher CA-DNA and CA-RNA levels were older, had been living 
with and treated for HIV for a longer period, and had lower nadir CD4+ T cell counts 
(Supplementary Figure 2A). We observed no significant differences in CA-RNA and 
CA-DNA between PLHIV with plasma HIV-1 RNA <50 copies/mL (205/210 [98%]) and 
those with plasma HIV-1 RNA 50-200 copies/mL (5/210 [2%]; Supplementary Figure 2B). 
PLHIV with at least once a viral load of >50 copies/mL during year prior to study visit 
(23/210 [11.0%]) had higher levels of CA-RNA (p=0.0077), but no differences in CA-DNA 
(p=0.076; Supplementary Figure 2B).
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Age, years 52.5 (13.2) 30.0 (27.1) <0.0001
Sex, female, n/N (%) 19/211 (9.0) 22/56 (39.3) <0.0001
BMI, kg/m2 24.1 (4.0) 23.6 (3.6) 0.41
Time since HIV diagnosis, years 8.5 (9.5) - -
Way of transmission, n/N (%) - -
MSM 159/211 (75.4) - -
Heterosexual contact 9 (4.3) - -
IDU 3 (1.4) - -
Other or unknown 40 (19.0)
Nadir CD4+ cell count, cells/μl 250 (230) - -
CD4+ count, cells/μl 660 (330) - -
Zenith HIV-RNA, copies/mL 100 000 (341 182) - -
HIV-RNA >50 copies/mL ≤1 yr. prior to inclusion, n/N (%) 23/210 (11.0) - -
CA-DNA (copies per million CD4+ cells) 1547 (2270)
CA-RNA (copies per million CD4+ cells) 157 (224)
cART-naive, n/N (%) 30/211 (14.2) - -
Time on cART, years 6.6 (7.7) - -
ARV classes, n/N (%)
NNRTI 63/211 (29.9) - -
PI 32/211 (15.2) - -
INSTI 141/211 (66.8) - -
Co-medication, n/N (%)
Cholesterol lowering drugs 58/211 (27.5) - -
Antihypertensive drugs 50/211 (23.7) - -
Metformin 9/211 (4.3) - -
Active smoking, n/N (%) 63/211 (29.9) 2/56 (3.6) <0.0001
Heavy drinking, n/N (%)* 28/211 (13.3) 11/56 (19.6) 0.29
Regular substance use, n/N (%)† 61/211 (28.9) 3/56 (5.4) <0.0001
Data depicted as median (IQR) unless stated otherwise. Data analyzed using Mann-Whitney U or χ2 
(or Fisher’s exact) where applicable. 
* Classified according to the CDC definition: for men, ≥15 drinks per week and for women, ≥8 drinks/week. 
† Defined as use of any psychoactive substance (with the exception of alcohol and tobacco) during 
periods ≥ 1 time per week including ≥ 1 time during the 30 days prior to the study visit.
ARV, antiretroviral drug; BMI, body mass index CA-DNA: CD4-cell-associated HIV-1 DNA; CA-RNA: 
CD4-cell-associated HIV-1 RNA; HC: healthy control; cART, combination antiretroviral therapy; INSTI, 
integrase inhibitor; IDU, intravenous drug use; MSM, men who have sex with men; NNRTI, non-nucleo-
side reverse transcriptase inhibitor; PLHIV: people living with HIV; PI, protease inhibitor
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Figure 1 Differences in WBC percentages between PLHIV and healthy individuals 
(A) Principal component biplot showing standardized variance for the two principal component of all 
WBC subsets. The ovals represent the different cohorts. (B) Differences in WBC percentages (n=108 
WBC subsets) between PLHIV (n=211) and healthy controls (n=56) (C) Boxplots showing examples of 
150
cohort differences in cell percentages and Th17/Treg ratios (Treg identification marker CD25++). In-
verse-rank transformed data were analyzed using multiple linear regression and adjusted for age, sex, 
sampling time, and season. For color coding of the FDR-adjusted p-values see legend.
Alterations in WBC composition and cell-cell associations in chronic 
HIV 
We analyzed 108 WBC populations, including 93/107 (87%) B and T cell subsets and 14/107 
(13%) innate cell subsets (neutrophils, monocytes, natural killer [NK] and natural killer T cells 
[NKT]). Figure 1 and Supplementary Figure 3 show the differences in WBC composition 
between PLHIV and controls. An overview of median (IQR) WBC percentages and 
numbers in PLHIV and controls can be found in Supplementary Table 5.
Principal component analysis (PCA) of all WBC populations only explained a limited 
amount of the total variance. Still, the PCA plot showed clear differences in clustering 
between PLHIV and controls (Figure 1A). As expected, PLHIV exhibited an expansion 
of CD8+ and a reduction of CD4+ T cell numbers and percentages (Figure 1B and 
Supplementary Table 5). Functionally, CD4+ T cells comprise a diverse population of 
cells. CD4+ T helper (Th) cells fulfill essential roles for viral (Th1, CCR6-CXCR3+CCR4-), 
parasitic (Th2, CCR6-CXCR3-CCR4+), and mucosal (Th17, CCR6+CXCR3-CCR4+) 
immunity30. In addition, CD4+ Tregs are essential for controlling inflammation31. Despite 
reduced CD4+ T cell counts, numbers of all Th cell subsets (CD4+ CD45RA- CD25-) 
were markedly increased in PLHIV compared to controls (Figure 1B and Supplementary 
Table 5). Within the Th pool, Th2 percentages were reduced in PLHIV compared to 
controls, whereas Th1 percentages did not differ. Remarkably, Th17 percentages and 
numbers were increased in PLHIV (Figures 1B, C and Supplementary Table 5). While 
Treg percentages (of CD4+ cells), including highly suppressive Tregs co-expressing the 
transcription factors FoxP3 and Helios, were also increased in PLHIV, absolute Treg 
numbers were reduced (Figures 1B, C and Supplementary Table 5). This relative increase 
of Tregs may result from a loss of other CD4+ subsets32. Among Tregs, we found no 
differences in the percentage of activated (HLA-DR+) and effector Tregs (CD45RA-). 
The relationship between pro-inflammatory Th17 cells and Treg must remain balanced 
to preserve functional immunity. Altered ratios have been described in untreated HIV 
(lower Th17/Treg), autoimmune disease and cancer (higher Th17/Treg)9,33,34. Here, we found 
increased Th17/Treg ratios among virally suppressed PLHIV, irrespective of the Treg 
identification marker used (Figure 1C and Supplementary Figure 4). Furthermore, out of 
the Treg population, the percentage of Th17-like CCR6+ Tregs was increased in PLHIV, 
further contributing to a pro-inflammatory state. Developmentally, T cells evolve from 
naive T cells to antigen experienced central memory (CM), effector memory (EM), and 
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effector cells35,36. HIV not only differentially affects functional subpopulations, but also 
disrupts these developmental stages. While naïve CD4+ and CD8+ T cells were reduced, 
memory and effector cells were expanded in PLHIV (Figure 1B and Supplementary 
Table 5). Likewise, we found higher percentages of proliferating (Ki67+) CD4+ and CD8+ 
T cells in PLHIV, indicating increased cell turnover37. These results suggest a shift from 
naive cells towards terminally differentiated cells in HIV, even if viral replication is under 
control, which cannot be explained by age, sex, or season as we corrected our models 
for these factors.
Changes in the B cell compartment have also been described in PLHIV, including loss 
of CD27+ memory B cells38,39. Furthermore, viremia and low CD4+ T cell counts have 
been associated with the expansion of terminally differentiated B cells and immature B 
cells respectively38,39. In our study, we observed clear differences in B cell development 
in PLHIV illustrated by increased percentages of naïve B cells (IgD+IgM+CD27-) 
and reduced percentages of memory B cells (IgD+IgM+CD27+), transitional B cells 
(CD24++CD38++) and natural effector B cells (CD24+CD38+IgD+IgM+). In addition, 
the number of plasmablasts (IgD- IgM- CD38++) was increased in PLHIV, (Figures 1B, 
C and Supplementary Table 5). Adequate B cell maturation further requires optimal 
communication between B and T cells. We therefore sought to identify differences in 
WBC co-regulation between PLHIV and HIV-uninfected individuals by comparing cell-
cell associations between PLHIV and participants from the 500FG cohort. Details of 
this 500FG cohort have been reported previously (500FG, n=534)19. Using the same 
immunophenotyping techniques, we observed weaker correlations between naïve, CM 
and EM CD4+ T cells and several B cell subpopulations (including class-switch memory 
B cells) within PLHIV than in participants of the 500FG cohort, suggesting altered B/T 
cell interactions (Figure 2). These differences were not attributable to the influence of 
age, sex, or season as these factors were regressed out of the analysis.
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Figure 2 Differences in cell-cell associations between PLHIV and healthy individuals
Exploratory analysis depicting cell-cell associations between a total of 77 available WBC subsets 
that were significantly stronger (red) or weaker (blue) in PLHIV compared to healthy controls (n=534). 
FDR-adjusted p-values are obtained after 10 000 permutations and adjusted for age, sex, sampling 
time and season. HC: healthy control; PLHIV: people living with HIV; WBC: white blood cells.
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Apart from changes in the adaptive cell compartment, we observed clear changes in the 
innate WBC compartment in PLHIV. Monocyte and NKT cell numbers and percentages 
were increased, whereas NK cell numbers and percentages were reduced, specifically 
the cytokine-producing NK bright cells (Figure 1B and Supplementary Table 5). Together, 
these data show a widespread functional and developmental dysregulation of the 
immune system in virally suppressed PLHIV. This dysregulation encompasses both 
the innate and the adaptive compartment and results in a pro-inflammatory immune 
environment with an expansion of monocytes, pro-inflammatory Th and effector T cells, 
and dysregulated B cell memory responses.
Lifestyle, Demographic, and Clinical Factors Influence the WBC 
Composition in Chronic HIV Infection
Apart from the effects of HIV, demographic and lifestyle-related factors may influence 
the composition of the circulating WBC populations. Indeed, we found that older age 
was associated with an increase of innate immune cells and differential effects on B and 
T cell populations, for example with lower percentages of naïve T cells (CD4+ T cells β=-
0.29, p=0.00020; CD8+ T cells β=-0.29, p=0.00020) and B memory cells (β=-0.39, p=1.5·10-
7) and higher percentages of memory T cells (e.g. CD8+ CM β=0.22, p=0.00064) and 
mature naïve B cells in PLHIV (β=0.25, p=0.00087, Figure 3 and Supplementary Table 6). 
Sex-dependent influences of the WBC composition, reflected by more effector and EM 
cells and fewer naïve (B and T) cells in males in HIV infection, resembled those observed 
previously observed in healthy individuals21,40.
Lifestyle risk behaviors such as smoking [63/211 (29.9%)], heavy drinking [28/211 (13.3%)], 
and regular drug use [61/211 (28.9%)] were highly prevalent in PLHIV (Table 1). We 
found that packyears (reflecting total tobacco exposure) were associated with higher 
frequencies of neutrophils (β=0.22, p=0.033), Treg (β=0.22, p=0.033), CD8+ subsets (e.g. 
CCR6-CXCR3-CCR4+ β=0.24, p=0.025), and class switched memory B cells (β=0.20, 
p=0.042, Supplementary Table 6). Active smoking correlated with higher percentages of 
Th17 (β=0.21, p=0.031) and CCR6+ Tregs (β=0.26, p=0.0028, Figure 3 and Supplementary 
Table 6). Neither heavy drinking, nor regular drug use affected the WBC composition.
We further assessed the effects of relevant clinical factors on the WBC composition in 
PLHIV, by exploring associations with the history of immune suppression and treatment-
related factors. We found that nadir CD4+ cell counts were closely associated with both B 
and T cell percentages in PLHIV (Figure 3 and Supplementary Table 6). For example, higher 
counts were associated with higher percentages of naïve CD4+ T cells (β=0.45, p=1.2·10-9) and 
memory B cells (β=0.18, p=0.034). In contrast, we observed no effects of the duration of HIV 
infection or cART (regimen) on the WBC composition (Supplementary Tables 6).
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Figure 3 Clinical determinants of WBC percentages in PLHIV 
(A) Heatmap of WBC percentages (n= n=108 WBC subsets) that were significantly associated with any 
of the clinical determinants tested in 211 PLHIV; WBC subsets that showed no significant correlations 
with any of the parameters (n=37) have been removed from the figure. (B) Examples of WBC subsets 
that were significantly associated with age, sex, smoking, or CD4 nadir. Inverse-rank transformed data 
were analyzed using linear regression and adjusted for age, sex, sampling time, and season. For color 
coding of the FDR-adjusted p-values see legend. PLHIV: people living with HIV; WBC: white blood 
cells.
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HIV-1 reservoir and CMV affect the WBC composition in chronic HIV 
infection
First, we explored the relationship with markers of the HIV reservoir. CA-DNA was 
negatively associated with CD4+ T cell percentages (β=-0.33, p=9.8·10-5) and positively 
with CD8+ T cell percentages (β=0.34, p=7.0·10-5). Within the CD4+ T cell pool, CA-
DNA correlated with higher percentages of CM and Th17 cells (β=0.21, p=0.026 and 
β=0.24, p=0.0081 respectively; Figure 4 and Supplementary Table 7) Higher CA-DNA 
was also associated with more CD4+ T cell proliferation (Ki67+, β=0.35, p=3.3·10-5) and 
Treg activation (HLA-DR+, β=0.23, p=0.0081). We found similar associations between 
T cells and CA-RNA, whereas we found no relation between T cells and the relative 
HIV transcription level (CA-RNA/CA-DNA ratios; Supplementary Table 7). Lastly, 
we observed several associations between CA-DNA and B cells: higher CA-DNA 
levels correlated with reduced percentages of IgD+ only memory B cells (β=-0.27, 
p=0.00068) and, albeit non-significantly, with reduced percentages of natural effector 
B cells (CD24+CD38+IgD+IgM+, β=-0.18, p=0.056), and class unswitched memory B cells 
(IgD+IgM+CD27+, β=-0.18, p=0.053). Exclusion of PLHIV with HIV-RNA 50-200 copies/
mL at time of study visit (5/210 [2%]) did not change the main conclusions of our paper 
(Supplementary Tables 8, 9).
Second, CMV co-infection may contribute to immune dysregulation in both treated and 
untreated PLHIV. As CMV is known to affect WBC populations in healthy controls40, 
we explored the association of CMV serostatus with WBC composition. 198 of the 
PLHIV (93.8%) were seropositive for CMV. In line with findings in healthy individuals40, 
CMV seropositivity correlated with higher percentages of effector, EM T cells (e.g. with 
CD8+ effector cells β=0.43, p=1.7·10-9 and CD4+ EM cells β=0.30, p=0.00011; Figure 4 and 
Supplementary Table 7) and NKT cells (β=0.29, p=0.00029), yet with lower percentages 
of Th17 cells (β=-0.26, p=0.00065). We observed no associations between B cell subsets 
and CMV.
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Figure 4 The HIV-1 reservoir, CMV serostatus and WBC percentages in PLHIV 
(A) Heatmap of significant associations between WBC percentages (total n=108), CMV co-infection 
(serostatus and IgG titers in 198 seropositive PLHIV) and markers of the HIV-1 reservoir (CA -DNA and 
CA- RNA) in 211 PLHIV; WBC subsets that showed no significant correlations with any of the parame-
ters (n=41) have been removed from the figure. (B) Examples of WBC percentages that were significant-
ly associated with the viral reservoir or CMV IgG titers. Inverse-rank transformed data were analyzed 
using linear regression and adjusted for age, sex, sampling time, and season. For color coding of the 
FDR-adjusted p-values see legend. CA-DNA: CD4-cell-associated HIV-1 DNA; CA-RNA: CD4-cell-as-
sociated HIV-1 RNA; CMV: cytomegalovirus; PLHIV: people living with HIV; WBC: white blood cells.
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Microbial translocation, inflammation and Th17 differentiation in 
chronic HIV infection
Our main findings include a loss of naïve T cells and an expansion of Th17 in PLHIV 
compared to healthy controls, which related with lower nadir CD4+ T cells counts and 
higher levels of CA-DNA. To further assess the potential underlying mechanisms, we 
explored the relationship between these WBC subsets, markers of chronic inflammation, 
and markers of microbial translocation. As discussed above, naïve T cells are able to 
differentiate into different Th subsets depending on the cytokine environment41. We 
previously showed that PLHIV in our cohort exhibited a pro-inflammatory profile with 
increased levels of hsCRP (p=0.00022) and sCD14 (a marker of monocyte activation, 
p=0.0025; Figure 5A) as well as markedly elevated monocyte-derived cytokine 
responses, particularly IL-1β20). Such a pro-inflammatory cytokine environment may push 
the differentiation of naive CD4+ cells into Th17 cells41. Indeed, we observed positive 
associations between Th17 percentages and circulating IL-6 (β=0.21, p=0.014) and sCD14 
(β =0.17, p=0.035; Figures 5B, C). Notably, Th17 cells fulfill an essential role in mucosal 
defense and gut Th17 cells are known to be severely depleted during acute HIV9. To 
test whether gut integrity might have been compromised in our cohort, we measured 
levels of the microbial translocation marker IFABP and found increased levels in PLHIV 
compared to healthy controls (p=7.6·10-5; Figure 5D), suggesting ongoing microbial 
translocation in chronic treated HIV, especially in those with higher CA-RNA and CA-
DNA (CA-RNA β =0.18, p=0.0091 and CA-DNA β=0.21, p=0.0025, Figure 5E). Higher levels 
of IFABP were associated with an expansion of peripheral blood Th17 (β=0.17, p0.043; 
Figure 5B). Homing of Th17 to the gut (and other tissues, such as the skin) is directed 
by the chemokine CCL20, which is produced by tissue and immune cells (neutrophils 
and monocytes) and binds uniquely to the CCR6+ receptor42. Correspondingly, we 
found strong associations between CCL20 and Th17 percentages (β=0.22, p=0.0037), 
CCL20 and Th17/Treg (β=0.26, p=0.00081 for Th17/FoxP3+ Treg, β=0.27, p=0.00081 for 
Th17/CD127low Treg, and β=0.19, p=0.013 for Th17/CD25++ Treg), CCL20 and circulating 
IL-17A levels (β=0.47, p=1.2·10-11) and CCL20 and IFABP (β=0.24, p=0.0011; Figure 5F). 
Together, these results suggest that the pro-inflammatory environment in chronic HIV 
may promote the differentiation of circulating naïve CD4+ T cells into Th17 cells and that 
these changes may be associated with changes in gut permeability and gut homing
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Figure 5 Inflammation, microbial translocation, and Th17 cells in PLHIV 
(A) Boxplots showing differences in hsCRP and sCD14 between PLHIV (n=211) and healthy controls 
(n=56). (B) Heatmap showing associations between Th17 percentages, Th17/Treg ratios and sCD14, 
hsCRP, IFABP, and CCL20. (C) Associations between Th17 percentages and sCD14 and circulating 
IL-6 in PLHIV. (D) Levels of the microbial translocation marker IFABP in PLHIV and healthy controls. (E) 
Associations between IFABP and CA-RNA and CA-DNA in PLHIV. (E)Associations between CCL20 
and circulating IL-17A and IFABP. Inverse-rank transformed data were analyzed using linear regres-
sion analyses and corrected for sampling time. CA-DNA: CD4-cell-associated HIV-1 DNA; CA-RNA: 
CD4-cell-associated HIV-1 RNA; CCL20: Chemokine (C-C motif) ligand 20; HC: healthy control; 
hsCRP: high-sensitivity CRP; IFABP: intestinal fatty-acid binding protein; IL-6: interleukin 6; IL-17A: in-
terleukin 17A; Mem Tc: CD4+ memory T cell; PLHIV: people living with HIV; sCD14: soluble CD14; Th17 
percentages: T-helper 17 cell percentages (Mem Tc CCR6+ CXCR3-CCR4+ as percentage of CD4+ 
Mem Tc); Treg: regulatory T cells; WBC: white blood cells.
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Functional consequences of changes in adaptive immune cells in 
chronic HIV
As our results indicated significant changes in circulating immune cell populations in 
PLHIV, we next analyzed the possible functional consequences. First, we measured ex 
vivo cytokine responses of PBMCs after stimulation with different stimuli. We found 
strong correlations between NK and T-cell percentages and ex vivo IFN-γ, IL-17, and IL-
22 responses (Figure 6A and Supplementary Table 10): IFN-γ responses correlated with 
percentages of NK dim, CD4+ and CD8+ EM cells, whereas IL-22 responses correlated 
with CCR6+ CM CD4+ cell percentages. As expected, Th17 percentages were associated 
with increased circulating IL-17A (β=0.16, p=0.029) and ex vivo IL-17 responses to C. albicans 
(β=0.19, p=0.047) and with reduced IFN-γ responses (Figures 6A, E and Supplementary 
Table 10). Despite the expansion of Th17 cells among PLHIV compared to controls, ex 
vivo responses of IL-17 or IL-22 did not differ, suggesting that the functional capacity of 
these cells may have been compromised. In contrast, IFN-γ production upon stimulation 
with C. albicans hyphae (p=0.012) and M. tuberculosis (p=0.0025) was reduced in PLHIV 
(Figure 6B). Among PLHIV, lower ex vivo IFN-γ production to stimulation with Imiquimod 
(β =-0.21, p=0.0020) and S. pneumoniae (β=-0.22, p=0.0011) and lower circulating IFN-γ 
concentrations (β=-0.18, p=0.014) were associated with higher CA-DNA levels (Figures 
6C, D). No associations were found between ex vivo cytokine production and CMV 
seropositivity.
Second, we measured serum immunoglobulins and found significant correlations 
between serum IgM and IgM+ B cell populations (Figure 6F), but no cohort differences 
in IgM levels [median (IQR) 0.76 (0.56 – 1.05) g/L in PLHIV versus 0.82 (0.65 – 1.21) g/L 
in controls, p= 0.22] or IgG levels [10.03 (8.34 - 11.59) g/L in PLHIV versus 9.10 (7.59 – 
11.38) g/L in controls, p= 0.12]. These results indicate that while some of the alterations 
in adaptive immune function may be reversed by long-term cART43,44, others, such as 
impaired IFN-γ responses, remain.
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Figure 6 Functional consequences of WBC alterations in PLHIV 
(A) Heatmap of NK(T) and T cell percentages (total n=71) that were significantly associated with the 
ex vivo production of IFN-γ, IL-17, and IL-22 upon seven days ex vivo stimulation of PBMCs with dif-
ferent stimuli (n=7) in 211 PLHIV; WBC subsets that showed no significant correlations with any of the 
parameters (n=44) have been removed from the figure.  (B) Boxplot showing differences in ex vivo 
IFN-γ responses upon stimulation with C. albicans and M. tuberculosis between PLHIV (n=211) and 
healthy controls (n=56). (C) Association between CA-DNA and ex vivo IFN-γ responses to stimulation 
with Imiquimod and S. pneumoniae in PLHIV.(D)Association between CA-DNA and circulating IFN-γ 
in PLHIV. (E) Association between Th17 percentages and circulating IL-17A in PLHIV. (F) Heatmap of B 
cell percentages (total n=28) that were significantly correlated with IgM or IgG levels in PLHIV; WBC 
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subsets that showed no significant correlations with any of the parameters (n=21) have been removed 
from the figure. Inverse-rank transformed data were analyzed using linear regression analyses and 
corrected for sampling time. For cohort comparisons, data were corrected for age, sex, sampling time, 
season and the CD4+ and CD8+ cell percentages. For color coding of the FDR-adjusted p-values see 
legend. CA-DNA: CD4-cell-associated HIV-1 DNA; HC: healthy control; IFN-γ: interferon gamma; Ig: 
immunoglobulin; IL-17(A): interleukin 17(A); IL-22: interleukin 22; Mem Tc: CD4+ memory T cell; NK(T) 
cells: natural killer (T) cells; PBMC: peripheral blood mononuclear cell; PLHIV: people living with HIV; 
sCD14: soluble CD14; Th17 percentages: T-helper 17 cell percentages (Mem Tc CCR6+ CXCR3-CCR4+ 
as percentage of CD4+ Mem Tc); WBC: white blood cell
DISCUSSION
In this study we show that, despite suppressive cART, the circulating innate and adaptive 
immune cell composition in PLHIV differs from that of HIV-uninfected individuals. We 
confirm that PLHIV exhibit a WBC profile characterized by proliferating memory and 
effector CD4+ and CD8+ T cells. While untreated HIV infection has been associated 
with a loss of circulating Th17 cells9, we observed an expansion of circulating Th17 
cells and increased Th17/Treg ratios during stable suppressive treatment, which was 
associated with plasma concentrations of IL-6, CCL20 and the microbial translocation 
marker IFABP. Furthermore, PLHIV showed clear changes in B cell maturation with 
reduced memory B cell percentages and increased plasmablast numbers. In the innate 
compartment, we observed an expansion of monocytes together with a loss of NK cells, 
specifically NK bright cells. In addition to age, sex, smoking, and CMV, we found strong 
associations between WBC populations and markers of the HIV-1 reservoir (CA-DNA 
and CA-RNA). Functionally, Th17 responses seemed to be preserved, whereas IFN-γ 
responses to C. albicans and M. tuberculosis were compromised, especially in those 
with higher CA-DNA. The compromised IFN-γ responses may affect host defense 
against some important bacterial pathogens (including M. tuberculosis) and the HIV-1 
reservoir.
Prior studies have shown that untreated HIV infection results in a massive depletion of 
Th17 cells from the peripheral blood and the mucosa9, a process that may partially be 
reversed by cART45-47. We recently showed that PLHIV from the same cohort exhibited 
a pro-inflammatory profile with increased monocyte-derived cytokines, particularly 
IL-1β20. IL-1β and IL-6 are among the critical cytokines driving differentiation of Th1741, 
and we postulate that these cytokines may have contributed to the higher circulating 
Th17 numbers. Th17 cells in the peripheral blood poorly reflect mucosal Th17 numbers48 
and it is possible that mucosal Th17 depletion with increased microbial translocation 
162
and altered Th17 recruitment occurs in the participants of our study. The gut-
inflammatory marker generating islet-derived protein 3α (REG3α) would be of interest 
for future studies on the interplay between Th17 and epithelial gut damage in PLHIV49.
Concurrently to increased Th17 cells and pro-inflammatory Th17-like (CCR6+) mTregs, 
PLHIV showed increased peripheral blood Th17/Treg ratios. Increased Th17/Treg ratios 
have been linked to cardiovascular disease and atherosclerosis33, cancer34, and major 
depressive disorder50, which are all highly prevalent in long-term treated PLHIV. Th17-
mediated auto-immune diseases like psoriasis are also common among PLHIV, although 
they mostly occur during periods of severe immunosuppression and resolve upon cART 
initiation51. Despite these changes in Th17, IL-17 and IL-22 cytokine responses did not 
differ between PLHIV and healthy controls. In contrast, we observed reduced ex vivo 
IFN-γ responses to C. albicans and M. tuberculosis in PLHIV. IFN-γ is predominantly 
produced by NK(T) cells, Th1, and CD8+ cells43. Given that CD8+ cells were increased 
in PLHIV and Th1 cells did not differ between PLHIV and controls, we postulate that 
the reduced IFN-γ responses may have resulted from the loss of NK cells, which has 
been reported previously in both untreated and treated PLHIV52,53. In line with prior 
data, we observed an inverse relationship between IFN-γ responses and CA-DNA, 
suggesting that the failure to restore the NK cell compartment after cART initiation 
may be important for the containment of the HIV-1 reservoir54.Moreover, IFN-γ is a key 
cytokine in the immune response against M. tuberculosis which remains an important 
pathogen in treated PLHIV55. Improving IFN-γ responses, may therefore be relevant in 
the context of M. tuberculosis and HIV cure.
Different factors may contribute to the variation in T-cells repertoire in PLHIV. First, the 
effects of demographic factors such as age, sex, and smoking resembled those observed 
previously in healthy individuals19,40. Second, PLHIV in our study were almost universally 
coinfected with CMV and, in line with earlier data in HIV-infected and uninfected 
individuals, CMV seropositivity was associated with the expansion of effector and 
EM CD4+ and CD8+ T cells14,40,57. Of note, high CMV IgG levels may reflect frequent 
CMV reactivations or result from a stronger immune response (including adequate 
B/T cell interactions and B cell responses) and, consequently, fewer activations58. 
Importantly, higher CMV IgG titers have been linked to microbial translocation and the 
development of non-AIDS-defining events such as cardiovascular disease14,59. Third, we 
found substantial associations between WBC subsets and CD4+ nadir and markers of 
the HIV-1 reservoir. Overall, CA-DNA showed more and stronger correlations with WBC 
subsets than did CA-RNA, which may be explained by the fact that CA-RNA levels, 
reflecting transcriptional activity, are low during viral suppression and subtle effects may 
be missed13,60.
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Next to T cell dysfunction, HIV is characterized by aberrant B cell responses and B 
cell dysfunction. Using a different set of B cell markers than earlier studies in PLHIV61,62, 
we confirm their observations that percentages of naïve B cells are increased and 
memory B cells are reduced in PLHIV. Moreover, adequate B cell maturation requires 
optimal communication between T and B cells, which, according to our data, might be 
compromised in chronic stable PLHIV. B/T cell interactions take place in the germinal 
centers in lymph nodes and are orchestrated by follicular Th cells (Tfh)63. As these 
cells are known to be highly permissive to HIV infection and serve as reservoirs during 
chronic infection, they could potentially explain these disrupted B/T cell interactions63-65. 
Clinically, compromised B/T cells interactions may contribute to impaired immune 
responses to vaccination as well as increased risks for infections, such as invasive 
pneumococcal disease5,66. Finally, improvement of B/T cell communication is crucial for 
the development of broadly neutralizing antibodies and thus functional cure in PLHIV67.
Our findings support the relevance of new immune modulating strategies in ART-
treated PLHIV. Examples of interventions with potent anti-inflammatory properties in 
PLHIV include the IL-1β-inhibiting agent canakinumab68 and the epigenetic modifier 
panobinostat (HDACi)69,70. Moreover, checkpoint inhibitors (e.g. those targeting PD1, PD-
L1, and CTLA4) have been shown to, transiently, reverse latency of the viral reservoir, to 
restore cytotoxic T cell functions71-74, and to enhance B-cell germinal responses to HIV-1 
envelope vaccines75. Further research is required to establish whether these agents are 
safe and effective long-term options to mitigate inflammation and to reverse immune 
exhaustion and HIV latency in stable HIV infection.
Several limitations should be considered when interpreting our data. First, the 
observational study design limits causal inferences. Second, generalizability of our 
findings to women, children and non-European populations requires further studying. 
Third, participants from the HIV cohort were older and more often male and age and 
sex both have known effects on the immune system19,21. To adjust for these differences, 
we used multivariable regression models which allowed us to take into account the 
effects of these independent predictors (age and sex) on our outcome of interest (HIV 
status). Fourth, we used a predefined set of markers and flow cytometry panels. While 
this standardized approach enhances validity and reproducibility and enabled us to 
compare our results with those of a large cohort of healthy controls, some interesting 
WBC subsets and markers for HIV have not been included (e.g. Tfh cells, CD38 HLA-DR 
co-expression, and PD-1/CD57 expression in the context of B/T cell interactions, T-cell 
activation, and immune cell exhaustion respectively). Furthermore, data on intracellular 
production of IL-17 and IFN-γ in maximally stimulated sorted cell populations (e.g. Th17 
or NK cells) may provide a better understanding of the changes in cytokine production 
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capacity per WBC subset. Finally, our WBC data are limited to the peripheral blood 
and we have no data on tissue-specific WBC composition (e.g. lymph nodes or the gut).
In summary, we show that the circulating innate and adaptive immune cell composition is 
altered in a large group of PLHIV receiving cART for more than six months. Furthermore, 
our findings suggest that some of the adaptive immune responses (Th17) are preserved 
while IFN-γ responses are compromised. Our comprehensive approach provides new 
insight into the changes in the immune cell architecture and functional immunity in 
treated HIV and highlights associations with the HIV-reservoir, underlining the need 
for early cART initiation. Our results are currently validated and extended in a multi-
omics study including 2000 virally suppressed PLHIV (clinicaltrials.gov identifier: 
NCT03994835).
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Supplementary Figure 1 Flow cytometry gating strategies of the chemokine receptor 
(CCR) panel (E)
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Supplementary Figure 2 
(A) Spearman’s correlations between CA-DNA and CA-RNA and clinical factors (B) Differences in CA-
RNA and CA-RNA between PLHIV with (205/210 [98%]) and without HIV-1 RNA 50 <copies/mL (5/210 
[2%]) at study visit and between PLHIV with (23/210 [11%]) and without plasma HIV-RNA>50 copies/
mL (187/210 [89%]) in the year prior to study visit.CD-DNA: CD4-cell associated HIV-1 DNA; CA-RNA 
CD4-cell associated HIV-1 
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Supplementary Figure 3 Differences in WBC percentages between PLHIV and 
healthy individuals (previous page) 
Differences in WBC percentages between PLHIV (n=211) and healthy individuals (n=56) ordered in an 
hierarchical tree like structure in whole blood (A) and peripheral blood mononuclear cells ( B). In-
verse-rank transformed data were analyzed using linear regression and adjusted for age, sex, sam-
pling time, and season. For color coding of the FDR-adjusted p-values see legend.
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Supplementary Figure 4 Differences in Th17/Treg ratios with different markers. 
(A) Th17/Treg ratio based in which Tregs were identified using FoxP3 and Helios. (B) Th17/Treg ratio 
based in which Tregs were identified using CD25 and CD127. Results are comparable with results re-










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 2 Stimulation scheme for the ex vivo cytokine production assays
Stimulus Final Concentration Strain/Manufacture
RPMI  + serum 10% human serum Life technologies
Staphylococcus aureus 1 x 106/mL ATCC 29213 (in house)
Cryptococcus gattii 1 x 107/mL A1M-R265, AFLP type 6 (clinical isolate)
Candida albicans conidiae 1 x 106/mL UC820 (in house)
Candida albicans hyphae 1 x 106/mL UC820 (in house)
Streptococcus pneumonia 1 x 106/mL TIGR4
Mycobacterium tuberculosis 1 μg/mL H37Rv (in house)
Imiquimod (TLR7 ligand) 2.5 ug/mL Invivogen
PBMCs: peripheral blood mononuclear cells; TLR: Toll-like receptor.
*All 7 day PBMC stimulation experiments were supplemented with 10% human pool serum.
Supplementary table 3 Primers and probes to calculatie CA-DNA and CA-RNA
Assay Oligo Modification Sequence 
Total HIV-1 DNA




Probe 6FAM/MGB Eclipse 5’-AAGTRGTGTGTGCCC-3’
Reference gene RPP30 Forward 5’-AGATTTGGACCTGCGAGCG-3’
Reverse 5’-GAGCGGCTGTCTCCACAAGT-3’
Probe HEX/ZEN/3’ IBFQ 5’-TTCTGACCTGAAGGCTCTGCGCG-3’
Reference gene B2M Forward 5’-TGTCGGATGGATGAAACCCAGA-3’
Reverse 5’-TGCTCGCGCTACTCTCTCTTT-3’
Reference gene ACTB Forward 5’-CCGATCCACACGGAGTACTT-3’
Reverse 5’-TGGACATCCGCAAAGACCTG-3’




HIV-1 DNA and cell-assicioated HIV-1 RNA quantification in CD4+ T 
cells
See Methods for the description of the HIV-1 DNA and RNA extraction. Before PCR 
amplification, 8.65μl of genomic DNA was restricted by EcoRI (Promega) in a total volume 
of 10μl restriction digest for a minimum of 1 hour at RT. Total HIV-1 DNA and HIV-1 RNA 
were measured by adding respectively 2μl and 4μl in triplicates to ddPCR mix containing 
10μl 2x ddPCR Supermix for Probes, 500nM primers and 300 nM probe (Table X). DNA 
was amplified by PCR with an initial denaturation step of 10min at 95°C, followed by a 
denaturation step for 30 sec at 95°C, an annealing/elongation step for 1 min at 56°C for 
40 cycles, and a final step of 10min at 98°C. Total HIV-1 DNA was normalized by measuring 
the reference gene RPP30 (Table X) in duplicate by ddPCR and expressed per million 
CD4+ T cells. Droplets were read by QX200 droplet reader (Bio-Rad) and automatic 
threshold setting was done using ddpcRquant software28. For HIV-1 RNA normalization, 
three reference genes per patient, B2M, ACTB and GAPDH (Supplementary Table S3) 
were measured with LightCycler 480 SYBR Green I Master mix. HIV-1 RNA copies were 




For surface staining, cells were incubated in 25 μl surface staining master mix for 20 min 
at RT and washed twice in PBS + 0.2% BSA. Before acquisition, whole blood-derived 
cells were resuspended in 100 μl PBS + 0.2% BSA. For intracellular staining, surface-
stained PBMCs were fixed and permeabilized using Fixation/Permeabilization solution 
(eBioscience, Vienna, Austria) for 30 min at 4°C protected from light. After washing the 
cells twice in permeabilization buffer (eBioscience, Vienna, Austria), cells were stained 
with 25 μl intracellular staining master mix for 30 min at 4°C protected from light. After a 
second washing step with permeabilization buffer, cells were resuspended in 100 μl PBS 
+ 0.2% BSA for acquisition.
Flow cytometry
For each panel, single cells within the leukocyte (CD45+) population were identified 
by plotting the forward scatter (FSC) against FSC time of flight (FSC TOF), followed 
by characterization of the major myeloid or lymphoid lineages 17. The absolute number 
of WBC per ml of blood determined by the Sysmex XN-450 hematology analyzer was 
used to calculate absolute numbers of leukocyte (CD45+) cell subsets as measured by 
flow cytometry.
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Panel 1 (general) identified granulocytes, lymphocytes (both by FSC, side scatter 
[SSC]) and monocytes (CD14+). Lymphocytes were further characterized into T cells 
(CD3+CD56-), NK cells (CD3-CD56+), NKT cells (CD3+CD56+ ), and B cells (CD19+HLA-DR+). 
Cell subsets were determined for T cells (CD4 and CD8), NK cells (CD56 and CD16) 
and monocytes (CD14 and CD16). Panel 2 (T cell) covered CD4+ regulatory T cells (Treg; 
CD4+CD25+CD127 low) and maturation stages of CD4+ and CD8+ T cells (using CD45RA/
CD27 and CD45RO/CD27). Panel 3 (B cell) explored CD19+ B cell maturation stages by 
the expression of IgM/IgD and/or CD24/CD38 and B cell subsets by differential CD19/
CD20 and IgD/CD5 expression, as previously described 17. In panel 4 (intracellular T cell/
Treg), the major T cell populations (CD4, CD8 and Treg) were identified and analyzed for 
proliferation status by intracellular Ki67 expression. Tregs (CD4+CD25+CD127low FoxP3+) 
were analyzed for expression of Helios, CD45RA, and HLA-DR. Absolute cell counts in 
this panel were calculated as described above by subtracting the granulocyte number 
(determined by panel 1) from the PBMC WBC counts (Sysmex XN-450). In panel 5 
(chemokine), monocytes and T cell populations (CD8, CD4 including memory T cells 
[Mem Tc; CD45RA-CD25-] and Treg [CD45RA-CD25++]) were analyzed for the expression 




The following regression formula was used:
Y1 ~  X1 + age + sex + sin(2 * pi * numDaysFromJan2015/365) + cos(2 * pi * 
numDaysFromJan2015/365) + numDaysFromJan2015
where sin(2 * pi * numDaysFromJan2015/365) and cos(2 * pi * numDaysFromJan2015/365) 
capture seasonality patterns with a periodicity of one year19. The cell count data 
showed some slight drift over time which was corrected using the linear term 
numDaysFromJan2015, indicating after how many days after Jan 1st 2015 the sample 
was collected.
Analysis of correlation structures between 200HIV and 500FG
Correlations were performed on absolute WBC counts instead of WBC proportions.
To properly ascertain cell count correlations, we first corrected the IRT-normalized cell 
counts for age, sex, and seasonal effects, by regression out these factor using a model 
similar to the one described above. We calculated inter-cohort differences in strength 
of cell count associations using the following method. First, we defined the test statistic: 
D_real=correlation_X1_Y1_cohort1 - correlation_X1_Y1_cohort2=C1-C2
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With hypotheses: H0: c1=c2 and H1: c1≠c2
where X1 and Y1 refer to the different cell types. Within each cohort the ID-labels were 
shuffled 10,000 times for each WBC type and the correlation between the cell types 
in both cohorts were calculated for all 10,000 permutations, yielding 10,000 unique 
correlation differences. 
D_permuted = correlation_X1_Y1_cohort1 - correlation_X1_Y1_cohort2
P-values were obtained using two different methods. First, P-values were calculated by 
dividing the number of times the absolute shuffled test statistics were higher than the 
real absolute test statistic. 
(number of times abs(D_permuted) >= abs(D_real)) + 1)/number of permutations
Second, p-values were obtained by applying a half-normal distribution to the absolute 
D_permuted values. P-values were calculated out of the percentage of the area with 
absolute permuted values higher than the real correlation. This second approach 
yielded more precise p-values without increasing the number of permutations (as for the 
discrete permutation analysis the lowest possible p-value is 1/number of permutations). 
Here, the p-values from the fitted distribution are reported. Using the p-values from the 
discrete method (first method) showed very similar pattern, and therefore selecting one 
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ABSTRACT
Chronic inflammation and immune dysfunction play a key role in the development of 
non-AIDS related comorbidities. The aim of our study was to characterize the functional 
phenotype of immune cells in people living with HIV (PLHIV). We enrolled a cross-
sectional cohort study of PLHIV on stable antiretroviral therapy and healthy controls. 
We assessed ex vivo cytokine production capacity and transcriptomics of monocytes 
and T-cells upon bacterial, fungal and viral stimulation. PLHIV exhibited an exacerbated 
pro-inflammatory profile in monocyte-derived cytokines, but not in lymphocyte-
derived cytokines. Particularly, the production of the IL-1β to imiquimod, E. coli LPS 
and Mycobacterium tuberculosis was increased, and this production correlated with 
plasma concentrations of high-sensitivity C-reactive protein and soluble CD14. This 
increase in monocyte responsiveness remained stable over time in subsequent blood 
sampling after >1year. Transcriptome analyses confirmed priming of the monocyte IL-1β 
pathway, consistent with a monocyte trained immunity phenotype. Increased plasma 
concentrations of β-glucan, a well-known inducer of trained immunity, were associated 
with increased innate cytokine responses. Monocytes of PLHIV exhibit a sustained pro-
inflammatory immune phenotype with priming of the IL-1β pathway. Training of the innate 
immune system in PLHIV likely plays a role in long-term HIV complications and provides 




Persistent inflammation and immune dysfunction play an important role in the 
development of non-AIDS related comorbidities in people living with HIV (PLHIV). 
Those include cardiovascular disease (CVD), neurocognitive dysfunction and cancer 1-4. 
Reducing inflammation is considered to be an attractive therapeutic target to reduce 
the burden of non-AIDS related events. However, immune dysfunction and persistent 
inflammation in PLHIV are complex processes that are still incompletely understood. 
These involve changes in the adaptive immune system, including dysfunction and 
senescence of T-cell lymphocytes 5, as well as changes in the innate immune system. 
Mediators of the latter, including soluble (s)CD14, sCD163 and high-sensitive C-reactive 
protein (hsCRP) are indicative of persistent immune activation and are associated with 
non-AIDS related events 6-8. 
Ongoing exposure to microbial products, for example by cytomegalovirus virus (CMV), 
continuing HIV replication or microbial translocation, may be one of the drivers of 
persistent inflammation 2,9-12. Increased inflammation can also result from a functional 
adaptation of innate immune cells induced by epigenetic reprogramming; a process 
termed ‘trained immunity’ 13-16. Trained immunity is recognized to play an important 
beneficial role in host defense processes, but may also contribute to conditions like 
atherosclerosis or type 2 diabetes mellitus 17,18. Whether trained immunity contributes to 
persistent inflammation in PLHIV is currently unknown. 
 
The Human Functional Genomics Project (HFGP) aims to investigate variation in the 
immune responses 19. Studies in HFGP cohorts in healthy individuals have yielded 
different novel insights in the genetic and non-genetic regulation of inflammatory 
cytokine responses in response to microbial ligands 20-23. We established a HFGP cohort 
of Dutch PLHIV and in this cohort we describe alterations in the function and phenotype 
of peripheral blood mononuclear cells (PBMC) by using an integrative approach of 
functional and transcriptional analyses. We also explored underlying mechanisms of 
the inflammatory monocyte profile, including the possible contribution of exposure to 




A total of 211 PLHIV on combination antiretroviral therapy (cART) and 56 HIV-uninfected 
controls were included in the analyses. Baseline characteristics are shown in Table 
1. Compared to the healthy controls, PLHIV were more often male (91.5% vs. 60.7%; 
p<0.001) and of older age (median [IQR] age of 52.5[13.2] vs 30.0 [27.1] years, p<0.0001). 
The median (IQR) duration of cART use in PLHIV was 6.6yr (4-12yr) and 89% were virally 
suppressed (HIV viral copies ≤50 copies/mL) for more than one year. 
Circulating inflammatory markers and innate cytokine responses
We first measured concentrations of circulating inflammatory markers. Compared to 
healthy controls PLHIV had significantly higher concentrations of sCD14, hsCRP, IL-18, 
IL-18 binding protein (IL-18BP) and IL-6 (Figure 1A-G). These differences remained after 
adjusting for age, sex, body mass index (BMI), or seasonality (Figure 1A). Concentrations 
of adipokines were similar between groups after correction (Figure 1A). 
Next, we analyzed functional changes in the innate and adaptive immune response. 
PBMCs were incubated with 12 stimuli (4 bacterial, 3 fungal, 1 viral and 6 Toll like receptor 
(TLR) ligands), followed by measurement of different monocyte-derived (IL-6, IL-1β, 
TNFα) and lymphocyte-derived (IL-17, IL-22, IFNγ) pro-inflammatory cytokines, as well 
as anti-inflammatory cytokines (IL-10, IL-1Ra) in the supernatant. We observed markedly 
increased monocyte-derived cytokine responses in PLHIV, especially IL-1β responses 
upon stimulation with LPS (TLR4), imiquimod (TLR7) and Mycobacterium tuberculosis 
(Figure 2A,C,D). Production of TNFα and IL-6 were also increased in PLHIV (Figure 2A,E), 
except for lower production in response to Staphylococcus aureus (TNF-α) and Candida 
albicans (IL-6; Figure 1F,G). This increased pro-inflammatory cytokine response in PLHIV 
was not associated with a concurrent increase in the anti-inflammatory cytokines IL-1Ra 
or IL-10. However, the release of IL-1Ra by unstimulated cells was higher in PLHIV (Figure 
2H), which is consistent with increased basal IL-1β production (Figure 2A). The number 
of monocytes in the isolated PBMCs (Supplemental Figure 1A-B) may influence cytokine 
production, but adjusting for the monocyte fraction in PBMCs did not significantly 
alter the outcome (Supplemental Figure 1C. T-cell-derived cytokine responses were 
generally lower for most stimuli in the PLHIV cohort (Supplemental Figure 2), but these 
differences were abrogated following adjustment for age, sex and seasonality (Figure 
1A), except for IFNy responses to M. tuberculosis and C. albicans hyphae (Figure 2A-
B). There were no associations between cytokine production capacity and smoking or 
different HIV-specific traits, including recent CD4 cell count, CD4/8 cell ratio, CD4 nadir, 
cART-regimen or co-medication (metformin, statins or aspirin) (Supplemental Figure 3). 
189






Sex (% Male) 193 (91.5) 34 (60.8)A
Age (years, mean (SD)) 51.4 (10.8) 39.9 (17.3)B
BMI (kg/m2, mean (SD)) 24.5 (3.6) 24.1 (3.1)
HIV infection duration (years, median [IQR]) 8.5 [4.9, 14.2]





CD4 nadir (10^6 cells/mL; median [IQR]) 250.0 [135.0, 360.0]
CD4 count (10^6 cells/mL; median [IQR]) 660.0 [480.0, 810.0]
HIV load below 200 copies/mL (n (%)) 211 (100)
HIV load below 50 copies/mL for >1yr (n (%)) 188 (89%)
CD4/CD8 ratio (median [IQR]) 0.8 [0.6, 1.1]
cART duration (years; median [IQR]) 6.6 [4.2, 11.8]
cART regimen
NRTI (%) 203 (96.2)
NtRTI (%) 99 (46.9)
NNRTI (%) 63 (29.9)
PI (%) 32 (15.2)
Maraviroc (%) 3 (1.4)
INSTI (%) 141 (66.8)
Smoking (%) 62 (29.4)
Pack years (median [IQR]) 13.9 [0.0, 28.0]
Hypercholesterolemia (%) 58 (27.5)
Hypertension (%) 41 (19.4)
Diabetes Mellitus (%) 9 (4.3)
No cardiovascular risk factors (%) 50 (23.7)
Statins (%) 58 (27.5)
Aspirin (%) 19 (9.0)
Metformin (%) 9 (4.3)
BMI: body mass index. cART: combination antiretroviral therapy. NRTI: Nucleoside reverse tran-
scriptase inhibitor. NRTI: nucleotide reverse transcriptase inhibitor. NNRTI: non-nucleoside reverse 
transcriptase inhibitor. PI: protease inhibitor. INSTI: integrase inhibitor. ABC: abacavir. DTG: dolutegra-
vir. EVG: elvitegravir. RAL: raltegravir. ASignificantly different between cohorts using Students T-test. 



















































































































Figure 1. Circulating factors in people living with HIV (PLHIV) vs uninfected healthy 
controls (HC).
(A) Circulating factors in PLHIV and uninfected controls. Crude model is linear regression after inverse 
rank-based transformation. Adjusted model included age, sex, and seasonality as covariates. Red 
depicts the marker is significantly increased in PLHIV; blue depicts the marker is decreased in PLHIV 
compared to healthy controls. All P values are FDR corrected (Benjamini-Hochberg method). (B-G) 
Boxplots depicting circulating factors of inflammation stratified by cohort, PLHIV (blue), uninfected 
controls (yellow). P values are calculated using Student’s t test. Boxplots are depicted according to 
Tukey with median (line), interquartile range (edge of boxplot), range (whiskers) and outliers 3 times 
interquartile range are depicted as dots. All plots include data from PLHIV (n = 211) and HC (n = 56). 
hsCRP: high-sensitivity C-reactive protein; sC14: soluble CD14; sCD163: soluble CD163; IL-6: interleu-


















































































































































Figure 2. Cytokine production capacity in PLHIV vs uninfected healthy controls (HC). 
(A) Ex vivo cytokine production capacity between PLHIV and HC after 24hr (in case of IL-1β, TNFα, IL-
6, IL-10 and IL-1Ra) and 7 days stimulation (IL-22, IL-17 and IFNγ). FDR-corrected (Benjamini-Hochberg 
method) P values are depicted from an adjusted model included age, sex, seasonality as covariates. 
Red depicts significantly higher in PLHIV, blue depicts lower in PLHIV compared to HC. (B-H) box-
plots depicting ex vivo cytokine production capacity stratified by cohort. PLHIV depicted in blue and 
uninfected controls in yellow. P values, depicted in boxplots were calculated using Student’s t test 
after log-transformation. All boxplots are depicted according to Tukey with median (line), interquartile 
range (edge of boxplot), range (whiskers) and outliers three times interquartile range are depicted 
as dots. All plots include data from PLHIV (n = 211) and HC (n = 56). LPS: lipopolysaccharide; oxLDL: 
oxidized low-density lipoprotein; Pam3Cys: synthetic Toll-Like-Receptor (TLR)2 ligand; Poly IC: TLR3 
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Figure 3. Cytokine production capacity vs circulating factors.
(A) Correlation plot with adjusted p-value shown after correcting for age, sex, seasonality as covar-
iates. Red depicts a significant positive correlation and blue depicts a negative correlation within 
people living with HIV (PLHIV). All P values were FDR corrected per circulating factor. (B-I) Correlation 
plot without cofactor adjustment. Pearson’s coefficient (r) with P value after log-transformation are 
shown. All plots include data from PLHIV (n = 211) and HC (n = 56). LPS: lipopolysaccharide; oxLDL: ox-
idized lipodensityprotein; Pam3Cys: synthetic Toll-Like-Receptor (TLR)2 ligand; Poly IC: TLR3 ligand; 
imiquimod (IMQ): TLR7 ligand. hsCRP: high-sensitivity C-reactive protein; sC14: soluble CD14; sCD163: 
soluble CD163; IL-6: interleukin-6; IL-18: interleukin-18; IL-18BP: interleukin 18 binding protein. *P < 0.05 
after FDR-correction.
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Next, we assessed associations between innate cytokine responses, circulating 
inflammatory markers, and monocyte phenotypes (Figure 2A-I). Increased ex vivo 
cytokine responses were associated with persistent inflammation. For example, we 
found positive associations between IL-6 responses and circulating hsCRP (Figure 2A,I), 
and between LPS induced IL-1β responses and plasma sCD14 and IL-18BP (Figure 2A,D). 
In addition, non-classical and intermediate monocyte subsets (Figure S4A-F), which 
are considered pro-inflammatory monocyte phenotypes, correlated with higher IL-1β 
and IL-6 production after LPS or imiquimod, respectively (intermediate monocytes vs 
LPS-IL-1β R=0.23, p<0.001; Figure 2A-C) 24. Taken together, we show that PLHIV have an 
altered innate immune profile with markedly elevated monocyte cytokine responses, 
particularly IL-1β, which correlates with blood biomarkers of persistent inflammation.
Increased IL-1β production capacity of PLHIV is stable over time
We then assessed the longevity of the elevated monocyte-derived cytokine responses. 
We resampled 28 male PLHIV, aged >45yr after >1yr and stratified them on the basis of 
their initial IL-1β production capacity in a group of low (lowest quartile) and high (highest 
quartile) IL-1β producers. Fourteen age and sex-matched uninfected controls were 
enrolled concurrently (Supplemental Table 1). Upon resampling, those assigned to the 
high IL-1β producer group still exhibited higher IL-1β and IL-6 production compared to 
participants in the low IL-1β producer group and matched healthy controls, suggesting 
that the enhanced monocyte responsiveness is stable over time (Figure 4A-B). TNF-α 
followed a similar, but non-significant pattern (P = 0.075; Figure 4C). To examine if 
the presence of T-lymphocytes affected the outcome, we isolated monocytes using 
magnetic beads (purity >95%, Supplemental Figure 4G) and repeated the stimulation 
experiments. We found that IL-1β production remained increased, suggesting that the 
elevated monocyte-derived cytokine response is due to an enhanced functional state 
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Figure 4. Ex vivo cytokine production capacity of monocytes in a validation cohort. 
(A) IL-1β production upon 24h stimulation with imiquimod (1ug/mL), lipopolysaccharide (LPS; 100ng/
mL) or M. tuberculosis (1ug/mL) in PBMCs or monocyte only culture (magnetic beads CD14+ isolation). 
(B) IL-6 production upon imiquimod stimulation. (C) TNFα production upon imiquimod stimulation. All 
data are stratified by healthy controls (HC; n = 14), people living with HIV (PLHIV) low initial IL-1β pro-
ducers (n = 13) and PLHIV high producers (n = 15). P- values in panel A-C were calculated by Student t 
test. All boxplots are depicted according to Tukey; median (line), interquartile range (edge of boxplot), 
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Figure 5. Transcriptome analysis of monocytes. 
(A) Principal component (PC) analysis (PCA) plot of transcriptome of monocytes from people living 
with HIV (PLHIV) and healthy controls (HC) directly after isolation. (B) PCA plot of transcriptome of 
monocytes from PLHIV and HC after 24 hours macrophage differentiation in medium only. (C) Hierar-
chical clustering plot PLHIV vs HC. (D) Gene ontology of differentially expressed genes (PLHIV vs HC) 
including adjusted P value and gene count. (E) Top pathways of gene ontology plot after macrophage 
differentiation (GO interaction terms). PLHIV: n = 8, HC: n = 4. 
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Enhanced pro-inflammatory functional state of monocytes
Based on the previous findings, we postulated that a trained immunity functional 
phenotype contributes to the enhanced monocyte responsiveness in PLHIV. Hence, we 
isolated monocytes from eight PLHIV and four age and sex matched uninfected controls 
and analyzed their transcriptomes by RNA sequencing. Using principal component 
analysis (PCA), we observed clustering of the PLHIV and controls (Figure 5A). This 
clustering was even more pronounced when monocytes were differentiated towards 
macrophage phenotype by culture for 24hr in serum-free medium (RPMI; Figure 5B) 
and was also observed using hierarchical clustering (Figure 5C). Gene ontology (GO) 
analysis of 303 upregulated and 30 downregulated genes (Supplemental data) showed 
that pro-inflammatory pathways were upregulated in PLHIV, including the ‘inflammatory 
response’, ‘regulation of innate immune response’ and ‘IL-1β production’ pathways 
(Figure 5D-E). Among the upregulated genes in these pathways were intracellular 
signaling proteins and inflammasome related molecules (e.g. NLRP3, STAT1), cytokines 
(e.g. IL1B, CCL2, MMP9, IL1RN), and pattern-recognition receptors (e.g. TLR2, TLR4, TLR7 
and NOD2), underlining the broad upregulation of inflammatory pathways in PLHIV on 
long-term cART.
Enhanced IL-1β gene expression in monocytes of PLHIV
The release of active IL-1β from blood monocytes involves a priming signal that is mostly 
transcriptionally driven, which results in the synthesis of the IL-1β precursor (proIL-1β). 
This precursor is subsequently processed via caspase-1 into active IL-1β 25.  Using qPCR 
on monocytes stimulated with IMQ, we found that the IL1B (gene encoding for proIL-1β) 
RNA expression was higher in monocytes from PLHIV compared to controls (Figure 
3F, P = 0.021). IL6 mRNA followed a similar trend (Figure 6A, P = 0.027), whereas TNFA 
expression did not (data not shown, P = 0.74). Additionally, we measured intracellular 
proIL-1β and active IL-1β protein by ELISA and both were significantly elevated in 
PLHIV (Figure 6D-E). The inflammasome promotes the proteolytic cleavage of proIL-
1β into active IL-1β, resulting in reduced proIL-1β/active IL-1β ratios in situations with 
increased caspase-1 activity 25. Instead, we observed a trend towards an increased ratio 
of intracellular proIL-1β and active IL-1β (Figure 6F) in the high IL-1β producing PLHIV, 
and no differences in levels of NLRP3 expression (Figure 6C). Together, these results 
demonstrate that the enhanced IL-1β transcription, rather than increased processing 
through caspase-1, is the biological process that primarily drives the increased IL-1β 






















































































Figure 6. IL1B gene expression and intracellular (pro)IL-1β. 
(A) IL1B gene expression after imiquimod 1ug/mL stimulation depicted as fold change (FC) from medi-
um (RPMI). (B) IL6 gene expression after imiquimod stimulation depicted as fold change from medium. 
(C) NLRP3 gene expression (by ΔCT) in RPMI. (D) Intracellular levels of proIL-1β protein after Imiquimod 
stimulation. (E) Intracellular mature IL-1β protein after imiquimod stimulation. (F) Ratio of intracellular 
proIL-1β vs IL-1β after imiquimod stimulation protein. All data are stratified by healthy controls (HC; n 
= 14), people living with HIV (PLHIV) low initial IL-1β producers (n = 13) and PLHIV high producers (n = 
15). All boxplots are depicted according to Tukey; median (line), interquartile range (edge of boxplot), 
range (whiskers) and outliers three times interquartile range are depicted as dots. P-values were cal-
culated by ANOVA and subsequently by pair-wised Student’s t test.
β-glucan exposure induces a pro-inflammatory monocyte phenotype
We next examined possible pathways underlying the pro-inflammatory monocyte 
phenotype in PLHIV. Persistent exposure to microbial ligands derived from gut microbes, 
CMV or HIV itself has been suggested to play a role in the persistent inflammation in 
PLHIV2,9-12. We postulated that these factors also play a role in the pro-inflammatory 
monocyte phenotype. We, therefore, first assessed whether innate cytokine responses 
were associated with parameters of the HIV viral reservoir. The HIV reservoir was 
assessed by analyzing CD4+ cell-associated HIV-1 DNA (CA-DNA) and CA-RNA. In 
virally suppressed patients, the CA-DNA roughly equals the integrated HIV-1 DNA, 
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Figure 7. Parameters of HIV reservoir, CMV seropositivity and microbial integrity. 
(A-D) Log10-transformed cell associated HIV-1 DNA (CA-DNA) in CD4+ cells correlation with: (A) circulat-
ing IL-6 levels, (B) IL-1β production after LPS (100ng/mL) stimulation, (C) IL-1β production after imiquimod 
(IMQ; 1ug/mL) stimulation and (D) soluble CD14 plasma concentration. (E-H) Log10-transformed cell 
associated HIV-1 RNA (CA-RNA) in CD4+ cells correlation with: (E) circulating IL-6 levels, F) IL-1β produc-
tion after LPS stimulation, (G) IL-1β production after imiquimod stimulation and (H) soluble CD14 plasma 
concentration.  (I-L) Stratified by Cytomegalovirus (CMV) seropositivity: (I) Log10-transformed cell asso-
ciated HIV DNA (CA-DNA) in CD4+ cells, (J) IL-1β production after LPS stimulation, (K) IL-1β production 
after imiquimod stimulation and (L) soluble CD14 plasma concentration. (M) Intestinal fatty-acid binding 
protein (iFABP) in plasma, a marker of intestinal integrity, between healthy controls (HC; n = 56) and peo-
ple living with HIV (PLHIV; n = 211). (N-P) Plasma iFABP concentration correlation with: (N) IL-1β production 
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after LPS stimulation, (O) IL-1β production after imiquimod and (P) soluble CD14 plasma concentration. 
All boxplots are depicted according to Tukey; median (line), interquartile range (edge of boxplot), range 
(whiskers) and outliers three times interquartile range are depicted as dots. Pearson’s coefficient (r) after 
log-transformation is shown in correlation plots. Data in boxplots are analyzed using Student’s t test 
after log10-transformation. All plots depict data from PLHIV only (n = 211) unless otherwise stated.
transcriptional activity and serves as a proxy for the active proviral reservoir27. While 
cell associated HIV-1 CA-DNA levels in CD4+ T-cells were associated with plasma IL-6 
concentrations (Figure 7A), there was no association between IL-1β cytokine responses 
(Supplemental Figure 5) or plasma sCD14 concentrations and HIV-1 CA-DNA or CA-
RNA levels in our cohort (Figure 7B-H). 
Next, we assessed associations between cytokine responses and CMV seropositivity. In 
total 198/211 (93.8%) of participants were CMV seropositive. There were no differences 
in IL-1β cytokine responses,sCD14 concentrations or HIV-1 CA-DNA between CMV 
seropositive vs. seronegative individuals (Figure 7I-L, Supplemental Figure 5). Another 
source of chronic microbial ligand exposure in PLHIV is increased microbial translocation 
9. Plasma concentrations of Intestinal fatty acid binding protein (IFABP), a marker for 
microbial translocation, were significantly increased in PLHIV compared to controls (Figure 
7M). We found a modest negative correlation of IFABP concentrations with IL-1β cytokine 
responses (Figure 7N-O), but no correlation with sCD14 concentrations (Figure 7P). 
Increased intestinal translocation may also increase circulating concentrations of β-glucan, 
which is a well-known inducer of trained immunity 28. We therefore determined serum 
β-glucan concentrations in the subsequent cohort of 28 PLHIV and 12 controls. Compared 
to controls (4/14; 29%), a significantly higher proportion of PLHIV (16/28; 57%), and especially 
those in the high IL-1β producer group (11/15; 73%), had detectable β-glucan in serum (Figure 
8A-B). Individuals with detectable serum β-glucan had elevated IL-1β production (Figure 
8C-D), showed increased IL1B gene expression (Figure 8E) and increased intracellular 
proIL-1β upon stimulation (Figure 8F). Concurrently, IL1ra production was increased in 
PLHIV with detectable β-glucan concentrations (Figure 8G). A similar, non-significant trend 
was observed for IL-6 and TNF responses (Figure 8H-I). A similar, non-significant trend was 
observed for IL-6 and TNF-α responses (Figure 8I-L). Next, using a well-established in-vitro 
training protocol of trained immunity 29, we confirmed that pre-stimulation of adherent 
monocytes with β-glucan resulted in a pronounced enhancement of IL-6 release upon 
re-stimulation with LPS at day 6 (Figure 8M). We also investigated the effects of pre-
stimulation with LPS. As previously reported, pre-stimulation with LPS induced immune 
tolerance (Figure 8D) 15. Taken together, these findings suggest that circulating β-glucan is a 















































































































































































































Figure 8 β-glucan induces a pro-inflammatory phenotype in monocytes. 
(A) β-glucan (βG) in serum stratified by healthy controls (control), people living with HIV (PLHIV) with 
low or high initial IL-1β response. (B) percentage of detectable levels of β-glucan in serum, stratified 
by control, PLHIV with high and low initial IL-1β response. (C-D) IL-1β production after 24h stimulation 
with imiquimod (C; 1ug/mL) or Mtb (D; 1ug/mL) in PLHIV stratified by detectable β-glucan levels. (E) 
IL1B gene expression after imiquimod stimulation depicted as fold change (FC) from medium (RPMI). 
(F) Intracellular levels of proIL-1β protein after Imiquimod stimulation. (G-H) IL1Ra production after 
24h stimulation with imiquimod (G) or Mtb (H) in PLHIV stratified by detectable β-glucan levels. (I-J) 
IL-6 production after 24h stimulation with imiquimod (I) or Mtb (J) in PLHIV stratified by detectable 
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β-glucan levels. (K-L) TNFα production after 24h stimulation with imiquimod (K) or Mtb (L) in PLHIV 
stratified by detectable β-glucan levels. (A-L) PLHIV n = 28, healthy controls (HC) n = 14. All boxplots 
are depicted according to Tukey; median (line), interquartile range (edge of boxplot), range (whiskers) 
and outliers three times interquartile range are depicted as dots. Data were analyzed using Student’s t 
test after log10-transformation. (M) Initial training with either LPS (TLR4 ligand), β-glucan (10ug/mL) or 
medium only (RPMI + 10% serum) was performed for 24h at day 1. Thereafter a 5-day resting period in 
medium only (supplemented by 10% serum), at day 6 adherent monocytes were restimulated with LPS 
10ng/mL. IL-6 was measured in the supernatant and fold change from training with medium only are 
depicted. Data shown are from three separate experiments (n=9). Data were analyzed using Wilcoxon 
matched pairs signed-rank test. * P < 0.05 ** P < 0.01. 
DISCUSSION
In this study, we investigated the functional phenotype of circulating immune cells in a 
cohort of PLHIV on stable cART. We show that PLHIV exhibit a sustained elevation in 
monocyte cytokine responsiveness, whereas lymphocyte-derived cytokine responses 
were mostly unaffected. Our immune profiling data, which included transcriptome 
analysis of circulating monocytes, further showed an increased expression and 
activation of the IL-1β pathway. HIV infection is associated with increased microbial 
translocation 9 and we identified a, so far unrecognized, role for elevated circulating 
β-glucan concentrations in the altered inflammatory monocyte phenotype in PLHIV. 
These data corroborate findings from earlier, smaller studies in PLHIV, which reported 
an increased production of pro-inflammatory cytokines to stimulation with ligands 
of TLR4 30,31 or TLR7 32,33, or M. tuberculosis 34. The increased monocyte-derived 
cytokine responsiveness in our PLHIV cohort was associated with increased plasma 
concentrations of different circulating inflammatory markers, such as hsCRP, sCD14, 
IL-18 and IL-6, suggesting a functional link between changes in the innate immune 
profile and systemic inflammation in PLHIV. Remarkably, HIV infection had little effect 
on lymphocyte-derived cytokine responses, despite the fact that alterations in T-cell 
immune phenotype have been described in long-term viral suppressed PLHIV35,36. 
Previous research in HFGP cohorts of HIV-uninfected individuals showed that age, 
environmental, microbial and genetic factors have a clear impact on the function of 
circulating T-cells 21-23,37.
The observed intrinsic pro-inflammatory phenotype of monocytes in PLHIV was 
stable over time and associated with upregulation of pro-inflammatory pathways, most 
notably the IL-1β pathway. This corroborates a recent study showing a pronounced 
202
pro-inflammatory phenotype, including upregulation of IL1B, of monocyte derived 
macrophages in PLHIV 38. Long-term epigenetic reprogramming of monocytes in 
response to microbes has been termed ‘trained immunity’. This functional adaptation 
of monocytes enables a greater response when subjected with a secondary stimulus as 
protective mechanism against a secondary infection 14-16. Nonetheless, a trained immunity 
phenotype of monocytes has also been related to conditions such as cardiovascular 
diseases and diabetes 39-42. In PLHIV, altered epigenetic profiles such as DNA 
methylation have been reported 43-46. Specific DNA methylation patterns in PLHIV were 
associated with progressive aging and non-AIDS related co-morbidities, such as insulin 
resistance, neurocognitive disorders and chronic kidney disease 17,46-48. Interestingly, HIV/
Simian immunodeficiency virus (SIV) DNA vaccination was recently shown to induce a 
trained immunity phenotype in vivo through upregulation of IL-1β related genes 49. This 
upregulation correlated with protection against subsequent SIV infection in macaques. 
Furthermore, HIV-1 itself has also been shown to increase IL-6 production via epigenetic 
modification of STAT3 in microglial cells 50. Although epigenetic modification has been 
shown to underlie the trained immunity phenotype, we did not determine epigenetic 
changes in the current study. Future studies are warranted to investigate the epigenetic 
processes underlying the trained immunity phenotype reported here. 
Another question concerned the identification of the possible mechanisms responsible 
for the observed changes in innate immune responses.  CMV 10, microbial translocation 9, 
and HIV reservoir 11 have each been related to persistent inflammation in PLHIV. However, 
our data did not show a positive correlation between monocyte responsiveness and 
CMV seropositivity, levels of IFABP (microbial translocation marker), or parameters of 
the HIV reservoir. Although, we do not exclude a possible accessory role for these 
markers of microbial exposure, we did find an association of circulating β-glucan 
concentrations and IL-1β responsiveness. β-glucan is a component of the cell wall of fungi 
and is known to be a strong inducer of trained immunity 16. Furthermore, IL-1β signaling 
is reported to be important in β-glucan induced trained immunity in vivo 51. Our present 
data corroborate earlier reports that increased circulating β-glucan concentrations can 
be found in virally-suppressed PLHIV 28,52,53. Acute HIV infection leads to an early and 
pronounced loss of mucosal Th17 CD4+ T cells 54. This cellular compartment is critical 
for regulation of mucosal host defense against Candida and regulation of epithelial cell 
permeability 55. Increased levels of other microbial products, including LPS, have also 
been reported in PLHIV 28,56. However, in contrast to β-glucan, LPS generally induces 
immune tolerance, even at low concentrations 15,16, a notion we confirmed in vitro. This 
notion is supported by our observation that microbial integrity, as measured by iFABP, 
is associated with decreased monocyte responsiveness. An HIV infection is associated 
with alterations in the bacterial gut microbiome composition and these changes play 
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a role in the incidence of co-morbidities and inflammation 2,57,58. While studies on the 
mycobiome in PLHIV are limited, fungal dysbiosis with a high prevalence of Candida 
species has been found in stool samples of PLHIV 59. Furthermore, our data showed 
lower IL-6 and higher IL-10 production by monocytes upon Candida stimulation in PLHIV 
compared to uninfected controls, suggesting an altered fungal immune response. This 
defective immunity could contribute to fungal dysbiosis in virally suppressed PLHIV. 
Hence, our present data support the need for future studies exploring the role of the 
mycobiome in persistent inflammation in PLHIV, as well as possible strategies to reduce 
β-glucan exposure.
Reducing inflammation is considered an attractive therapeutic target to reduce the 
burden of cardiovascular diseases. The CANTOS (Canakinumab Anti-Inflammatory 
Thrombosis Outcome Study) trial that was carried out in HIV uninfected subjects who 
were at risk for a cardiovascular event. The trial revealed that specific neutralization 
of IL-1β reduced in the incidence of subsequent cardiovascular events and death from 
lung cancer 60,61. Similarly, the anti-inflammatory drug colchicine reduced cardiovascular 
events in patients with coronary disease 62. In contrast, the immunosuppressive drug 
methotrexate did not reduce CVD, underlining the importance of IL-1β in CVD 63. Recent 
findings that canakinumab reduced atherosclerotic inflammation in PLHIV at high-risk 
for CVD are therefore promising 64 and support the importance of IL-1β pathway in 
HIV. Orally administrated drugs that inhibit the IL-1β pathway, such as inflammasome 
inhibitors, may form an attractive alternative 65. This also applies to epigenetic modifying 
drugs, such as histone deacetylase (HDAC) inhibitors. These drugs have been shown 
to reduce CRP concentrations, IL-1β expression in PBMCs 66 and IL-1β production to 
LPS stimulation in whole blood from PLHIV 67. Taken together, our present data support 
the use of interventions targeting the IL-1β pathway or reduce B-glucan exposure as an 
adjunctive therapy to reduce non-AIDS related co-morbidities. 
A particular strength of our study is that in-depth functional analysis of adaptive and 
innate immune cell function in a relatively large cohort of PLHIV. The same HFGP 
approach was successfully used to investigate genetic, environmental and microbial 
factors influencing the immune system in HIV-uninfected individuals 21-23,37. Limitations 
of our study include that PLHIV and control cohort differed in age and sex distribution. 
All analyses were therefore adjusted for these differences using multivariate analyses 
with sufficient sample size. Moreover, the primary findings were confirmed when we 
resampled a selection of age and sex matched PLHIV and controls. However, we could 
not correct for men who have sex with men (MSM), as this information was not available 
for the control group68. Second, the nature of our cross-sectional study does not allow 
to draw strong causal inferences, for example on the role of HIV or β-glucan in the 
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observed immune changes. Third, the heterogeneity and activity of the HIV reservoir 
is not fully determined by HIV CA-DNA and HIV CA-RNA measurement only, residual 
viremia with single copy assay could quantify recent HIV activity.   Fourth, recently 
monocyte alterations in PLHIV were linked to cART induced oxidative stress 69. The 
enrolment in our cohort was limited to virally-suppressed PLHIV on cART and, therefore, 
a possible independent effect of cART on immune responses could not be assessed. 
However, an effect of different cART regimens appears unlikely, since no differences 
in cytokine responses were found across the different cART regimens. Finally, due 
to limited inclusion of women in our cohort, generalizability to women or sex-specific 
analyses were not feasible. 
In conclusion, we found that PLHIV on stable cART exhibit a marked and long-lasting 
increase in the production of IL-1β with subsequent downstream monocyte-derived 
cytokines, suggesting a trained immunity phenotype of monocytes. Increased translocation 
of β-glucan from the gastrointestinal tract was identified as a possible inducer of this 
innate immune phenotype. Our findings provide mechanistic insights and shed new light 
on the usefulness of interventions targeting the innate immune system, as well as the gut 
mycobiome, as an adjunctive therapy to reduce non-AIDS related co-morbidities. 
METHODS 
Study population
A total of 211 PLHIV were recruited from the HIV clinic of the Radboud university medical 
center between December 2015 and February 2017 with a follow up measurement 
in 2018. Caucasian individuals age ≥ 18 years, on cART > 6mo with an HIV-RNA load 
<200 copies/mL and showed no signs of opportunistic infections or active hepatitis 
B/C were included. The control group consisted of 56 healthy individuals not using 
any medication at inclusion. Inclusion, sampling and sample processing of both cohorts 
were conducted simultaneously and uninfected controls were sampled every three 
months during the inclusion of PLHIV. In the follow-up measurement, we resampled 28 
male PLHIV, aged >45yrs after >1yr and stratified them on the basis of their initial IL-1β 
production capacity in a group of low (lowest quartile) and high (highest quartile) IL-1β 
producers.  A control group of fourteen age-sex matched healthy controls was also 
included. These groups were used for monocyte-only, RNA expression and β-glucan 
measurements. All experiments were performed by the same personnel using the HFGP 
methodologies (http://www.humanfunctionalgenomics.org) 19. General information from 
all participants was recorded in an electronic case report form (CastorEDC, Amsterdam, 
The Netherlands). Clinical data were extracted from the electronic hospital information 
system and the ‘Stichting HIV Monitoring’ registry (Amsterdam, The Netherlands). 
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Ex vivo PBMC and monocyte stimulation
Venous blood was collected in sterile 10 mL EDTA and 8 mL serum BD Vacutainer® tubes 
and processed within 1-4h. Isolation of PBMCs was performed freshly collected blood 
by density centrifugation over Ficoll-Paque (VWR, Amsterdam, The Netherlands) as 
described previously 70. Monocytes were isolated by magnetic activated cell sorting using 
negative bead selection with the Pan Monocyte Isolation kit according to manufacturer’s 
instructions (Miltenyi Biotec, Leiden, the Netherlands). Cell counts, cell purity and 
composition were evaluated by XN-450 hematology analyzer (Sysmex  Corporation, 
Kobe, Japan). Fresh isolated cells (monocytes 1.105 cells per well, PBMCs 5.105 cells per 
well) were incubated with different bacterial, fungal, viral stimuli (Table S2) at 37°C and 5% 
CO2 for either 24h or 7d. For the 7d stimulation, 10% human pooled serum was added to 
the wells. IL-1β, IL-6, IL-1Ra, IL-10 and TNF-α were determined in the supernatants of the 
24hr PBMC or monocyte stimulation experiments, using enzyme-linked immunosorbent 
assays (ELISA; Duoset ELISA, R&D Systems, Minneapolis, MN, USA). IL-17, IL-22 and IFNγ 
were measured after 7d stimulation of PBMCs (PeliKine Compact or R&D Systems). 
For intracellular cytokine measurements of active IL-1β and pro IL-1β (Quantikine, R&D 
Systems), cell pellets were lysed using Triton X-100 (Sigma, Zwijndrecht, The Netherlands). 
Measurements of plasma markers and immunophenotyping
Intestinal fatty acid binding protein (IFABP), a marker of enterocyte damIage, resistin, 
adiponectin, leptin, IL-18 binding protein (IL-18BP), IL-18, hsCRP, sCD14 and sCD163 were 
measured using ELISA (Duoset or Quantikine, R&D Systems). IL-6, TNF-α, IL-10 and IL-1Ra 
were measured using SimplePlex Cartridges (Protein Simple, San Jose, CA, USA). 1,3-β-D-
glucan (β-glucan) levels were measured with Fungitell ((Associates of Cape Cod, Liverpool, 
UK) and CMV IgG by ELISA (Genway Biotech, San Diego, CA, USA). All assays were 
performed according to manufacturer’s recommendations, and samples of the different 
cohorts were measured simultaneously in the same plates or SimplePlex Cartridges. 
Monocyte subsets were measured in whole blood on a Navios flow cytometer (Beckman 
Coulter, Brea, CA, USA) as described elsewhere. Antibodies used are listed in Table S3 22. 
RNA extraction and gene expression
For qPCR analyses, total RNA was extracted from monocyte cell pellets (5.105 
cells), collected in TRIzol (Life Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s instructions. Subsequently, cDNA was synthesized using iScript reverse 
transcriptase according to manufacturer’s instructions (Invitrogen) with 500ng RNA 
input in 10ul reaction mix. Relative expression of genes NLRP3, TNF, IL6, IL1B was 
measured using SYBR Green assays (Invitrogen, Carlsbad, CA, USA) on an Applied 
Biosciences Step-one PLUS qPCR machine (Thermo Fischer Scientific, Carlsbad, CA, 
USA). Reaction volumes of 10 µL with 2 µL cDNA input. Normalization was performed 
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using ΔΔCq based on two (18S and B2M) reference genes which were stable after 
stimulation. Cycling conditions included: 95°C for 10mins, [95°C for 15 seconds, 60°C 
for 1min seconds] (40 cycles), followed by dissociation curve analysis. Primers were 
designed to be intron-spanning and are listed in table S4.
For transcriptome analysis by RNAseq, total RNA was extracted from monocytes (5.105) 
using the QIAGEN RNeasy RNA extraction kit (Qiagen, Venlo, The Netherlands), using 
on-column DNase treatment. Next, ribosomal RNA removal and library preparation for 
next generation RNA-sequencing was achieved utilizing KAPA RNA HyperPrep Kit with 
RiboErase (Roche, Basel, Switzerland), following the manufacturer’s protocol. The integrity 
and quality of prepared libraries were assessed using Agilent 2100 Bioanalyzer (Santa 
Clara, CA, USA). Sequencing was performed using Illumina NextSeq 500 machine (San 
Diego, CA, USA) in a paired end sequencing fashion. Sequencing reads obtained from 
RNA-seq measurement were aligned to the hg38 human genome reference using STAR 
71. A lower cutoff of average 50 reads among all samples was used to designate a gene 
as being expressed in our cohort. R software and DESeq2 differential analysis package 
72 were used to normalize and assess differentially expressed genes, utilizing FDR 5% 
and log2(Fold change) > 1 as the significance cutoff. The network of genes connected to 
their corresponding gene ontology was generated using cytoscape 73. The processed 
RNA-seq data including normalized read counts can be accessed via GEO (GSE160184). 
HIV Reservoir quantification
HIV-1 CA-DNA and CA-RNA were measured in triplicate by droplet digital PCR 
(ddPCR QX200 – Bio-Rad, Hercules, CA, USA) (Table S3) in CD4+ T cells isolated 
using EasySep Human CD4+ T Cell Isolation Kit (Stemcell technologies, Vancouver, 
Canada) as described previously 74. Briefly, genomic DNA was extracted using the 
DNeasy Blood & Tissue kit (Qiagen) according to the manufacturer’s protocol with 
an additional step of adding 75µl elution buffer on the column heated at 56°C for 10 
min. CA-RNA was extracted using the Innuprep RNA kit (Westburg, Leusden, The 
Netherlands) with 30µl elution buffer. Total RNA was reversely transcribed to cDNA 
by qScript cDNA SuperMix according to manufacturer’s protocol (Quantabio, Beverly, 
MA, USA). Before PCR amplification, genomic DNA was restricted by EcoRI (Promega, 
Madison, WI, USA) and cycling conditions were implemented as described previously 74. 
Total HIV-1 DNA measurements were normalized by measuring the reference gene 
RPP30 (Table S4) in duplicate by ddPCR and expressed per million PBMCs. CA-RNA 
was normalized using three reference genes per patient, (B2M, ACTB and GADPH), 
which were measured with LightCycler 480 SYBR Green I Master mix (Bio-Rad). HIV-1 
RNA copies were divided by the geometric mean of the reference genes and expressed 
per million PBMCs. Droplet classification and absolute quantification was performed 
using the ddpcRquant analysis tool with standard settings 75.
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Statistics
Depending on normality, log- or inverse rank-based transformation was applied. Values 
outside the assay quantification limits were imputed at the respective limit. Parameters 
for which one of the detection limits contained > 50% of the measurements were 
excluded. Comparisons in baseline characteristics between groups were made using 
Student’s T-test or Mann-Whitney U test depending on data distribution. Differences 
in non-continuous data were analyzed by the Pearson’s Chi-square test or Fisher’s 
exact test in case of expected counts less than five. Data were analyzed using a linear 
regression model. The crude model included an  adjustment for sampling time and the 
primary analyses included age, sex and seasonality as co-variates. P-values less than 
0.05 were considered statistically significant and correction for multiple testing was 
applied using the Benjamini-Hochberg method (FDR-correction). Data were analyzed 
using R (R Core Team, 2015). 
Study approval
The study protocol was approved by the Medical Ethical Review Committee region 
Arnhem-Nijmegen (CMO2012-550) and experiments were conducted in accordance 
with the principles of the Declaration of Helsinki. Written informed consent was 
obtained from all participants.
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SUPPLEMENTARY MATERIAL 






Male sex, no. (%) 28 (100) 14 (100)
Age, median (IQR) years 56.3 (9.6) 64.3 (12.5)
cART regimen, no. (%)
NNRTI 6 (21.4) -
PI 2 (7.1) -
INSTI 20 (71.4) -
DTG 16 (57.1) -
ELV 1 (3.6) -
RAL 3 (10.7) -
cART: combination antiretroviral therapy. NNRTI: non-nucleoside reverse transcriptase inhibitor. 
PI: protease inhibitor. INSTI: integrase inhibitor. DTG: dolutegravir. EVG: elvitegravir. RAL: raltegravir.
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Supplementary table S2. Stimulations scheme for the ex vivo cytokine production 
assays.
Stimulus Final Concentration Strain/Manufacture
Stimulation of PBMCs for 24 hours
LPS 1 and 100 ng/mL E.coli/Sigma
Pam3Cys 10 μg/mL EMC microcollections
RPMI (+ serum 10% human serum Life Technologies
Poly I:C 100 μg/mL Sas Invivogen
Imiquimod (TLR7 ligand) 5 ug/mL Invivogen
Influenza + serum 1.25 x 106 PFU/mL + 10% human 
serum
H1N1 (in house)
Mycobacterium tuberculosis 1 μg/mL H37Rv (in house)
E.Coli 1 x 106/mL ATCC 35218 (in house)
Candida albicans conidiae 1 x 106/mL UC820 (in house)
Candida albicans hyphae 1 x 106/mL UC820 (in house)
Staphylococcus aureus 1 x 106/mL ATCC 29213 (in house)
Cryptococcus gattii + serum 1 x 107/mL + 10% human serum A1M-R265, AFLP type 6 (clinical 
isolate)
Streptococcus pneumonia 1 x 107/mL TIGR4
Stimulation of PBMCs for 7 days*
RPMI  + serum 10% human serum Life technologies
Staphylococcus aureus 1 x 106/mL
Cryptococcus gattii 1 x 107/mL A1M-R265, AFLP type 6 (clinical 
isolate)
Candida albicans conidiae 1 x 106/mL UC820 (in house)
Candida albicans hyphae 1 x 106/mL UC820 (in house)
Streptococcus pneumonia 1 x 106/mL TIGR4
Mycobacterium tuberculosis 1 μg/mL H37Rv (in house)
Imiquimod (TLR7 ligand) 2.5 ug/mL Invivogen
PBMCs: peripheral blood mononuclear cells; LPS: lipopolysaccharide; TLR: Toll-like receptor.
*All 7-day PBMC stimulation experiments were supplemented with 10% human pool serum
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Supplementary table S3. Antibodies for immunophenotyping







mAb CD16 HLA-DR CD14 CD4 CD25 CD56 CD8 CD19 CD3 CD45
Distributor BC BC BC BC BD BC BC BC BC BC
10-color flow cytometry panel. Samples were analyzed by a 3-laser Navios (BC).
mAb: monoclonal antibody; BC: Beckman Coulter, CA, USA, BD: BD biosciences, CA, USA
Supplementary table S4. Primers and probes






















 Supplemental figure S1. 
Adjusted P-value are depicted from a corrected model including age, sex, seasonality and monocyte 
fraction (of PMBCs) as covariates. Red depicts significantly higher in PLHIV, blue depicts lower in 
PLHIV compared to controls. All p-values are FDR corrected.
 
Supplemental Figure S2. Crude values 24h and 7 days cytokine production 
Circulating factors in PLHIV and uninfected controls. Crude model is linear regression after inverse 
rank-based transformation. Corrected model included age, sex, and seasonality as covariates. Red 
depicts the marker is significantly increased in PLHIV; blue depicts the marker is decreased in PLHIV 




Adjusted P-value are depicted from a corrected linear regression model including age, sex, seasonal-
ity as covariates. Red depicts a significant positive correlation; blue depicts negative correlation. All 



















































































































































p = 0.0034 p = 0.037 p = 0.81
p = 0.12 p = 0.083 p = 0.00063
p = 0.57
Supplemental figure S4. Monocytes 
A-C Circulating monocyte subset concentrations determined by immunophenotyping. Classical 
monocytes(A): CD14++CD16-, Intermediate(B): CD14++CD16+, non-classical(C): CD14+CD16+. D-F sub-
sets are depicted as % of total monocytes. G: Monocyte purity after CD14-negative selection magnet-
ic bead isolation determined by Sysmex XN-450 hematology analyzer.
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Supplemental figure S5. HIV reservoir, CMV seropositivity and microbial integrity
P-value are depicted from linear regression. Red depicts a significant positive correlation; blue depicts 







HIV infection remains an important worldwide public health threat, whereby the burden 
is highest in countries in sub-Saharan Africa. Since the start of the pandemic in 1981, 
77 million people have become infected with HIV and more than 35 million have died 
from AIDS-related illnesses1. Combination antiretroviral therapy (cART) has dramatically 
increased the life expectancy of people living with HIV (PLHIV). However, cART does 
not eradicate HIV from the human body and cure remains a distant prospect. This thesis 
addresses persistent challenges for PLHIV, divided into two different sub-domains: 
cART-related neurotoxicity and immune dysregulation in PLHIV on long-term cART. 
These two domains are first discussed separately, followed by an integrative view and 
overarching future perspectives.
PART 1 –  NEUROTOXICITY OF ANTIRETROVIRAL 
THERAPY
In order to maintain virological suppression, PLHIV have to take lifelong daily cART. This 
makes the occurrence of side effects and their effect on quality of life a very important 
topic, especially in vulnerable populations such as children and pregnant women. In 
chapter 2, we reviewed the available evidence on neuropsychiatric side effects of the 
non-nucleoside reverse transcriptase inhibitor efavirenz in adults and children. Until 
recently, efavirenz was considered a cornerstone of first-line cART in adults, children, 
and pregnant women. The World Health Organization (WHO) guidelines nowadays 
recommend dolutegravir-based regimens as the preferred first-line therapy2. While most 
countries are starting to phase out efavirenz, its use remains high due to limited availability 
of dolutegravir in some areas (including Kilimanjaro region, Tanzania, where the study 
described in chapter 3 was conducted). In adults, the discussion on neuropsychiatric 
side effects of efavirenz benefitted from evidence from numerous studies in different 
populations using a variety of psychiatric assessment tools. In contrast, available data 
on efavirenz toxicity in children, including children exposed to efavirenz in utero, were 
much more limited and mainly restricted to case reports. Side effects of efavirenz are 
closely linked to its plasma levels. Therefore, trials have investigated the effectiveness 
and safety of reduced efavirenz doses, which may lead to revision of the adult efavirenz 
dose in 400mg instead of 600mg in future guidelines3. In children and infants, genetic 
variation and immaturity of efavirenz’ main metabolizing enzymes (cytochrome P450 
2B6) limit predictability of the plasma levels. This high interindividual variability resulted 
in subtherapeutic plasma levels of efavirenz in a substantial number of children using 
original recommended efavirenz doses,4-6 leading to an increment of the dosage in the 
2013 WHO guidelines at the risk for increasing toxicity7. Furthermore, indications for 
efavirenz were extended to infants as young as three months old and the advice not to 
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use efavirenz during pregnancy was omitted after a meta-analysis showed only small risks 
for teratogenicity. These changes further compelled the reason to study neurotoxicity in 
efavirenz treated or exposed children. 
The hypotheses on the mechanisms of efavirenz’ central nervous system side effects are 
based on in vitro and animal studies. Both efavirenz and its major metabolite 8-hydroxy-
efavirenz are known to disturb energy metabolism of neurons, astrocytes, and glial cells.8 
In addition, efavirenz has been shown to bind to several neurotransmitter transporters 
and receptors, mainly the serotonin receptors.9,10 These effects of efavirenz on cell 
energy metabolism and neurotransmitter receptors underlined the need for further 
research on its effects during brain development. Therefore, we studied the effects of 
exposure to efavirenz during childhood and the perinatal period in chapter 3 and 4, 
respectively.
In chapter 3, we conducted a cross-sectional observational study in which we compared 
behavior, cognitive performance, and adherence between school-aged children on 
efavirenz- vs. non-efavirenz-based regimes. As the pediatric HIV epidemic has developed 
most substantially in sub-Saharan Africa, this study was conducted in Tanzania. In 2016, 
120 000 children were living with HIV in Tanzania of whom 46% received cART11. To 
date, Tanzanian guidelines have included efavirenz in first-line cART options for children 
with HIV. Our study showed that children on efavirenz had more attention problems at 
school, which translated into poorer school performance, despite similar intelligence 
scores. In addition, we observed trends towards higher problem scores on the Child 
Behavior Checklist (CBCL) in the efavirenz group, particularly internalizing problems 
such as anxiety or depression, withdrawn behavior, or somatic complaints. These effects 
became more pronounced after exclusion of children who were prescribed lower doses 
than recommended by the WHO, suggesting a dose-effect relationship of efavirenz 
toxicity in our cohort. Although the cross-sectional, observational design of our study 
has obvious limitations, the results suggest that efavirenz use in children may lead to 
significant neuropsychiatric side effects and underline the importance of the narrow 
therapeutic window of this drug. A previous study from our group demonstrated that 
depression scores were reduced in adolescents, but increased in adults on efavirenz.12 
A large trial in South Africa found no differences in neuropsychiatric symptom scores 
in children aged three years and older, who used ritonavir-boosted lopinavir and 
were randomly assigned to switch to efavirenz-based therapy or continue ritonavir-
boosted therapy. Nevertheless, sleeping problems and nightmares were more common 
in the efavirenz group after 4 weeks randomization and two out of the 150 children 
experienced efavirenz related seizures.13 It is not unlikely that the presence and severity 
of efavirenz’ neuropsychiatric side effects are age-dependent, as similar phenomena 
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are seen for other serotonergic drugs, e.g. serotonin reuptake inhibitors (SSRIs). Our 
results therefore underscore the need for adequate monitoring and follow-up of these 
symptoms, especially during vulnerable periods, such as the transition to adolescence 
and adulthood.
Clinical studies on the effects of perinatal efavirenz exposure come with additional 
challenges. Perinatally exposed school-aged children are usually HIV-uninfected and 
not being followed-up regularly. In addition, use of efavirenz during pregnancy was 
contraindicated until 2012. Consequently, long-term developmental data (animal and 
human) were unavailable at the time of start of this PhD project. In chapter 4, we 
investigated long-term neurodevelopmental effects of perinatal exposure to efavirenz 
using a rat model. Rats mature much faster than humans, yet the sequence of brain 
developmental milestones is remarkably similar14. This rat model also enabled us to 
perform additional mechanistic analyses. Pregnant rats were treated with efavirenz or 
vehicle until post-natal day 7 (this day resembles the human functional brain maturity 
around birth15) and their male offspring underwent behavioral testing during early life, 
adolescence, and adulthood. After post-natal day 70, rats were sacrificed and their 
brains were removed for immunohistochemistry analyses. Using an efavirenz dose 
of 100 mg/kg, we found detectable, yet subtherapeutic, plasma levels of efavirenz in 
pregnant rats. We observed a transient delay in reflex and motor development in the 
male offspring. The fact that maternal care did not differ between efavirenz-treated and 
vehicle-treated litters, suggests a direct toxic effect of efavirenz on the developing brain. 
As our findings correspond with findings from a prior study in rats perinatally exposed to 
SSRIs16, this effect may be, at least partially, mediated by its serotonergic actions. Indeed, 
at the cellular level, we found that efavirenz was associated with a disrupted cortical 
organization and an excess of serotonergic innervation in the primary motor cortex and 
the medial prefrontal cortex17, in which the former is essential in motor development 
and the latter in emotional regulation. Moreover, perinatal efavirenz exposure elicited 
apoptosis of mature neurons and astrocytes in all cortical layers of these brain areas. 
As we only have histological data from adult rats, the exact underlying mechanisms still 
need to be elucidated. Nevertheless, these findings shed new light on the mechanisms 
of perinatal efavirenz neurotoxicity.
Recent clinical studies affirmed our findings in rats. Among 3759 HIV-exposed, but 
uninfected American children, in utero efavirenz exposure was associated with a 
50% higher risk of a neurologic diagnosis including a two to three times higher risk 
for microcephaly18,19. Strikingly, the magnitude of this effect was even stronger than that 
for fetal alcohol exposure. Those with microcephaly had lower cognitive, motor, and 
language Bayley-III scores than those without microcephaly. Moreover, among 493 
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HIV-exposed but uninfected children in Botswana, in utero exposure to efavirenz was 
associated with lower performance-based receptive language scores, as well as less 
well-developed motor and social-emotional skills20. Notably, the infant elimination half-
life of efavirenz is over twice that of mothers.21 While the prolonged half-life may improve 
the efficacy of prevention of mother-to-child transmission (PMTCT), it may also increase 
risks of toxicity, warranting further studies on the safety of efavirenz in children, and 
pregnant and lactating women.
Though still widely used in many countries, efavirenz’ primacy has been challenged by 
the arrival of newer antiretrovirals (ARVs) with improved efficacy and safety profiles. 
One of these newer drugs is dolutegravir. In 2016, a retrospective study from The 
Netherlands reported unexpectedly high discontinuation rates of dolutegravir, mostly 
due to intolerability22. Reported symptoms included sleep disturbances, depression, 
anxiety, and headache. This study was followed by a number of other real-life studies, 
which consistently showed higher discontinuation rates than expected. Moreover, 
recent studies have suggested a potential increased risk of neural tube defects after 
periconception dolutegravir exposure23. Mechanistically, dolutegravir penetrates the 
blood brain barrier and inhibits organic cation transporter 2 (OCT2), which is involved in 
the transport of serotonin and dopamine24,25. Indeed, one study showed that dolutegravir-
treated individuals with a genetic variant of the gene encoding for the OCT2 (SLC22A2 
C->A) were at higher risk of having abnormal scores of the Symptom Checklist (SCL)-
90-R25. However, due to the lack of a control group of PLHIV receiving non-dolutegravir, 
a causal conclusion cannot be made. Other studies did not use validated psychiatric 
tools and often relied on spontaneous recording of side effects in medical records. 
Furthermore, most studies did not take other potentially relevant lifestyle-related 
factors into consideration, such as the use of recreational drug use. 
In chapter 5, we applied standard validated questionnaires on mood, impulsivity, and 
substance use in 194 virally suppressed, mostly male, individuals of whom 42% received 
dolutegravir-containing regimens. One-fourth of individuals scored above the normal 
cut-off for depressive, anxious, or stress symptoms, and 14% were classified as highly 
impulsive. Regular substance use was reported by almost one-third of individuals. 
Despite the high prevalence of psychiatric symptoms and regular substance use, there 
was no association with the use of dolutegravir or other integrase inhibitors. Therefore, 
these data did not substantiate concerns that arose in real-life studies regarding 
dolutegravir-related neurotoxicity. Correspondingly, more recent studies support our 
observation that dolutegravir is generally well tolerated, with only a minority of patients 
reporting neuropsychiatric side effects26-31. 
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Together, the studies from part 1 of this thesis suggest that the use of efavirenz in 
infants, children and pregnant women needs to be carefully (re)considered because of 
efavirenz’ propensity to cause neuropsychiatric side effects. While our study supports 
the safety of dolutegravir in Caucasian males, safety data in women and children remain 
scarce. This is particularly problematic for low- and middle-income countries with a high 
prevalence of HIV among women and children, limited ARV options, and public health 
directed cART policies. 
Several recommendations for future ARV safety profile testing can be derived from 
this thesis. First, mental health and quality of life are essential aspects when evaluating 
lifelong treatments, and safety assessments of new ARVs should include monitoring of 
neuropsychiatric symptoms. Adequate reporting of neuropsychiatric symptoms requires 
use of validated, culturally adapted, assessment tools. Second, more priority should be 
given to early data collection in women and (ARV-exposed) children. Women account for 
more than half the number of PLHIV worldwide. The success of PMTCT programs has 
resulted in more than 1 million HIV-exposed uninfected children being born each year, 
including nearly 1 out of every 4 infants born in some parts of sub-Saharan Africa32. Drug 
developers, academic researchers and funding agencies should be strongly encouraged 
to increase the inclusion of these groups in studies in order to prevent potential harms 
created by their exclusion or omission. Third, preclinical animal models should include 
long-term neurodevelopmental and functional assessments and the generated data 
should be transparent and made publicly available. Our group did several attempts to 
obtain results from the efavirenz registration files, but failed to get access to the data. 
Fourth, in order to increase reproducibility, studies should acknowledge the complex 
interaction between HIV, cART, the host, and the (cultural) environment and try to 
incorporate these different aspects in their study design. 
Despite these efforts, not all side effects can be identified from pre-marketing trials, 
emphasizing the need for continuous safety monitoring of ARVs. In the Netherlands, 
drug safety surveillance is being carried out by the Pharmacovigilance Centre Lareb and 
its Teratology Information Service, which monitors the safety of drugs during pregnancy. 
These systems strongly depend on voluntarily reporting of side effects by patients 
and health professionals. This spontaneous character is vulnerable to underreporting 
as professional may not always recognize side effects. As illustrated in this thesis, 
underreporting may not only result in underestimation of side effects, but also increase 
the risk for bias due to selective reporting. Moreover, drawing conclusions on causality 
requires systematic post-marketing research. For the majority of new drug approvals, 
authorities request pharmaceutical companies to conduct supplementary longitudinal 
surveillance studies. Unfortunately, due to variable quality of study designs, these 
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studies often have limited added value to the knowledge of drug safety, especially when 
it comes to specific populations33. Funding for side effect monitoring of older drugs 
is even more difficult. Being available in generic versions, additional research on drug 
safety of efavirenz generally does not lie in the interest of pharmaceutical companies. 
Other funding agencies rather focus on groundbreaking studies on pathophysiology or 
development of new treatment strategies, than on side effect monitoring of existing 
drugs. Luckily, the relevance of our study subject was acknowledged by Radboud 
university medical center and Aidsfonds. Still, the current studies have been completed 
and these funds have dried up. In the Netherlands, ZonMw fulfils a central role as 
national research funding organization, covering a range of topics on medicines, such as 
personalized medicine, polypharmacy, and adherence research. The thesis advocates 
for inclusion of a topic on long-term side effects of existing drugs. 
PART 2 –  IMMUNE DYSREGULATION DESPITE 
LONG-TERM SUCCESSFUL CART 
While part 1 of this thesis focused on long-term psychiatric side effects of HIV drugs, part 
2 focused on the immunological alterations that persist despite adequate use of cART. 
These alterations are thought to explain, at least partially, the increased prevalence 
of non-AIDS-related comorbidities among PLHIV. To identify long-term immunological 
alterations and their underlying mechanisms, we established a cohort of 211 Dutch 
PLHIV on suppressive cART. This cohort was embedded within the Human Functional 
Genomics Project (HFGP), using a similar multi-omics approach to investigate the 
variation in inflammation and host immunity in PLHIV.
In chapter 6 we characterized 108 peripheral blood immune cell populations using flow 
cytometry and show that despite suppressive cART, the white blood cell composition 
remains different compared to healthy controls. As expected, PLHIV had reduced 
CD4+ T cell proportions, while CD8+ T cell proportions were expanded. CD4+ cells 
can be functionally divided into T helper (Th) cells and regulatory T cells (Treg), which 
are essential for controlling inflammation. The relationship between Th (e.g. the pro-
inflammatory Th17) and Treg must remain balanced to preserve functional immunity. In 
our study, Th17 proportions were expanded and Th17/Treg ratios were increased in PLHIV 
compared to controls. These changes related to circulating inflammation markers, gut 
homing chemokines (CCL20), and intestinal fatty acid binding protein (IFABP, a marker 
of enterocyte damage), suggesting that the changes in circulating Th17 may be associated 
with changes in gut permeability and gut homing. Our findings warrant further study as 
increased Th17/Treg ratios have been implicated in cardiovascular disease34, cancer35, 
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and major depressive disorder36, which are among the common non-AIDS-related 
comorbidities in PLHIV receiving long-term treatment. 
Next to differences in functional T cell profiling, we observed differences in B and T cell 
development, reflected by a loss of naïve T cells and memory B cells, and an expansion 
of effector cells. Moreover, in the innate arm of the immune system, we observed 
an expansion of pro-inflammatory monocytes and a loss of natural killer (NK) cells, 
especially the cytokine-producing CD56bright NK populations. 
To identify relevant factors that shape these alterations in PLHIV, we explored the 
effects of both basic demographic and lifestyle variables, as well as HIV-specific factors. 
The effects of demographic and lifestyle factors, including age, sex, and smoking were 
largely similar in PLHIV as previously observed in HIV-uninfected healthy volunteers37,38. 
Regarding HIV-specific effects, cART regimen had no effect on the immune composition, 
but we found clear associations between nadir CD4+ counts and both T and B cell 
populations, underlining the importance of early start of cART in HIV. Furthermore, early 
start of cART restricts the HIV-1 viral reservoir. The viral reservoir is established early 
during infection and represents a major obstacle to HIV cure as it cannot be eliminated 
by cART. It consists of latently infected CD4+ cells that do not produce virus constitutively 
but are able to produce infectious virus upon activation. We measured CD4+ T cell 
associated HIV-1 DNA (CA-DNA) and RNA (CA-RNA) and observed detectable levels 
of total CA-DNA and CA-RNA in nearly all patients, despite having suppressed plasma 
viral loads. Higher CA-DNA was associated with an expansion of central memory CD4+ T 
cells and Th17 cells. One of the most important co-infections during HIV, cytomegalovirus 
(CMV), also exhibited strong effects on the WBC architecture, leading to an expansion 
of effector memory and effector CD4+ and CD8+ T cells. It is for a reason that CMV is 
referred to as the ‘smoking gun’ of immunosenescence among co-infected persons. 
We next analyzed functional changes in innate and adaptive immune responses. Th17 
mediated responses (IL-22 and IL-17) seemed to be preserved, whereas the ex vivo 
production capacity of the lymphocyte-derived cytokine interferon gamma (IFN-ɣ) was 
compromised, especially in those with higher CA-DNA levels. IFN-ɣ is predominantly 
produced by Th1 cells, NK cells, and CD8+ cells39. In our population, Th1 cells did not 
differ between PLHIV and controls, while CD8+ cells were expanded. We therefore 
postulated that the loss in IFN-ɣ responses might have resulted from the loss in the 
cytokine-producing CD56bright NK bright population, which is in line with previous 
finding among treated and untreated PLHIV40. Clinically, compromised IFN-ɣ responses 
may increase the risk for infection or reactivation with Mycobacterium Tuberculosis, which 
remains an important pathogen in treated PLHIV40,41. Moreover, the associations with 
CA-DNA suggests that the reduced IFN-ɣ responses may be important for containment 
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of the HIV-1 reservoir, with potential consequences for HIV cure.42 In contrast to the 
reduced IFN-ɣ responses, the ex vivo production capacity of the monocyte-derived 
pro-inflammatory cytokine IL-1β in PLHIV was increased and correlated with blood 
biomarkers of immune activation (e.g. sCD14, IL-18 bp) and pro-inflammatory monocyte 
subsets. 
In Chapter 7, we further explore the underlying mechanisms by integrating cytokine 
responses with transcriptional analyses. We found that IL-1β remained stable over time, 
pinpointing towards a process called trained immunity, in which long-term functional 
reprogramming of innate immune cells results in an altered response towards a challenge 
with a second stimulus (such as imiquimod or LPS)43. Indeed, transcriptome analyses of 
isolated monocytes revealed that pro-inflammatory pathways, including the IL-1β pathway, 
were upregulated in PLHIV compared to controls. The HIV-1 reservoir, CMV, and microbial 
translocation from the gut have each been associated with inflammation in HIV44-46. We 
observed higher levels of IFABP in PLHIV, suggesting microbial translocation. While 
IFABP concentrations were positively related to Th17 percentages, we found no direct 
relationship with IL-1β responsiveness. Moreover, IL-1β responses seemed unrelated to 
CA-DNA and CMV seropositivity. Instead we identified a, so far unrecognized, role for 
elevated levels of plasma β-glucan. β-glucan is a component of fungal cell walls and 
fungal dysbiosis has been found in stool samples from PLHIV47. Increased microbial 
translocation may increase levels of plasma of β-glucan, which may partially explain 
the pro-inflammatory monocyte phenotype in PLHIV. Together the results from part 
2 show that despite adequate cART, PLHIV have a generalized dysregulated immune 
cell architecture, affecting both the innate and adaptive compartment. Functionally, 
we observed the largest changes in the innate compartment, reflected by exacerbated 
monocyte-derived IL-1β responses and compromised IFN-ɣ responses – although the 
latter may also reflect a compromised functional capacity of Th1 or CD8+ T cells. These 
changes in chronic PLHIV partly resemble those seen in elderly and may pinpoint 
towards a process called premature immunosenescence48.
Clinically, our results may be relevant for both care and cure in chronic HIV. In the 
context of care, our immunological data may explain part of the overrepresentation of 
non-AIDS-related comorbidities, increased susceptibility to pneumococcal infections, 
and impaired vaccination responses in PLHIV on suppressive cART49,50. For example, 
inflammation and exacerbated IL-1β responses have been linked with cardiovascular 
disease in HIV-uninfected subjects. In this context, our study paves the way for 
studies on new therapeutic targets: either directly by inhibiting the IL-1β pathway using 
canakinumab, a human monoclonal antibody against IL-1β, or indirectly by targeting the 
gut mycobiome and microbial translocation. In addition, our data may have important 
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implications for cure strategies. During cART, HIV-1 persists indefinitely within different 
CD4+ T cell subsets. Our data may help to improve our understanding on the interaction 
between peripheral blood cell populations and the HIV-1 reservoir, which is crucial in 
the context of new cure strategies. For example, the association between the HIV-1 
reservoir and reduced IFN-ɣ responses may warrant further research into the potential 
of NK cell based immunotherapies in PLHIV. Although we found no direct relationship 
between inflammation and markers of the reservoir, others have suggested that the 
pro-inflammatory environment may lead to increased reservoir sizes46. Hence, the IL-
1β-targeted strategies proposed above, may eventually also have consequences for 
treating the reservoir and cure.
CONCLUSIONS AND FUTURE DIRECTION
In 2014, the Joint United Nations Program on HIV and AIDS (UNAIDS) and partners 
established the 90–90–90 targets aiming to diagnose 90% of all PLHIV, provide cART 
for 90% of those diagnosed, and achieve viral suppression for 90% of those treated 
by 2020. As a result of increased HIV testing and better access to effective treatment, 
59% of PLHIV were virally suppressed in 201932. While this number is promising, it is 
still far below the intended percentage of 73%. Moreover, viral suppression should not 
be the sole endpoint of HIV care. Good HIV care should also involve monitoring of 
mental health and neuropsychiatric side effects (part 1) and immunological optimization 
in order to prevent long-term non-AIDS-related complications (part 2). 
Traditionally, basic immunology and mental health are considered to be very distinct 
fields and the intimate relationship between physical conditions and psychological 
function is often neglected. By integrating different disciplines, ranging from basic 
cognitive neuroscience to child behavioral science and clinical internal medicine, this 
thesis challenges this Cartesian mind-body dualism. Furthermore, the studies in this 
thesis show the diversity of the groups affected by HIV. Treatment of HIV in children in 
sub-Saharan Africa poses different challenges than in males in Western Europe as these 
groups probably differ in more dimensions than they have in common. By including these 
diverse groups, the impact of this thesis goes beyond age, sex and country borders, 
eventually having consequences for many PLHIV globally.  
Specifically, the results of this thesis have contributed to two important future projects 
integrating behavioral science with immunology in different areas of the world. First, our 
studies from part 1 have resulted in a collaboration with the Botswana-Harvard AIDS 
Institute Partnership for HIV Research and Education. Starting at December 2020, the 
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Motheo Study will evaluate long-term neurodevelopmental outcomes in HIV-exposed 
uninfected children exposed to either efavirenz or dolutegravir in utero, including 
potential biological mechanisms (e.g. by measuring platelet serotonin levels). Following 
part 2 of this thesis, the cohort is being expanded with another 2000 PLHIV, who are 
recruited in four different HIV treatment centers in The Netherlands. This larger cohort 
includes different clinical phenotypes (elite controllers, immunological non-responders, 
and rapid progressors) as well as different key populations (men who have sex with 
men, females, and people from sub-Saharan Africa). By integrating molecular (genomics, 
metabolomics), immunological, virological, and clinical data (including cART regimens, 
lifestyle data, and mental health measures), the results from this cohort will further 
improve our understanding of immune dysregulation in different patient groups with 
chronic HIV.
As The Lancet HIV puts it, “It is not enough that people living with HIV are alive. They 
should also be living well”.
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Hiv blijft een belangrijk probleem voor de volksgezondheid, met name in landen in Sub-
Sahara Afrika. Sinds de start van de hiv-epidemie in 1981 zijn er al 77 miljoen mensen 
geïnfecteerd met het virus en zijn er 35 miljoen mensen overleden ten gevolge van aids. 
Verbeterde behandeling met een combinatie van verschillende antiretrovirale middelen 
(cART) heeft de levensverwachting van mensen met hiv fors doen stijgen. cART kan het 
virus echter slechts onderdrukken en niet verdrijven, waardoor genezing vooralsnog 
toekomstmuziek blijft en er dus een groeiende groep is van mensen met een chronische 
hiv infectie. In mijn proefschrift bespreek ik verschillende uitdagingen die op het pad 
van deze mensen komen.
Om het virus adequaat te kunnen onderdrukken moeten mensen met hiv levenslang 
dagelijks vaak meerdere pillen slikken. Medicatiebijwerkingen zijn dan van bijzonder 
belang. Waar sommige bijwerkingen, zoals bijvoorbeeld nierfunctiestoornissen, 
eenvoudig zijn te meten, worden centraal zenuwstelsel bijwerkingen vaak over het hoofd 
gezien. Desondanks kunnen dergelijke bijwerkingen grote gevolgen hebben voor de 
kwaliteit van leven van mensen met hiv. In het eerste deel van mijn proefschrift beschrijf 
ik de effecten van eerstelijns hiv-medicijnen op het centraal zenuwstelsel in verschillende 
groepen. Ondanks goede behandeling herstelt daarnaast het immuunsysteem niet 
volledig, waardoor mensen met hiv vatbaarder blijven voor sommige infecties en 
een groter risico lopen op niet-aids-gerelateerde comorbiditeit waaronder niet-aids-
definiërende kanker en hart- en vaatziekten. In het tweede deel van mijn proefschrift ga 
ik verder in op dit incomplete herstel van het immuunsysteem.
In hoofdstuk 2 geven we overzicht van de kennis over neuropsychiatrische bijwerkingen 
van het hiv-medicijn efavirenz bij kinderen. Tot voor kort vormde efavirenz de hoeksteen 
van de eerstelijns hiv-behandeling. Er is inmiddels veel bekend over neuropsychiatrische 
bijwerkingen van efavirenz bij volwassenen. Deze treden bij ongeveer een derde van de 
mensen op, waarbij symptomen variëren van concentratiestoornissen en slaapproblemen 
tot depressie, angst en hallucinaties. Er zijn nog maar weinig data beschikbaar over 
centraal zenuwstelsel bijwerkingen van efavirenz bij kinderen. De weinige studies die er 
ten tijde van dit opiniestuk beschikbaar waren, betroffen vaak kleine groepen, waarin er 
geen gevalideerde psychiatrische instrumenten waren gebruikt om symptomen te vast te 
leggen. Het meten van psychische symptomen bij kinderen is ingewikkeld en al helemaal 
in gebieden met een slechte toegang tot de gezondheidszorg. Tijdige detectie is van groot 
belang omdat centraal zenuwstelsel bijwerkingen van een medicijn tijdens periodes van 
breinontwikkeling gevolgen kunnen hebben op de lange termijn. Wanneer we kijken 
naar de werking van medicijnen maken we onderscheid tussen farmacokinetiek (de 
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processen waaraan het medicijn in het lichaam wordt onderworpen) en farmacodynamiek 
(de wijze waarop het medicijn in het lichaam zijn werking uitoefent). Er zijn een aantal 
farmacokinetische en farmacodynamische principes van belang als we het hebben 
over bijwerkingen van efavirenz bij kinderen. Allereerst bestaat er een grote variatie in 
plasmaspiegels van efavirenz, wat deels voortkomt uit verschillen in metabolisme van 
efavirenz. Efavirenz wordt in de lever gemetaboliseerd door cytochroom P450 enzymen 
CYP2B6 en CYP3A4. Door onrijpheid van deze enzymen is het lastig om plasmaspiegels 
te voorspellen bij jonge kinderen. Daarnaast bestaat er genetische variatie van deze 
enzymen. Zo kunnen mensen met het CYP2B6 516 T/T genotype efavirenz minder 
goed omzetten, wat leidt tot hogere plasmaspiegels en meer centraal zenuwstelsel 
bijwerkingen. Dit genotype komt ook nog eens veel vaker voor in Sub-Sahara Afrika, 
waar de hiv-epidemie het hardst toegeslagen heeft. Een aantal farmacodynamische 
mechanismen spelen een rol bij het ontstaan van centraal zenuwstelsel bijwerkingen 
van efavirenz. Zowel efavirenz als haar metaboliet passeren de bloed-hersenbarrière 
en kunnen hier de energiehuishouding van neuronen (: zenuwcellen) verstoren. Deze 
verstoring in de energiebalans heeft consequenties voor de differentiatie en uitrijping 
van neuronen en kan zelfs tot celdood kan leiden. Daarnaast grijpt efavirenz in op een 
aantal neurotransmittersystemen, waaronder het serotoninesysteem. Tijdens de vroege 
breinontwikkeling fungeert serotonine als belangrijke groeifactor. Verstoringen van het 
serotoninesysteem tijdens de zwangerschap of de vroege kindertijd (bijvoorbeeld door 
blootstelling aan antidepressiva van de klasse serotonineheropnameremmers [SSRIs]) 
kunnen zo langdurige gevolgen hebben voor de ontwikkeling van het kind. Ook efavirenz 
zou op deze manier gevolgen kunnen hebben voor de breinontwikkeling van kinderen. 
In hoofdstuk 3 en 4 onderzoeken we dit in meer detail.
In hoofdstuk 3 vergeleken we competentie, psychopathologie, cognitief functioneren 
en therapietrouw tussen Tanzaniaanse schoolkinderen met hiv die behandeld werden 
met efavirenz en kinderen die behandeld werden met een gelijkwaardig alternatief. 
Kinderen die behandeld werden met efavirenz scoorden lager op competentieniveau, 
wat met name het resultaat was van lagere schoolprestaties. Alhoewel kinderen die 
behandeld werden met efavirenz tevens hoger leken te scoren op internaliserende 
problematiek (zoals angst en somberheid), waren deze verschillen niet significant. De 
groepen verschilden niet in intelligentie (Raven’s Progressive Matrices) of werkgeheugen 
(digit span test). Ook zagen we geen verschillen in therapietrouw. Opvallend in onze 
studie was dat slechts 40 (56%) kinderen de juiste dosering efavirenz kregen; 28 (39%) 
kinderen kregen te lage doseringen en 3 (4%) te hoge doseringen. We herhaalden 
onze analyses na exclusie van de kinderen die te lage efavirenz doseringen ontvingen 
(56%) en observeerden zowel lagere competentie- en schoolprestatiescores als hogere 
probleemscores in de efavirenz groep in vergelijking met de controlegroep. Deze 
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bevindingen impliceren dat we de bijwerkingen van efavirenz in onze studie mogelijk 
hebben onderschat als gevolg van te lage medicatiedoseringen. Onze resultaten 
suggereren dat efavirenzgebruik bij kinderen is geassocieerd met een milde stijging 
van neuropsychiatrische symptomen, met name bij kinderen die normale of te hogere 
doseringen krijgen. Gezien de potentiële gevolgen op de lange termijn is het belangrijk 
dat er aandacht is voor deze bijwerkingen in de dagelijkse praktijk.
Efavirenz wordt niet alleen aan kinderen gegeven, maar ook aan zwangere vrouwen. 
Hierdoor kan de kans op transmissie van het virus van moeder naar kind worden 
teruggebracht naar minder dan 5%. Hoewel er eerder geen aanwijzingen werden 
gevonden voor teratogeniciteit van efavirenz, waren de effecten van efavirenz op de 
ontwikkeling van het ongeboren kind onbekend. In hoofdstuk 4 onderzochten we 
daarom de gevolgen van blootstelling aan efavirenz tijdens de zwangerschap voor 
de gedrags- en breinontwikkeling. We gebruikten hiervoor een diermodel waarin we 
zwangere ratten behandelden met efavirenz of met een placebo. We onderzochten 
vervolgens systematisch de gedragsontwikkeling van de mannelijke nakomelingen 
tijdens de eerste drie weken na de geboorte, de pubertijd en de volwassen periode. 
Daarnaast onderzochten we de breintjes onder de microscoop. We zagen dat 
perinatale blootstelling aan efavirenz resulteerde in een lager lichaamsgewicht en in een 
vertraagde ontwikkeling van de reflexen en de motoriek. De motorische hersencortex 
van volwassen dieren die perinataal waren blootgesteld aan efavirenz bevatte een 
verminderd aantal cellen en neuronen en een hogere expressie van serotonerge vezels 
en van Caspase-3 – een enzym dat betrokken is bij de geprogrammeerde celdood. 
Deze resultaten wijzen erop dat perinatale blootstelling aan efavirenz kan leiden tot 
een ontwikkelingsachterstand en blijvende afwijkingen in de hersenen. Onze resultaten 
werden later bevestigd in klinische studies. Zo vertoonden Botswaanse kinderen die 
perinataal waren blootgesteld aan efavirenz meer problemen met de ontwikkeling van 
taal, emoties en motoriek.1 Daarnaast werd perinatale blootstelling aan efavirenz in een 
Amerikaans cohort van 3.759 kinderen gerelateerd aan een 50% hogere kans op een 
neurologische diagnose en een 2-3 maal verhoogd risico op microcefalie.2
Hoewel efavirenz nog op veel plekken wordt gebruikt, zijn er inmiddels nieuwe hiv-
medicijnen op de markt die snel aan populariteit hebben gewonnen, zoals dolutegravir. 
Dolutegravir is uitermate effectief, heeft een hoge barrière tegen resistentie en wordt in 
het algemeen goed verdragen. Sinds 2016 zijn er meerdere studies gepubliceerd waarin 
een aanzienlijk deel (tot 15%) van de patiënten het medicijn vroegtijdig staakte, o.a. ten 
gevolge van neuropsychiatrische bijwerkingen. Het betrof hier veelal data uit medische 
dossiers of farmacovigilantiesystemen. Goede systematische studies waarin patiënten 
werden getest met gestandaardiseerde psychiatrische instrumenten ontbraken. In 
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hoofdstuk 5 vergeleken we stemming (Depression Anxiety Stress Scale-42 [DASS-42]), 
impulsiviteit (Barratt Impulsiveness Scale-11 [BIS-11]) en middelengebruik (Measurements 
in the Addictions for Triage and Evaluation Questionnaire [MATE-Q]) tussen mensen 
die behandeld werden met dolutegravir en mensen die behandeld werden met 
een gelijkwaardig alternatief. In totaal analyseerden we 194 deelnemers, waarvan 
het merendeel (176 [91%]) man was en waarvan er 82 (42%) dolutegravir gebruikten. 
Veel studiedeelnemers rapporteerden psychiatrische klachten: 51 (26%) deelnemers 
scoorden boven de normale afkapwaarde van de DASS-42 en 27 (14%) konden worden 
geclassificeerd als hoog impulsief. Bijna een derde van de deelnemers gebruikte 
regelmatig partydrugs, waaronder cannabis, GHB en poppers. In tegenstelling tot 
dolutegravirgebruik was regelmatig drugsgebruik positief geassocieerd met depressie 
en stress scores. Alhoewel deze resultaten geruststellend zijn voor het gebruik van 
dolutegravir in de algemene populatie, kunnen we met deze studie het optreden van 
bijwerkingen in kleine subgroepen niet uitsluiten. 
De resultaten van het eerste deel van mijn proefschrift stellen de veiligheid van 
efavirenz in kinderen en zwangere vrouwen ter discussie. Waar dolutegravir in de 
westerse mannelijke populatie over het algemeen veilig lijkt te zijn, is ook op dit punt 
meer onderzoek naar de veiligheid bij kinderen en vrouwen noodzakelijk. 
In het tweede deel van mijn proefschrift kijk ik naar de lange termijn gevolgen van 
chronische hiv-infectie op het immuunsysteem. Het immuunsysteem wordt van oudsher 
onderverdeeld in het aangeboren immuunsysteem en het verworven immuunsysteem. 
Het snelle aangeboren immuunsysteem vormt de eerste verdedigingslinie. Na detectie 
van lichaamsvreemd materiaal zorgen monocyten en andere cellen van dit aangeboren 
immuunsysteem voor een snelle aspecifieke immuunreactie. Het tragere verworven, of 
adaptieve, immuunsysteem bestaat uit B en T cellen die zich specifiek richten tegen een 
bepaalde ziekteverwekker en voor immunologisch geheugen zorgen. De cellen van het 
immuunsysteem communiceren onderling door middel van signaalstoffen, cytokines. Hiv 
richt zich specifiek op de CD4+ T cellen van het verworven afweersysteem en gebruikt 
deze cellen om zich te vermenigvuldigen. Onbehandeld zal het aantal CD4+ T cellen fors 
dalen, waardoor de afweer steeds slechter wordt en er uiteindelijk aids kan ontstaan. 
Behandeling remt de vermenigvuldiging van hiv en zorgt er zo voor dat de CD4+ T cellen 
weer in aantal kunnen toenemen. cART bereikt echter niet alle virusdeeltjes, waardoor 
hiv in sommige cellen aanwezig blijft als latent viraal reservoir en genezing op deze 
manier tot op heden onmogelijk is. Daarnaast herstelt het immuunsysteem niet volledig. 
Enerzijds vertonen mensen met hiv tekenen van verminderde immuniteit zoals slechtere 
vaccinatieresponsen en grotere risico’s op infecties als invasieve pneumokokken-
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infecties en tuberculose. Anderzijds zorgt chronische laaggradige ontsteking voor een 
grotere kans op niet-aids-gerelateerde comorbiditeit. Kortom, er lijkt sprake te zijn van 
een disbalans van het immuunsysteem van mensen met hiv ondanks goede behandeling. 
Meerdere factoren kunnen hierbij een rol spelen, zoals leefstijl, het virale reservoir en 
co-infecties met bijvoorbeeld het cytomegalovirus. Ook microbiële translocatie zou 
kunnen meespelen. Normaliter vormt het lymfatische weefsel in de darm (Engels: gut 
associated lymphoid tissue [GALT]) een effectieve barrière die verhindert dat micro-
organismen vanuit het darmlumen de bloedbaan binnendringen. Door massale infectie 
en verwoesting van de lokaal aanwezige CD4+ T cellen kan hiv deze barrièrefunctie 
verminderen, waardoor micro-organismen kunnen passeren die, eenmaal in de 
bloedbaan, ook het immuunsysteem kunnen beïnvloeden. In hoofdstukken 6 en 7 
beschrijven we de immunologische gevolgen van chronische behandelde hiv-infectie. 
Dit onderzoek hebben we gedaan binnen de kaders van het Human Functional 
Genomics Project (HFGP). Het HFGP is een grootschalig project dat met behulp van 
big data onderzoekt waarom de ene persoon ziek wordt en de ander niet. Binnen het 
HFGP hebben wij een cohort opgericht van 211 adequaat behandelde mensen met een 
hiv-infectie, waarin we de samenstelling en functie van het afweersysteem inclusief de 
relevante determinanten nauwkeurig in kaart brengen. 
In hoofdstuk 6 brengen we met behulp van flowcytometrie de samenstelling van 
circulerende immuuncellen van mensen met hiv in kaart. Zowel de differentiatie en 
rijping van witte bloedcelpopulaties verschilde duidelijk tussen mensen met hiv en 
gezonde controles. Zo bevatte het bloed van mensen met hiv minder CD4+ T cellen 
en meer CD8+ T cellen. CD4+ T cellen kunnen worden opgesplitst in verschillende 
soorten T helper (Th) cellen en in anti-inflammatoire regulatoire T cellen. Mensen met 
hiv hadden een toename van T helper 17 cellen (Th17) in verhouding tot het aantal 
regulatoire T cellen. Deze pro-inflammatoire Th17 cellen waren positief geassocieerd met 
met biomarkers van ontsteking (IL-6 en sCD14) en microbiële translocatie. Ook de T cel 
ontwikkeling leek verstoord: zo was er een duidelijke toename van het aantal geheugen 
en effector T cellen in hiv, terwijl de voorraad naïeve T cellen uitgeput leek. Niet alleen T 
cellen bleken aangedaan door hiv; zo observeerden we een duidelijke verstoring van de 
B cel rijping (met een verlies van geheugencellen) en in de samenstelling van de cellen 
van het aangeboren immuunsysteem. Zowel leeftijd en geslacht, als het hiv-reservoir, als 
co-infectie met het cytomegalusvirus hadden invloed op de immuuncelpopulaties van 
mensen met hiv. 
In het laatste deel van hoofdstuk 6 en in hoofdstuk 7 onderzoeken we of de functie van 
de immuuncellen is veranderd in hiv. Daarbij keken we naar productie van signaalstoffen, 
zogenaamde cytokines, na blootstelling van geïsoleerde witte bloedcellen (PBMCs) aan 
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een scala van ziekteverwekkers. In hoofdstuk 6 observeerden we dat de productie van 
de cytokine interferon-gamma (die geproduceerd wordt door T cellen en NK cellen) was 
afgenomen in mensen met hiv. Deze afgenomen productie van interferon-gamma kan 
consequenties hebben voor de afweer tegen verschillende ziekteverwekkers, waaronder 
Mycobacterium tuberculosis. In hoofdstuk 7 zagen we daarnaast dat de monocyten van 
het aangeboren afweersysteem van mensen met hiv meer IL-1β produceerden en dat dit 
was geassocieerd met biomarkers van chronische ontsteking zoals hsCRP. Toen we een 
jaar later deze metingen herhaalden, bleek dat de productie van IL-1β stabiel verhoogd 
bleef, wat kan wijzen op intrinsieke veranderingen van de monocyt. Deze observatie 
wordt ook wel ‘getrainde immuniteit’ genoemd, waarbij ook cellen van het aangeboren 
afweersysteem zoals monocyten een soort van geheugen kunnen opbouwen door 
veranderingen in de afleesbaarheid van het DNA van de cel. Zo zagen wij inderdaad 
dat het RNA-profiel van de monocyten was veranderd. De veranderingen in IL-1β 
correleerden met circulerend β-glucan. β-glucan is een component van de celwand van 
schimmels die in het geval van microbiële translocatie vanuit de darm de bloedbaan kan 
binnendringen en zo voor getrainde immuniteit zorgen. 
Concluderend laten hoofdstuk 6 en 7 zien dat ondanks behandeling met cART, het 
immuunsysteem van mensen met hiv sterk verstoord blijft en dat dit geldt voor zowel het 
aangeboren immuunsysteem als het verworven immuunsysteem. Het immuunsysteem 
heeft pro-inflammatoir profiel met versterkte IL-1β responsen en verminderde interferon-
gamma responsen, wat enerzijds kan leiden tot een hogere kans op niet-aids-gerelateerde 
comorbiditeit en anderzijds tot verminderde immuniteit tegen ziekteverwekkers.
In 2014 lanceerde UNAIDS de 90-90-90 doelstellingen (90% van de mensen met hiv 
weten hun status, 90% van de mensen met een hiv-diagnose zijn goed ingesteld op hiv-
medicatie en 90% van de mensen die medicatie gebruikt is viraal onderdrukt). Dankzij 
verbeteringen in het test- en behandelbeleid was eind 2019 59% van de mensen met hiv 
viraal onderdrukt. Hoewel dit percentage veelbelovend is, is 59% nog steeds fors lager 
dan het beoogde 73% en moet virale onderdrukking niet het enige behandeldoel zijn 
voor hiv. Met dit proefschrift pleit ik voor meer aandacht voor de geestelijke gezondheid, 
bijwerkingen van medicatie en voor de optimalisatie van het immuunsysteem tijdens 
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Nagenoeg vers uit de schoolbanken begon ik in 2015 vol enthousiasme aan dit 
promotietraject. De afgelopen jaren hebben mij verrijkt als arts, als wetenschapper en 
als persoon. Dit proefschrift is het resultaat van samenwerking met veel verschillende 
mensen en het zou zonder hun hulp en vertrouwen nooit geworden zijn tot wat het nu 
is. Ik wil hiervoor een aantal mensen in het bijzonder bedanken. 
André, mijn promotor en mentor door dik en dun: ontzettend bedankt voor jouw 
begeleiding de afgelopen jaren. Weinig mensen kunnen tippen aan jouw creativiteit 
en optimisme, waardoor we steeds weer originele ideeën en oplossingen voor onze 
projecten vonden. Jouw sterke maatschappelijke drijfveer voor het hiv-onderzoek vind 
ik erg inspirerend. Dat je aan het eind van jouw carrière nog even het 2000HIV project 
wist op te starten, is bewonderenswaardig maar zeker niet onverwacht. Ook buiten 
het onderzoek heb ik genoten van onze tijd. In mijn dank wil ik dan ook zeker Marjolein 
meenemen voor de gezellige avonden en de overheerlijke kaasfondue. Laat me afsluiten 
met jouw fameuze motto ‘niet te veel kak aan hangen Lisa’ dat ik tot op de dag van 
vandaag in ere houd. 
Quirijn, Q, dit proefschrift was er zonder jou nooit gekomen. Jouw enthousiasme voor 
het vak infectieziekten en global health werkt aanstekelijk. In de afgelopen tien jaar 
hebben we ons beziggehouden met malaria en hepcidine, dengue en plaatjes, witte 
raven op de EOV en natuurlijk hiv. Toen jij dan ook met dit promotietraject kwam, heb 
ik niet lang getwijfeld. Als ik nu terugkijk op alle ervaringen die ik de afgelopen tijd heb 
opgedaan en bij wie ik allemaal een kijkje in de keuken heb kunnen nemen, ben ik je 
daar nog steeds heel erg dankbaar voor. Daarnaast was je ook een hele fijne coach en 
uitstekend gezelschap in Tanzania. Ook ben je een uitmuntend schrijver. Ik hoop nog 
veel van je te leren. Groetjes L.
Arnt, professor Schellekens, ook jou heb ik leren kennen als een zeer sociale en kundige 
rasoptimist. Daarnaast ben jij een ijzersterke schrijver en vond ik het erg leuk om samen 
te sparren over scherpe teksten en lastige analyses. Dankjewel dat je daar elke keer tijd 
voor maakte. Dankjewel ook dat je me verwelkomde op het NISPA en introduceerde 
aan al die experts binnen het Donders instituut en de psychiatrie. Met jouw visie en 
drijfveer weet jij menig (internationaal) project naar een hoger niveau te tillen. Ik hoop 
dat we in de toekomst nog lang kunnen samenwerken om zo voor eens en altijd te 
bewijzen dat het Cartesiaanse dualisme verleden tijd is.
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Graag wil ik alle proefpersonen bedanken voor hun deelname aan de onderzoeken. 
Daarnaast wil ik alle coauteurs bedanken voor hun bijdragen aan de hoofdstukken die 
zijn opgenomen in dit proefschrift.
Leden van de manuscriptcommissie, veel dank voor het kritisch lezen en beoordelen 
van mijn manuscript.
Ik wil bij deze gelegenheid ook het Radboudumc bedanken voor de Personalized 
Healthcare Grant. Zoals ik al aangeef in de discussie van dit proefschrift, is het niet 
eenvoudig om geld te krijgen voor onderzoek naar medicatiebijwerkingen, al helemaal 
niet als dit psychische bijwerkingen betreft. Zonder het vertrouwen van het Radboudumc 
was het nooit gelukt om dit mooie project uit te voeren. Daarnaast wil ik de andere 
sponsoren, waaronder het Aidsfonds, hartelijk bedanken voor hun bijdrage.
Mijn speciale dank gaat uit naar de sectie infectieziekten en global health van het 
Radboudumc, die de afgelopen jaren mijn thuisbasis vormde. Monique, met jouw heerlijk 
eigenzinnige stijl introduceer jij menig (internationale) student in de wereld van de 
infectieziekten en ben je een waar voorbeeld voor mij. Meta, dankjewel dat ik de kunst van 
het onderzoek doen al vroeg van jou mocht afkijken tijdens mijn wetenschappelijke stage 
in Bandung. Reinout, Frank, Jaap, jullie kennis van de infectieziekten is indrukwekkend 
en ik kijk ernaar uit om het vak binnenkort van jullie te komen leren. Mieke en Janine, 
zonder jullie overzicht en organisatorische handigheden was ik hopeloos verloren 
geweest. Dank voor alle hulp en gezelligheid de afgelopen jaren. 
First floor Gang(sters)! Annelies, Anisa, Dian, Bonny, Berenger, Edwin, Fadel, Floor, Intan, 
Khutso, Mike, Nadira and Vesla dankjewel, terima kasih, asante sana and merci beaucoup 
for the great time we spent together. The endless discussions on platelets, puzzling data 
and food (chipsi mayai and nasi goreng) are unforgettable. 
Beste Judith, dankjewel dat je me zo hartelijk verwelkomde in de Translational 
Neuroscience Unit (TNU). Ik blijf onder de indruk van de efficiënte en uiterst zorgvuldige 
wijze waarop jij onderzoek doet en dat jij nu professor bent is daarvan het welverdiende 
resultaat. Sharon, ik kan me nog goed onze eerste ontmoeting herinneren, waarin we 
ons gezamenlijk verwonderden over het gebrek aan gegevens over de veiligheid van 
efavirenz tijdens de zwangerschap. Jouw expertise op het gebied van de moleculaire 
neuroanatomie was van grote waarde voor het onderzoek hiernaar. Dankjewel voor 
deze mooie samenwerking.
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Dear Juliette, despite endless working days in the animal laboratory, you always remained 
optimistic, cheerful and a great company. Thanks for all your efforts and I wish you all 
the best in Philly. Lidiane, Sabrina, Yvet, Anthonieke, Sjef, Michel and the others of the 
TNU, thank you so much for your warm welcome, your help with all the preparations, 
test settings, analyses and the fun we had together!
I spent seven unforgettable months of my PhD on the slope of the Kilimanjaro Mountain 
in Moshi and I would like to thank my colleagues and the inspiring people I met during 
these months. In particular I would like to thank my Tanzanian counterpart, Deborah, 
for her critical input for to the efavirenz kids study and her excellent sense of humor. 
Dr Grace Kinabo (head of Paediatrics KCMC) and prof Blandina Mmbaga (head of 
KCRI) for welcoming me in their departments and mentoring me during my stay. Sister 
Zawadiel Hillu, Stella Mbiri, Neema Mahimo, Yukunda Mrema, Adeline Lyimo, and Rose 
Mosile for their huge efforts in enrolling and examining the study participants. Finally, 
big thanks to all the colleagues of the DMU, KCRI and KCMC for their good company 
and help with the project.
Collega’s van het lab experimentele interne geneeskunde (EIG), dankjulliewel voor de 
fijne jaren. Mihai, ik bewonder je om jouw grote schat aan kennis en ideeën. Dank dat 
je, ondanks jouw drukke agenda, altijd tijd maakte om mee te denken. Beste Leo, dank 
dat ik kon kennismaken met al die interessante technieken in jouw laboratorium. Heidi 
en Helga wat een geoliede ELISA machine vormen jullie zeg. Heel veel dank voor al 
jullie hulp bij de 200HIV. Zonder de adviezen van jullie en van de andere analisten 
Cor, Kiki, Liesbeth, Trees, Anneke en Liesbeth waren wij promovendi hopeloos verloren 
geweest. Dear fellow PhD warriors and post docs from EIG: Andreea, Anna, Anne A. en 
Anne J., Arjan, Bas B., Bas H., Berenice, Charlotte dB en Charlotte vdH, Dennis, Diletta, 
Duby, Ekta, Freek, Hanne, Hedwig, Inge, Jacqueline, Jessica, Jelle, Jorge, Julia, Kathrin, 
Katharina, Laszlo, Leonie, Lily, Maartje, Mark, Mariolina, Mariska, Marlies, Michelle, 
Nico, Rinke, Rutger, Sam, Simone, Siroon, Tania, Theo, Valerie, Vera, Viola, Yvette and 
all I have forgotten, big thanks for all the hard work and the talks, drinks and fun! Rob, 
dankjewel dat ja naast dat alles ook nog het dak van Afrika met mij beklom. Ruud, wij 
delen natuurlijk meer dan alleen het EIG. Dankjewel voor deze liefdevolle jaren.
Beste David, dankjewel voor de fijne samenwerking al die jaren. Ik ben altijd diep onder 
de indruk geweest van jouw onuitputtelijke kennis over de farmacokinetiek van hiv 
medicatie. Samen zorgden we voor een mooie aftrap van dit promotietraject en ik vind 
het dan ook erg leuk dat je er tijdens mijn verdediging opnieuw bij zult zijn. Beste Rob, 
dank voor jouw enthousiasme voor onze dierstudie en je hulp bij het meten van de 
plasmaspiegels.
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Nanda, wij ontmoetten elkaar via Arnt. Ondanks jouw drukke agenda was jij van meet 
af aan enthousiast en gunde jij mij een kijkje in de kinderpsychiatrie. Jouw visie en 
begeleiding waren onmisbaar voor de efavirenz kinderstudie, dankjewel hiervoor. 
Hans en Irma, dankjulliewel dat jullie mij introduceerden in de wondere wereld van 
de regulatoire T cellen, T helper cellen en de CMV. Ik kijk met plezier terug naar onze 
leerzame meetings!
Wouter, waar moet ik beginnen? Zo’n promotietraject kan eenzaam zijn, maar eigenlijk 
heb ik al die tijd wel een maatje gehad. Ik denk zelfs dat er tijden zijn geweest dat ik jou 
vaker zag dan wie dan ook in mijn leven. Dankjewel voor die ontelbare keren sparren, 
puzzelen, aliquotten maar ook borrelen, fietsen en lol maken. Voor je engelengeduld 
tijdens mijn geklungel in het lab. Dat we nu onze proefschriften op dezelfde dag mogen 
verdedigen is wat mij betreft een kers op de taart!
Wat een klus was het 200HIV project zeg. Een aantal mensen verdienen wel wat extra 
aandacht.
Allereerst Martin. Dankjewel voor al jouw hulp met … nouja, waarmee niet? Naast 
het opzetten van protocollen, het urenlange labwerk en het includeren van al die 
proefpersonen, schoot je me ook als een speer te hulp toen mijn voortanden op het 
fietspad lagen. De positie als eindbaas van het lab heb jij dan ook absoluut verdiend!
Rob, afgaande op jouw statistieken hebben we elkaar minimaal 73 keer gezien, 30 keer 
gebeld en hebben we 34 meetings gehad. Normaliter twijfel ik geen moment aan jouw 
gedegen werk, maar nu vraag ik me wel af of je niet een paar borrels over het hoofd hebt 
gezien. Dank voor je geduld, inspirerende werk en gezelligheid!
Anouk, Sanne en Marije. Dankjulliewel voor de wonderschone samenwerking. Dat 
we naast het aliquotten van poep inmiddels ook bedreven zijn in het verzamelen van 
unstable unicorns en exploding kittens is wat mij betreft een mooie ontwikkeling die ik 
graag nog vele jaren vervolg.
Karin, Bert en Manon, we danken een groot deel van de deelnemers van de 200HIV 
aan hun vertrouwen in jullie. Het afscheidsboek van Bert liet me destijds goed realiseren 
wat een verschuiving er heeft plaatsgevonden binnen de hiv zorg. Karin, wat hebben we 
een fijne tijd gehad en wat vind ik het leuk dat we elkaar nog een beetje kunnen volgen 
via de sociale media. En Manon, ondanks dat voor jou alles nieuw was, was jij nooit te 
beroerd om ons te helpen, dankjewel daarvoor.
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Mijn dank gaat ook uit naar Linos Vandekerckhove, Wim Trypsteen en Sophie Rutsaert 
van de Universiteit Ghent, voor het uiterst zorgvuldig en snel in kaart brengen van het 
virale reservoir en aan Mike Van Verseveldt, voor de nauwgezette wijze waarop hij alle 
vragenlijsten analyseerde. 
Finally, I would also like to thank Viiv for their belief in the Human Functional Genomics 
Project and their very useful input for our papers. I am very pleased to see the that the 
200HIV study will be extended (2000HIV study) by a great team: Maartje, Louise, Elise 
and others I wish you all the best!
Beste NISPA en in het speciaal Dory en Baukje. Dank dat ik zo welkom was bij jullie ook 
al was ik wellicht een vreemde eend in de bijt. Ik heb veel geleerd van de presentaties 
en de vaart in menig artikel gekregen tijdens onze schrijfmarathons op de afdeling 
psychiatrie en in het Huissense Dominicanenklooster. 
De overstap van het onderzoek naar de kliniek werd mij uiterst gemakkelijk gemaakt 
door de kleurrijke groep internisten van het Rijnstate ziekenhuis. Dankjulliewel voor 
het warme welkom en de goede begeleiding tot op de dag van vandaag. Waar ik het 
solistische van promotieonderzoek af en toe behoorlijk lastig vond, geniet ik nu des te 
meer van het werken in een team. Lieve A(N)IOS groep, wat is het bovenal ook gewoon 
beregezellig samen!
Lieve Ellen, El, jeetje wat hebben we afgelopen 14 jaar een hoop meegemaakt. Van 
Cambodja, Thailand, Vietnam, tot Sziget en een krakersfeest in Berlijn. Niets was te 
gek. Wat voelt het dan ook fijn en veilig dat je nu straks naast mij staat in de aula. Lieve 
Joan, Joanna, iets meer dan twee jaar geleden stond ik glunderend naast jou tijdens je 
verdediging en nu zijn de rollen omgedraaid. Zonder al onze goede gesprekken en die 
heerlijk ontspannende dansjes was dit proefschrift er nooit geweest. Sharon, Shazza, Fat 
Melone. Dat samenwonen met jou geen straf zou zijn, wist ik natuurlijk van tevoren, maar 
ik denk niet dat een van ons had verwacht dat het zo ontzettend goed zou uitpakken. 
Onze tijd samen in de Ruisdaelstraat was legendarisch en stiekem heb jij mij misschien 
wel het meest van al zien zwoegen op de laatste loodjes van mijn proefschrift, dankjewel 
voor je steun hierbij! 
Anne Janas en Anne Verheijen, Anouk, Carlijn Roumans en Carlijn van der Steen (“de 
Carlijns”), Emma, Femke Van der Ven en Femke Wolters, Karien, Kyra, Martine, Mirte, 
Niels, Noor, Olinde, Tom en alle andere lieve vrienden en vriendinnen, wat kijken 
we terug op rijke jaren en wat zijn jullie steun en afleiding cruciaal geweest voor dit 
proefschrift. Dankjulliewel! 
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Lieve Janna, tot op de dag van vandaag blijf je inspirerend voor mij en ik koester de tijd 
die we samen hebben gehad.
Dank lieve familie (de “Van de Wijers” en “Murissen”) en dan natuurlijk in het speciaal 
Imma en Sjeng. Jullie stimuleerden mij vanaf jongs af aan om nieuwsgierig te zijn, open te 
staan voor andere culturen en meningen maar ook om kritisch te zijn en door te vragen. 
Kortom, jullie legden de perfecte basis voor dit proefschrift. Ik voel me gezegend met 
zo’n goede opvoeding en zo’n warm bad om thuis te komen, dankjulliewel. 
Saar, lieve zus, dankjewel voor al die jaren kletsen, kibbelen, lachen en huilen. De 
afgelopen jaren zijn allesbehalve eenvoudig geweest, maar wat er ook gebeurt, weet dat 
ik geloof in je talent en bevlogenheid.
Henk, Jacqueline, Ruud, Annieke, Geert, Loes, Joost, Marga, Sallie, Ebbie en Lea, 
dankjulliewel voor jullie warme welkom in de schoonfamilie!
Lieve Frankie (Fatboy Flanningan). Het mooiste cadeau van de wetenschap blijf jij. Ook 
al leerden wij elkaar pas kennen nadat ik weg uit het Radboudumc, jouw bijdrage aan dit 
proefschrift moet niet onderschat worden. Jouw oneindige voorraad aan knuffels, geduld 
en geloof in dit project hebben mij die streep overgetrokken. Jouw schwalbes zetten 
daarnaast alles in perspectief. De afgelopen twee jaar overtroffen al mijn verwachtingen 
en doen me ontzettend verheugen op de rest. 
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RESEARCH DATA MANAGEMENT
This thesis is based on the results of human and animal studies performed in The 
Netherlands and Tanzania. 
The animal experiments described in Chapter 4 were carried out in accordance with 
the European Communities Council Directive and approved by the Committee for 
Animal Experiments of the Radboud university medical center Nijmegen. Data were 
collected on paper forms. Scores were entered into a Microsoft Access database by 
two independent researchers. The raw paper data are stored in the Department Archive 
(International Health, Internal Medicine, Radboudumc, route 456). The data used for the 
analyses are stored on the H-drive of the Department of Experimental Internal Medicine 
(H:\Exp Int Gnk\Employees\Lisa Van de Wijer\Databases\EFV_CNS_animal).
Human studies were conducted in accordance with the principles of the Declaration 
of Helsinki. The study protocols were approved by the national and local research 
board of the Netherlands (Chapter 5, 6 and 7; Medical Ethical Review Committee 
region Arnhem-Nijmegen) and Tanzania (Chapter 3, institutional review board of the 
Kilimanjaro Christian Medical University College and the National Institute for Medical 
Research). Informed consent was obtained from all participants (Chapter 5-7), and their 
parents or legal guardians (Chapter 3) and hard copies are stored a locked closet at 
Radboud university medical center (M379.01.152, Chapter 5-7) and at the department 
archive of Kilimanjaro Clinical Research Institute (KCRI). The privacy of all participants is 
warranted by use of encrypted and unique subject codes.
For Chapter 3, all clinical assessment data were collected by trained local research 
nurses on paper forms. Where necessary, data were translated from Kiswahili into 
English by native speakers. Test scores obtained from the checklists were entered in 
duplicate into electronic case report forms (Castor EDC). Data where converged from 
Castor EDC to SPSS (SPSS Inc., Chicago, Illinois, USA). The raw paper data of Chapter 
3 are stored at the department archive of KCRI. The data used for the analyses is stored 
on the H-drive of the Department of Experimental Internal Medicine (H:\Exp Int Gnk\
Employees\Lisa Van de Wijer\Databases\EFV_CNS_child). For Chapter 5-7, general 
data were recorded in CastorEDC. Psychiatric data were entered by participants 
using self-report surveys generated by CastorEDC. All clinical and laboratory data are 
stored on the H-drive of the Department of Experimental Internal Medicine (H:\Exp Int 
Gnk\500FG_project\200HIV), which is backed-up daily on the Radboudumc server. In 
addition, transcriptome and clinical data were deposited in public archives: the Gene 
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Expression Omnibus (GEO; transcriptome data) database and the DANS EASY archive 
(clinical and psychiatric data).
To ensure interpretability of the data, all filenames, primary and secondary data, metadata, 
descriptive files and program code and scripts used to provide the final results are 
documented along with the data. The data will be saved for 15 years after termination of 
the studies (Chapter Dec 2032; Chapter 4 April 2031; Chapter 5-7 February 2032) and 
are available upon request. Using patient data in future research is only possible after a 
renewed permission by the patent as recorded in the informed consent.
All left-over samples are stored at M379.01; freezer 9; rack 9 at -80 degrees Celsius 
(with exact lay-out in folder: H:)\\umcfs073\aigdata$\ExpIntGnk\general\10 storage 
databases\Freezers. Furthermore, samples of the HFGP cohort are also stored at the 
Radboud biobank and available upon reasonable request
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PHD PORTFOLIO
Name PhD candidate: L. Van de Wijer
Department: Internal Medicine
Graduate School: RIHS
PhD period: 01-02-2015 – 31-12-2020
Promotor(s): Prof. A.J.A.M. van der Ven
Co-promotor(s): Prof. dr. A.F.A. Schellekens 
dr. Quirijn de mast
Year(s) ECTS
TRAINING ACTIVITIES
a) Courses & Workshops
Radboudumc Introduction day 2015 0.5
RIHS specific introductory course 2015 1.0
BROK course  2015 2.0
Management voor promovendi course 2015 3.0
Scientific integrity course 2016 1.0
Academic writing course 2017 3.0
Presentation skills course 2016 2.0
Basic course in R, Wageningen University 2017 2.0
Language course Kiswahili 2017 3.0
Post-CROI Conference 2017/2019 0.5
b) Seminars & lectures
Radboud Research Rounds (monthly; incl. 1 x oral) 2015-2019 1.0
Cytokine meetings Internal Medicine (weekly; incl. 5 x oral) 2015-2019 1.0
NISPA meetings (bimonthly; incl. 1x oral) 2015-2019 0.5
NVHB meeting (oral) 2016 0.5
Donder’s Institute Meeting (oral) 2016 0.5
NVHB meeting (oral) 2018 0.5
c) Symposia & congresses
PhD retreat (poster) 2015 1.0
Radboud Science Day Infectious Diseases (oral) 2015 0.5
NVTG Conference Essential Medicines (oral and organization) 2015 1.0
Dutch Neuroscience Meeting, Lunteren (oral) 2016 0.5
Nationaal Congres SOA, AIDS, seks, Amsterdam (oral/workshop) 2016 1.0
Radboud Science Day Infectious Diseases (poster) 2018 0.5
NVVP Congres, Maastricht (oral) 2018 0.5
AIDS Conference, Amsterdam (oral) 2018 1.75
Radboud Science Day Infectious Diseases (oral and organization) 2019 0.75
AIDS Conference, digital (poster) 2020 1.75
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d) Other
NISPA writing retreat 2015/2018 3.0
NVTG Conference Health of People on the Move (organization) 2016 1.0
Member and co-chair of Uniting Streams, research workgroup NVTG 2014-2019 3.0
Onderzoeker in de klas 2018 1.0
TEACHING ACTIVITIES
e) Lecturing
Providing a 1-week training in child cognitive/psychiatric assessments 2017 2.0
Lecturer in bachelor course Severe Infectious Diseases 2015-2019 1.5
Lecturer in minor Global Health & Infectious Diseases 2015-2019 1.5
f) Supervision of internships / other
Juliette Rando (total 9 months) 2015/2016 1.5




Lisa Van de Wijer werd op 11 april 1989 geboren in het Zuid-Limburgse Nuth. In 2007 
behaalde zij haar Gymnasium diploma aan het Sintermeerten college in Heerlen, waarna 
zij koos voor de studie geneeskunde aan de Radboud universiteit in Nijmegen. Zowel 
haar keuze co-schap als haar wetenschappelijke stage spendeerde Lisa in Indonesië, 
waar ze onder andere onderzoek deed naar de functie van bloedplaatjes tijdens 
denguevirusinfecties en gefascineerd raakte door het vakgebied infectieziekten. Na het 
behalen van haar artsexamen in 2014 begon zij als ANIOS interne geneeskunde in het 
Amphia ziekenhuis in Breda, om vervolgens in 2015 te starten met haar promotietraject 
in het Radboudumc. Onder begeleiding van prof. André van der Ven, dr. Quirijn de Mast 
en prof. Arnt Schellekens, onderzocht Lisa psychische bijwerkingen van de eerstelijns hiv-
medicijnen efavirenz en dolutegravir en bestudeerde zij de immunologische complicaties 
tijdens chronische hiv infectie. De onderzoeksresultaten staan in dit proefschrift 
beschreven. Sinds 2019 werkt zij met veel plezier als AIOS interne geneeskunde in het 
Rijnstate ziekenhuis te Arnhem, onder supervisie van dr. Louis Reichert en dr. Arianne 
van Bon (hoofdopleider dr. Gerald Vervoort, Radboudumc). Na haar basisopleiding, wilt 
Lisa zich verder toespitsen op de infectieziekten en de farmacologie. 
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